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INTRODUCTION
PREFACE
This thesis concerns aortic stenosis (AS) in contemporary clinical practice. First, an 
introduction will be given to provide background information on the normal aortic 
valve, and thereafter on the incidence, disease spectrum, diagnosis, treatment, and 
prognosis of AS disease. Second, the aim of the thesis and the research questions 
addressed in this thesis will be formulated. Finally, an overview of the thesis contents 
will be provided.
THE NORMAL AORTIC VALVE
The formation of the aortic valve starts already at week 4 of gestation and its de-
velopment is part of a complex process. A non-diseased aortic valve consists of 3 
leafl ets (tricuspid) which smoothly move in a one-way direction during contrac-
tions of the heart1,2 (Figure 1). During systole, the left ventricle (LV) contracts and 
increases pressure in the LV which results in an opening of the aortic valve leafl ets 
allowing blood fl ow from the LV into the aorta, the largest artery in the body. When 
systole ends, the pressure will rapidly decrease which allows the aortic pressure to 
close the aortic valve and blood fl ow from the left atrium into the LV.
AORTIC STENOSIS: PREVALENCE AND DISEASE SPECTRUM
AS disease is common and its prevalence increases with age up to 5% among people 
aged over 75 years.3 Within 40 years, in 2052, the estimated world population will 
have increased to 9.3 billion of whom at least 280 million inhabitants will have 
AS disease that requires treatment.3,4 AS disease will constitute a major worldwide 
health issue.5 Etiologically, the distinction can be made between calcifi c, congenital, 
and rheumatic AS.
  Figure 1. Normal and stenosed aortic valve.
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Calcific AS
Calcifi c AS is a common progressive valvular disorder among elderly people in 
industrialized countries and represents a major public-health problem for ageing 
societies.3,4 Up to 3% of the elderly aged 75 years and older have calcifi c AS while 
aortic sclerosis, the preceding stage of calcifi c AS, is prevalent in almost 30% of 
the adults aged over 65 years.3,6-8 Calcifi c AS counts for 50 to 80% of native valvular 
heart disease and has a male predominance.9-11
The pathway of calcifi c AS disease is complex and appears to be an actively regu-
lated disease process which comprises varying disease stages from initial altera-
tions in the cell biology of the leafl ets to end-stage calcifi cation.12,13 The stenosis of 
the calcifi c tricuspid aortic valve is located at valvular level (Figure 1). The progres-
sive valvular calcifi cation (Figure 2) causes a gradually decreasing leafl et opening to 
which the LV responds with hypertrophy. However, this compensatory mechanism 
fails as systolic LV dysfunction starts to develop, and the fi nal stage of AS disease 
is entered. In this stage, most patients become symptomatic which marks a critical 
point in the course of AS disease since prognosis worsens dramatically.14 When 
angina and heart failure develop, life expectancy is limited to a maximum of 5 
years.15 In asymptomatic patients with severe AS, the course of AS disease is more 
diffi  cult to predict and requires careful monitoring due to the progressive nature 
of AS disease and the risk of sudden death which is approximately 1% per year.14,16
Congenital AS
Congenital AS contributes importantly to the growing population of young adults 
with congenital heart disease (CHD) who have survived childhood (the so-called 
Grown-Up Congenital Heart (GUCH) patients) and increases the impact of valvular 
heart disease on global disease burden.17,18 The estimated worldwide prevalence 
of adult CHD for the year 2000 was 0.28% of whom half suff ered from moder-
ate to truly complex CHD.18,19 A bicuspid aortic valve, the most common cause of 
  Figure 2. Calcifi c aortic valve stenosis.
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congenital valvular AS (Figure 3), is present in 1 to 2% of the general population 
and counts for 5 to 40% of native AS disease.11,20-23 Although much less prevalent, 
also unicuspid and quadricuspid aortic valves exist in the disease spectrum of 
congenital AS.1
Bicuspid AS is characterized by a varying disease presentation ranging from 
severe valvular AS in utero to asymptomatic disease in the elderly.21 The presence 
of congenital AS in infancy is often due to commissural fusion and marks more 
severe disease with poor outcomes.21 Over 80% of the children with initially mild 
AS disease progress to more severe AS disease during a 30-year follow-up period.24 
In adults, congenital AS is often due to leafl et calcifi cation comparable to tricuspid 
aortic valve calcifi cation, except that calcifi cation is often already present at an aver-
age age of 40 years and requires earlier intervention.9,10,21,25
Although less prevalent, the disease spectrum of congenital AS also includes 
subvalvular and supravalvular AS disease.
Subvalvular AS counts for up to 30% of the pediatric LV outfl ow tract obstructions 
and usually presents after the fi rst year of life.26-28 The disease has two pathologi-
cal presentations; the focal, discrete membrane form (so-called discrete subaortic 
stenosis (DSS)) which is most often encountered (90%) with a prevalence of 6.5% 
among adults with CHD, and the diff use muscular narrowing form (with varying 
forms of tunnel stenosis and hypertrophic obstructive cardiomyopathy (HOCM) 
) which is associated with more severe AS.29-31 DSS is known for its unpredictable 
and progressive course during childhood due to the increasing obstruction of the 
LV outfl ow tract over time and severity of aortic regurgitation.30,32 It also may be part 
of complex multilevel and obstructive lesions; it is often associated with ventricular 
septal defects, coarctation of the aorta, and in almost one-fourth of the patients 
accompanied with a bicuspid aortic valve.30 Although studies concerning children, 
who survived CHD into adulthood, are now emerging, evidence about DSS evolu-
tion over time in adult patients, is limited.
   Figure 3. Severely calcifi ed bicuspid aortic valve.
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Supravalvular AS is a rare (1/20,000 to 1/50,000) congenital anomaly of the aortic 
root, often associated with the Williams-Beuren syndrome, a genetic defi ciency in 
elastin production, which is characterized by mental retardation, elfi n face, and 
hoarse voice production.30,33,34 The phenotype of this disease is may vary from the 
discrete form which is characterized by a ring-like thickening at the sinotubular 
junction which occur in 75% of the patients with supravalvular AS, to the diff use 
form which involves thickening and hypoplasia of the complete ascending aorta, 
sometimes including the pulmonary arterial system as well, and turns out a com-
plex disease to manage.33 Both disease entities require intervention at childhood 
age due to the consequence of LV outfl ow tract obstruction and because both are 
commonly associated with other pathology like subvalvular AS, bicuspid aortic 
valve, tricuspid aortic dysplastic thickening, pulmonary stenosis, and coronary 
stenosis and ischemia.30,35-37
Since congenital AS encloses a wide disease spectrum with an increasing num-
ber of GUCH patients and longitudinal studies are lacking, it is diffi  cult to provide 
detailed information about the prognosis of congenital AS disease. In the Nether-
lands, in 2009 only 1% of all cardiovascular deaths was due to CHD.38 Asymptom-
atic adults with a bicuspid aortic valve have the same life expectancy compared to 
the general population.39,40 On the other hand, when heart failure develops, the 
prognosis of patients with severe symptomatic AS disease without intervention is 
shortened to 2 or 3 years.12 In case of concomitant aortic root or ascending aorta 
dilatation in patients with a bicuspid valve, patients could die of a dissection or 
ruptured aneurysm.21,30
Rheumatic AS
Finally, rheumatic AS disease in the developing regions of the world and in indig-
enous populations in developed countries, contributes further to the incidence 
and burden of heart disease.41 While rheumatic heart disease has an estimated 
prevalence range from 15.6 to 19.6 million cases worldwide, rheumatic AS seems a 
less common cause of isolated AS with an estimated prevalence of 2 to 11% of the 
native valvular heart diseases.10,11,42,43
Rheumatic AS (Figure 4) is preceded by (acute) rheumatic fever, which is a con-
stellation of symptoms based on an abnormal autoimmune response following a 
group A streptococcal infection.44,45 Over one-third of the patients with rheumatic 
fever presents with carditis encompassing varying disease stages from valvulitis to 
myocarditis to pericarditis which can result in irreversible valve damage and heart 
failure.43,44 Although isolated rheumatic AS is rare as it is almost always accompa-
nied by mitral valve disease and aortic regurgitation, chronic progression can lead 
to fusion of the commissures of the aortic valve with scarring and eventual calcifi ca-
17
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tion of the cusps.45,46 Unfortunately, many patients present too late and severe heart 
failure with myocardial dilatation and dysfunction will ultimately lead to the death 
of these patients. The estimated annual number of deaths from rheumatic heart 
disease for the year 2000 was 332,000 worldwide and it remains a major cause of 
cardiovascular death of children and young adults in developing countries.43,44,47,48
AORTIC STENOSIS: DIAGNOSIS
The clinical presentation of patients with AS disease depends on the underlying 
etiology, the severity of stenosis, severity of calcifi cation, LV function, and concomi-
tant other disease.12 Calcifi c AS often presents at the age of 60 years and beyond, 
congenital AS often fi rstly presents at childhood and young adult age, and rheumatic 
AS presentation varies from the age of 20 to 50 years.44
History taking
History taking shows that exertional shortness of breath is the most common 
feature of AS disease at presentation, but angina, dizziness, and/or syncope could 
also exist. It is not uncommon that asymptomatic patients present themselves with 
a murmur which was identifi ed during a regular medical check-up. In an emergency 
setting, acute heart failure, an embolic event such as transient ischemic attack or 
cerebrovascular accident, infective endocarditis, or arrhythmia could be the fi rst 
presentation of AS disease. If young patients present with AS disease, it is impor-
tant to investigate the occurrence of AS disease in their relatives because of the 
familial clustering and high heritability of bicuspid aortic valve disease.49 Finally, a 
history of rheumatic fever may suspect for rheumatic etiology of AS disease.
  Figure 4. Post-rheumatic aortic valve.
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Physical examination
Physical examination reveals a systolic crescendo-decrescendo murmur along the 
left sternal border which radiates into the carotid arteries which is characteristic 
for AS.12 The intensity of the murmur does not correspond with the severity of AS 
disease, but the duration of the murmur increases as AS becomes more severe. In 
some patients, the murmur is ‘missed’; in obese patients and patients with lung 
disease where the murmur is muffl  ed, and in patients with LV dysfunction where 
the murmur is blunted.50 Patients with AS disease are classifi ed into the New York 
Heart Association to provide insight into their exercise tolerance. When severe AS 
is present and the left part of the heart could not compensate any longer, left heart 
failure starts to develop from LV hypertrophy to dilatation in the fi nal stage, result-
ing in pulmonary edema and severe respiratory distress. If also the right side of the 
heart is involved, edema of the lower limbs (or sacral edema if bedridden), nycturia, 
ascites, hepatomegaly, and increased central venous pressure appear.
Additional examination
Additional examination may consist of electrocardiography, chest radiography, 
echocardiography, exercise testing, and cardiac catheterization.
On electrocardiography, LV hypertrophy accompanied by secondary repolarization 
abnormalities occur in 85% of the patients with severe AS.12 Easy to obtain and at 
a relatively low cost, the absence of hypertrophy, conduction abnormalities such as 
left and right bundle branch block, atrial enlargement, atrial fi brillation (in patients 
with hypertension and in the elderly), prior myocardial infarction, and ischemia on 
electrocardiography provides useful negative information.14
As cardiomegaly is a late feature in AS disease, cardiac size is often normal on 
chest radiography, except the rounding of the LV border and apex due to hypertro-
phy.12 This examination also provides information about cardiac calcifi cation, and 
the pulmonary and systemic venous pressure.14 In patients with a bicuspid aortic 
valve, the ascending aorta may dilate whereas in advanced heart failure, dilatation 
of the right atrium and ventricle may occur.12
According to the American College of Cardiology, the American Heart Association 
(ACC/AHA), the European Society of Cardiology, and the European Association for 
Cardio-Thoracic Surgery (ESC/EACTS) guidelines for the management of patients 
with valvular heart disease, the (fi nal) hemodynamic diagnosis of AS is made by 
echocardiography (Figure 5).14,51 The severity of AS is defi ned as: Mild (aortic valve 
area > 1.5 cm2, aortic jet velocity < 3.0 m/s, or mean aortic gradient < 25 mmHg), 
moderate (aortic valve area 1.0-1.5 cm2, aortic jet velocity 3.0-4.0 m/s, or mean 
aortic gradient 25-40 mmHg), or severe (aortic valve area < 1.0 cm2, aortic jet veloc-
ity > 4.0 m/s, or mean aortic gradient > 40 mmHg).14
19
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The use of echocardiography in AS disease decreased the number of invasive 
cardiac catheterizations performed for measuring and monitoring hemodynamic 
AS severity.12 Two-dimensional echocardiography often diff erentiated between a 
tri-leafl et or bicuspid morphology and shows valve calcifi cation varying from fo-
cal areas of valve thickening to heavily calcifi ed and thickened leafl ets with limited 
reduction and a small aortic valve area.12,13
In addition to conventional echocardiography, one could approach AS disease 
severity in another way by estimating the LV response to the chronic overload as LV 
dysfunction is the main adverse physiological consequence of AS disease.12,52,53 In 
this regard left ventricular twisting and the presence of strain (as a marker for sub-
endocardial ischemia) may be better derivatives of systolic LV function and detect 
LV dysfunction earlier in order to optimize the timing of aortic valve intervention.54,55
Exercise testing is preserved for patients in which it is diffi  cult to distinguish the 
origin of their symptoms.14,52 Although a proven safety record even in asymptomatic 
patients with severe AS, this test is not often used in clinical practice.11
Cardiac catheterization is performed when there is a discrepancy between the 
clinical and echocardiography fi ndings and provides additional information about 
the presence and severity of AS disease.14 Compared to the above described ex-
aminations, cardiac catheterization is an invasive examination and therefore only 
preserved for specifi c indications. For example, when a patient presents with short-
ness of breath and angina, a cardiac catheterization will be applied to determine 
whether concomitant coronary artery disease is involved as well. The outcome of 
the cardiac catheterization will have diff erent implications for the treatment of this 
particular patient.
Finally, a more recent, additional approach is to either screen for or monitor 
calcifi c AS disease with the use of biomarkers. N-terminal pro-brain natriuretic 
peptide (NT-proBNP) is released from the myocardium in response to pressure 
and volume overload.56 Although biomarkers are subject of investigation in many 
A B C
Figure 5. A and B. Severe aortic valve stenosis. Ao = aortic valve, LV = left ventricle, LA = left atrium, 
RV = right ventricle, c. Discrete subaortic stenosis, arrow = subaortic membrane.
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studies, data on the capacity of NT-proBNP to mark the progression of AS disease 
in (a)symptomatic patients, are scarce.7,57
AORTIC STENOSIS: TODAY’S TREATMENT OPTIONS
There are several treatment options for AS disease.14,51 Asymptomatic patients with 
mild to moderate AS disease are treated conservatively and carefully monitored over 
time and treated conservatively while aortic valve replacement (AVR) is indicated 
(Class I, level of evidence B) for symptomatic patients with severe AS according 
to the ACC/AHA and ESC/EACTS guidelines for the management of patients with 
valvular heart disease.14,51
There are diff erent options for invasive treatment of AS: aortic valvuloplasty, 
aortic valve replacement with a prosthesis (mechanical or bioprosthetic) or hu-
man valve substitute (autograft or homograft), or transcatheter bioprosthetic valve 
implantation.
In the Netherlands, from 2007 to 2010, of the 63,601 open heart procedures per-
formed in adults, 16,662 ( 26.4%) consisted of aortic valve surgery with an opera-
tive mortality of 4.4%.58 Of the 16,662 aortic valve procedures, 7,372 (11.7%) were 
isolated AVRs with an operative mortality of 2.6 %.58 Reports published in 2010 by 
the European Association for Cardio-Thoracic Surgery and in 2009 by the Society of 
Thoracic Surgeons’ database, established in the USA, reported a consistent opera-
tive mortality.59,60 Worldwide, from 1997 to 2006, an estimated 200,000 patients 
underwent AVR each year.61-63
The following paragraphs outline the main invasive treatment options for severe 
AS.
Aortic valvuloplasty
Since several decades, surgical aortic valvuloplasty (mostly valvulotomy, some-
times repair) is performed in neonates, children, and youngsters to treat critical 
congenital AS and a known complication of this technique is residual stenosis.64-66 
The introduction of the transcatheter balloon aortic dilatation in the 1980s started 
the debate about the value of the balloon aortic valvuloplasty as compared to the 
surgical valvuloplasty. Since neonates, the most aff ected patients in the spectrum 
congenital AS, have similar 5-year survival rates after both techniques, the discus-
sion focused on intervention-free survival.67,68 Compared to surgical valvuloplasty, 
balloon dilation is associated with progressive aortic regurgitation which neces-
sitates earlier intervention.68,69 However, surgical and balloon valvuloplasty are both 
capable of delaying the need for childhood aortic valve replacement.67-70 In adults, 
21
INTRODUCTION
balloon aortic valvuloplasty may be performed as bridge to open heart surgery or 
applied as palliative care, but today, these patients usually undergo transcatheter 
aortic valve implantation.71,72
Bioprosthesis and mechanical valve prosthesis
In contemporary clinical practice, bioprostheses (also called xenografts or hetero-
grafts) are most frequently used to replace the diseased native aortic valve.14 Almost 
a decade ago, the European Heart Survey reported that of adult patients with AS 
(54% aged 70 years or older) who underwent AVR in 2001, 49% received a me-
chanical valve prosthesis and 50% a bioprosthesis.11 However, more recently, The 
Society of Thoracic Surgeons’ database showed a dramatic shift toward the use of 
bioprostheses from 44% in 1997 to 78% in 2006 corresponding with a concomitant 
decrease in the use of mechanical valve prostheses.62 This trend was confi rmed by 
data from US Department of Health and Human Services which contain informa-
tion on approximately 8 million hospital stays each year, and more recently by the 
Fourth Adult Cardiac Surgical Database Report 2010 and the Dutch cardiac surgery 
registry.60,73-75
Bioprostheses most often are stented, but stentless types are available. Bioprosthe-
ses are usually composed of porcine valve or bovine pericardial tissue (Figure 6a). 
They are easily available, have a low thrombogenicity and do not require lifelong 
anticoagulation therapy whereas the over the years decreasing hemodynamic per-
formance and limited durability are the main disadvantages.14
Mechanical valve prostheses nowadays are usually bi-leafl et valve prostheses 
(Figure  6b) which are easily implanted, readily available, and have the major 
advantage of lifelong durability.14 Unfortunately, the increased thrombogenicity of 
these valves necessitate lifelong anticoagulation therapy which is associated with 
an increased hazard of bleeding.14,76 This may require lifestyle adjustments (with 
regard to for instance: sports, food, and alcohol intake), and in addition young 
A B
Figure 6 A. Pericardial bovine bioprosthesis. b. Mechanical valve prosthesis.
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women who may contemplate pregnancy should be aware of the potential risks of 
anticoagulation therapy during pregnancy.
The choice for a particular aortic valve prosthesis depends not only on research 
evidence (compliance with clinical guidelines) and clinical-technical consider-
ations, but also on informed patient preference.61,62 The ESC/EATCS guidelines for 
the management of patients with valvular heart disease recommend a mechanical 
prosthesis 1) according to informed patient preference in patients without con-
tra-indications for long-term anticoagulation, 2) in patients at risk of accelerated 
structural valve deterioration, and 3) in patients already on anticoagulation as a 
result of having a another mechanical prosthesis (all Class I, level of evidence C).51 
In addition, mechanical prostheses should be considered in patients <60 years of 
age and those with a reasonable life expectancy, for whom future redo valve surgery 
would be at high risk (Class IIa, level of evidence C), and may be considered in pa-
tients already on long-term anticoagulation due to high risk of thrombo-embolism 
(Class IIb, level of evidence C).51
Bioprostheses are recommended 1) according to the desire of the informed 
patients, 2) when good quality anticoagulation is unlikely or contraindicated, and 3) 
for reoperation for mechanical valve thrombosis despite good long-term anticoagu-
lant control (all Class I, level of evidence C).51 In addition, bioprostheses should be 
considered 1) in patients for whom future redo valve surgery would be at low risk, 2) 
in young women contemplating pregnancy, and 3) in patients >65 years of age (all 
Class IIa, level of evidence C).51 Sometimes, younger patients prefer a bioprosthesis 
at the cost of a reoperation later in life to avoid the burden of anticoagulation, or the 
noisy ‘clicking’ sound of a mechanical valve prosthesis.
Homograft aortic valve replacement and pulmonary autograft procedure
Homografts and pulmonary autografts are mainly implanted in young patients 
with CHD such as congenital AS with or without concomitant other aortic valvular 
(regurgitation) or root disease.
From 2006 until 2009, of the adult patients with AS and/or aortic regurgitation, 
homografts count for 0.4 to 1.1% of the isolated AVRs.11,60,62,77 This human tissue 
valve consists of an aortic valve, root, and part of the aortic arch, and can be im-
planted subcoronary or as complete root which is the preferred technique in case of 
endocarditis with excessive tissue damage. Advantages are the excellent hemody-
namics and low thrombogenicity which makes anticoagulation therapy redundant. 
Because homografts are donated postmortem or retrieved from heart transplant 
recipients with native healthy aortic valves, availability is limited. Graft calcifi cation 
and infection are the main problems and often necessitates a reoperation later in 
life.78 Compared to porcine and pericardial bioprostheses, actual risk on homograft 
23
INTRODUCTION
reoperation is comparable, but when compared to the stentless porcine aortic root, 
homografts show higher calcifi cation scores, more valve dysfunction, and need 
more reoperations.79-81 Currently the main indication for the use of a homograft in 
aortic position is active endocarditis with extensive tissue damage.
Pulmonary autografts (so-called Ross procedure) were introduced in 1967 by 
Donald Ross and count for 0.3 to 0.4% of the isolated AVRs of AS patients with 
or without aortic regurgitation.11,60,62,82 This human valve substitute provides the 
potential for neo-aortic root diameter increase along with somatic growth, excellent 
hemodynamic performance, low risk on endocarditis, and low thrombogenicity and 
therefore avoidance of anticoagulation therapy.83-85 It is currently the only available 
living valve substitute. On the downside, it is technically demanding and creates 
double-valve disease by replacing the patient’s aortic valve the patient’s own 
pulmonary valve and implanting a pulmonary homograft, bovine jugular vein, or 
other valve substitute in pulmonary position.85-87 However, a major disadvantage of 
pulmonary autografts that are implanted using the unsupported freestanding root 
replacement technique is the progressive neo-aortic root dilation and concomitant 
aortic regurgitation, which necessitates redo surgery usually in the second postop-
erative decade.85,86,88,89 In addition, a valve substitute in pulmonary position may 
also require re-intervention usually due to calcifi cation.
A recent randomized controlled trial compared outcomes of pulmonary autografts 
and homografts and showed that long-term outcomes of the pulmonary autografts 
are superior to those of the homografts both with regard to survival and the need 
for reoperations.90
Transcatheter aortic valve implantation
As we face a growing elderly population with multiple co-morbidities and a limited 
life-span, not every symptomatic patient is a candidate for open-heart surgery or 
desires open-heart surgery. Transcatheter aortic valve implantation (TAVI) was 
introduced 10 years ago for the high-risk patients who were not surgical candi-
dates.91,92 In the past decade, TAVI has been performed in over 50,000 patients 
worldwide and the use of TAVI is expect to increase even more in the next years.93
In TAVI, the aortic valve prosthesis is retrogradely inserted into the body by the 
transfemoral, transiliac, transsubclavian, transaxillary arterial or aortic approach, or 
antegradely by applying the transapical approach. Positioning of the prosthesis at 
the level of the aortic valve and deploying it, must be adequately precise in order to 
reduce the risk on acute myocardial ischemia or acute mitral dysfunction.94
The advantage of TAVI is that it is a less invasive procedure compared to AVR 
because it does not require entry into the chest cavity (with the exception of the 
transapical approach) or use of cardiopulmonary bypass, with high post-procedural 
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immediate success rates are achieved, good initial hemodynamic valve function 
is good (severe aortic regurgitation is uncommon), a shorter hospital stay, and 
a faster and less complicated recovery as compared to surgical AVR.95,96 On the 
contrary, early outcomes (30 day results) raise concerns about vascular injury, 
stroke, and paravalvular regurgitation.96,97 In addition, long-term longitudinal data 
to evaluate the valve durability and safety are lacking. Until now, taking into account 
the high-risk patient profi les, satisfactory hemodynamic and functional results are 
achieved up to 5 years post procedure.98 With the ongoing improvements of trans-
catheter valve systems and implantation techniques, optimized multidisciplinary 
collaboration with formally trained experienced physicians, and refi ned patient 
selection including factors as frailty, TAVI becomes an appealing future option for a 
broader range of patients.97,99,100
Enucleation and myectomy in patients with discrete subaortic stenosis
For patients with DSS, diff erent surgical strategies exist which can be performed 
early in the disease or later on when there is a severe obstruction of the LV outfl ow 
tract.101 Enucleation of the subvalvular fi brous or fi bromuscular membrane or collar 
is performed, and in case of severe hypertrophy of the interventricular septum, 
a myectomy could be added to the surgical procedure. However, performing a 
myectomy is still a matter of debate among clinicians. Although adequate surgical 
excision, obstruction may reappear and aortic regurgitation could be progressive 
and subsequently urge reoperation.102 Data on postoperative outcome in adult DSS 
are limited. Patients with discrete and tunnel subvalvular AS had a 40-year survival 
of 94% and 84%, respectively, including hospital mortality.103
AORTIC STENOSIS: PATIENT PROGNOSIS
The prognosis of patients with severe aortic stenosis is determined by a multitude 
of interrelated factors that will be discussed extensively in this thesis, in the set-
ting of natural history, current clinical practice, and for specifi c subgroups such as 
patients with DSS and female patients of childbearing age. Not only will this thesis 
focus on determinants of clinical outcome but also on quality of life.
Clinical outcome is measured in patient survival and freedom of complications 
which preferably should be reported uniformly and transparent. Clinical outcome 
after a heart valve procedure is reported according to the guidelines for reporting 
mortality and morbidity after cardiac valve interventions.104 Generally, survival is de-
termined by the number of all patients dying during the fi rst 30 days postoperatively 
(operative or hospital mortality), and the number of patients dying during follow-up. 
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Survival can be reported as percentage or as an annual rate. Causes of death can be 
further specifi ed in all-cause, cardiac, valve-related, or sudden unexplained death.104
Another measure to assess clinical outcome is freedom from complications. Like 
mortality, complications should be defi ned uniformly and transparent and, after 
a cardiac procedure, reported according to the current guidelines.104 Valve-related 
complications that may occur over time after a cardiac procedure are defi ned as 
structural valve deterioration, nonstructural dysfunction, valve thrombosis, embo-
lism, bleeding events, operated valve endocarditis, and their consequences, such 
as death and reoperation.104
Another measure of patient outcome is quality of life. The increase in life-expec-
tancy has resulted in a growing population of elderly AS patients with a limited life 
span for which quality of life becomes important. Improvement in quality of life 
through a reduction in symptoms and a better physical function is therefore the 
main goal of valvular surgery in these elderly patients with AS.94 Quality of life, a 
measure of individual disease burden, is defi ned as the quality of life experienced by 
the patient at a particular moment in time and assessed with a questionnaire such 
as the Short Form-36® Health Survey (SF-36) questionnaire or its modifi cations.105 
Evidence on quality of life in patients with AS who are treated conservatively or 
surgically is limited.
One special aspect associated with patient prognosis concerns pregnancy: up to 
4% of the pregnancies in industrialized countries are complicated by cardiovascu-
lar disease and this number still increases.106 The number of young patients who 
had valve surgery and want to start a family afterwards, has increased. In clinical 
practice, the treating physician has to be aware that treatment concern not only the 
mother, but the fetus as well. A therapy which is favorable for the mother, could be 
unfavorable for the fetus, sometimes even cause the death of the fetus, and vice 
versa.106 However, knowledge on pregnancy outcomes in patients who underwent 
prior aortic valve surgery is not only important prior to conception, but already 
preoperatively when choosing the type of aortic valve substitute.
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AIM OF THIS THESIS
The aim of this thesis is to provide insight in several aspects of the natural history, 
treatment, and prognosis of adult patients with AS.
The following research questions are addressed:
1. What is the clinical course of severe AS disease in contemporary clinical prac-
tice? (With specifi c attention for new diagnostic markers, for quality of life and 
for DSS.)
2. What challenges do young females with prosthetic heart valves encounter 
during pregnancy? (With specifi c attention for human tissue valve substitute 
durability.)
OUTLINE OF THIS THESIS
Chapters 2, 3, and 4 describe the natural history of (elderly) patients with calcifi c 
AS and the results of a meta-analysis on AS progression. In addition, Chapter 5 
describes the potential predictors for progression of AS disease using mixed-eff ects 
analysis of longitudinal data of a cohort with severe AS patients.
To gain insights into the association between (mechanical) LV aspects and AS 
disease, Chapter 6 describes the rotation parameters of the LV in a large cohort of 
patients with severe AS, compared to age-matched healthy controls, whereas Chap-
ter 7 illustrates the association between electrocardiographic strain and systolic 
longitudinal shortening of the LV in patients with AS.
Chapter 8 describes the 2-year clinical course of a prospective cohort of symp-
tomatic and asymptomatic patients with severe AS in the wider Rotterdam area, 
while Chapters 9 and 10 describe the quality of life of these patients during the 
2-year follow-up period and in particular the association between AVR and quality 
of life in symptomatic patients.
Chapter 11 concerns a multicenter study that recorded the natural history of 
DSS in adults, while Chapter 12 describes the surgical outcome of DSS in a large 
multicenter cohort study. 
Chapter 13 describes the pregnancy outcomes of patients who underwent aortic 
valve or root replacement with a homograft, a pulmonary autograft, or a mechani-
cal valve prosthesis. Finally, Chapter 14 describes of the clinical course of female 
patients who received a homograft or pulmonary autograft in aortic position, and 
assesses the potential association between pregnancy and accelerated degenera-
tion of the human aortic tissue valves.
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INTRODUCTION
Aortic valve stenosis (AS) is the most common heart valve disease in the world, 
with a prevalence up to 3% of adults over the age of 75 years.1 One-third of US adults 
≥65 years has aortic valve sclerosis and of these at least one-third will develop some 
degree of AS within 5 years.2,3 The natural history, diagnosis, and cellular mecha-
nisms of this disease process have evolved over the past several decades. Over the 
last 10 years, the scientifi c progress in the fi eld of calcifi c aortic valve stenosis has 
increased exponentially. A critical discovery in our understanding of calcifi cation as 
the end-stage pathogenesis of a congenital bicuspid or tricuspid aortic valve is the 
osteogenic process.4-6
Progressive calcifi cation of the leafl ets usually leads to severe narrowing of the 
aortic valve orifi ce and fi brosis of the left ventricular wall, fi nally resulting in left 
ventricular outfl ow tract obstruction and severe aortic stenosis. After a prolonged 
asymptomatic period with low morbidity and mortality, the development of the clas-
sic triad of symptoms including: angina, syncope, or heart failure marks the critical 
point in the natural history of aortic valve disease. AS is a progressive disease 
and without intervening treatment associated with high morbidity and mortality 
rates within a few years of diagnosis.7 Survival declines when a patient with AS 
develops angina or syncope, and is even more limited when the patient develops 
congestive heart failure. Because AS is a disease of the elderly, it can be diffi  cult to 
distinguish the gradual decrease in physical functioning attributed to advanced age 
and multiple co-morbidities such as frailty, lung disease, neurological disease, and 
symptoms from the worsening AS disease. It is not uncommon that patients will 
lower their activity level below their symptom threshold, to accommodate to the 
progressive left ventricular outfl ow tract obstruction. This chapter will outline the 
studies in the fi eld of diagnosis and the impact of the evolving science of clinical 
risk factors for calcifi c aortic valve disease.
Patients with mild to severe asymptomatic AS are monitored until the develop-
ment of symptoms. Sudden death is a rare event with an occurrence of 1% per year 
without preceding symptoms.8 If symptomatic severe AS is present, according to 
the present ACC/AHA and ESC guidelines, aortic valve replacement is indicated.9-10 
An evolving option in the twenty-fi rst century for patients who are not candidates 
for surgery, is the transcatheter aortic valve implantation which is performed in 
specifi c patient populations in Europe and US. In an eff ort to assess AS severity and 
progression for the individual adult patient, it is important to consider the changing 
basic concept of AS disease, current knowledge about AS progression, and insight 
in the factors associated with AS progression. These topics will be described in the 
following paragraphs of this chapter.
CHAPTER 2
38
HISTORICAL PERSPECTIVE OF AS DISEASE
Early reports on the natural history of AS are based on post-mortem studies, 
invasive cardiac catheterization studies, and Doppler echocardiography. Histori-
cally, symptomatic AS was seen as a passive degenerative disease and associated 
with a signifi cant risk (>15%) of sudden death while asymptomatic AS reportedly 
had a risk of sudden death of 3-5%.11 According to the post mortem studies from 
the period 1930-1950, the time from symptom onset until death was on average 
less than 5 years for patients with angina and only 2 years for patients with heart 
failure as shown in Figure 1. With the development of cardiac catheterization in the 
1930s, hemodynamic assessment of AS severity became possible. Although the 
published catheterization studies in patients with AS often consist of small study 
populations, they provide the fi rst quantitative data of AS progression over time.12 
In the late 1980s, the non-invasive Doppler echocardiography technique became 
available and off ered an opportunity for longitudinal studies regarding AS disease 
and progression. These studies provide further information for the understanding 
of this complex disease process via non-invasive imaging.
On July 13, 1912, Theodore Tuffi  er, a French surgeon, performed the fi rst successful 
closed heart surgery in a young patient with severe AS by digitally invaginating the 
aortic wall into the aortic valve orifi ce to dilate the stenosed valve.13 Several diff erent 
invasive approaches to palliate severe AS followed with poor outcomes.14 The fi rst 
aortic valve replacements were performed with an caged-ball valve prosthesis in the 
Figure 1. Average course of valvular aortic stenosis in adults. Data assembled from post-mortem 
studies (reprinted with permission).
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1960s and were accompanied by mortality rates ranging from 25% to 50%, but over 
time, mortality rates decreased considerably, even for complex aortic valve proce-
dures.15 The introduction of cardiopulmonary bypass in the 1950s and cardioplegia 
in the mid 1960s was associated with the continuous improvements in operative 
techniques and postoperative care. The development of new valve substitutes, such 
as bioprosthetic valves, are important developments which have resulted in the 
extremely low morbidity and mortality that is observed in contemporary clinical 
practice.
In more recent years, the concept that AS is passive and degenerative is not 
valid anymore. It is now proven that AS represents a more active regulated disease 
process characterized by lipoprotein deposition, active leafl et calcifi cation, and 
chronic infl ammation for which medical treatment possibly could play a role.16-18 
The understanding of this biologic process may off er an opportunity to treat AS 
with medications, in order to prevent, reverse or slow down the disease as more 
scientifi c studies in this fi eld are performed.
WHAT IS KNOWN ABOUT AS PROGRESSION?
There are several studies investigating AS progression and its potential determi-
nants, however, due to small sample size, non-randomized retrospective study de-
sign, heterogenic study populations, large variability in AS progression estimates, 
and limited follow-up duration, it has been diffi  cult in the past to draw general con-
clusions. A meta-analysis on the diagnostic studies in cardiac catheterization and 
echocardiography demonstrates the diff erences in these diagnostic approaches, 
and the challenges that are present in following the natural history of this disease 
by echo and cardiac catheterization data.
Figure 2 shows progression of AS measured by cardiac catheterization according 
to nine published reports from the 1970s and 1980s, describing the course of AS 
disease over time in patients with a mean age of 55 years (range 37-61 years) of 
whom 75% males.19-27 The studies include predominantly male patients with ages 
ranging from 40 to 60 years with mostly non-severe AS who underwent serial mea-
surements for clinical reasons, for example for the evaluation of a systolic murmur. 
Progression of AS disease, as measured by the aortic valve area calculated with the 
Gorlin formula and the peak-to-peak aortic gradient, shows a large variability in the 
progression rates between studies. Annual reductions of the aortic valve area vary 
from 0.03 to 0.24 cm2/year and annual increase in aortic peak-to-peak gradients 
ranging from 2 to 11 mmHg/year.
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Figure 3 displays echocardiographic AS progression from a systematic review and 
meta-analysis of observational reports published between 1989 and 2009.28 The 
results of this analysis demonstrate a similar large variability in AS progression 
rates compared to cardiac catheterization studies. Annual reductions in aortic valve 
area vary from 0.04 to 0.22 cm2/year. There is an annual increase in maximum 
aortic jet velocity ranging from 0.06 to 0.40 m/s/year. The annual increase in peak 
and mean aortic gradient varying from 2 to 15 and from 2 to 8 mmHg respectively.28 
This meta-analysis for catheterization and echo variability demonstrates further un-
derstanding into the complex assessment of the hemodynamic parameters, which 
refl ects most probably institutional variability in measurements and diff erences 
in patients’ clinical risk factors. Assessing the degree of stenosis, hemodynamic 
severity, and anatomic criteria for TAVI is also evolving quickly and the results of 
this meta-analysis will help to further understand this process.
In addition to the measures above, assessing the amount of aortic valve calci-
fi cation can also be used to monitor AS severity and progression. This has been 
measured in a few studies in which diff erent methods were employed to assess 
aortic calcifi cation, often without a reference test to quantify the extent of aortic 
valve calcifi cation and the timing to progression.29-32 This textbook will provide an 
overview for why these diff erences may exist which include risk factors, diagnostic 
techniques, and understanding the variable stages of this disease by assessing the 
calcifi cation in the overall outcome of this patient population.
Figure 2. AS progression in cardiac catheterization studies. AS = aortic valve stenosis,
PAGt = peak-to-peak aortic gradient at time t, SE = standard error, t = time. Interrupted lines = indi-
vidual study estimates, solid line = pooled estimate.
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FACTORS ASSOCIATED WITH AS PROGRESSION AND CLINICAL 
OUTCOME
Many factors are reportedly potentially associated with faster AS progression and/
or impaired clinical outcome of AS disease: advanced patient age, male gender, 
obesity, smoking, hypertension, diabetes, coronary artery disease, chronic obstruc-
tive lung disease, severe pulmonary hypertension, signifi cant aortic valve calci-
fi cation, a higher maximum aortic jet velocity at baseline and faster progression 
rate, decreased aortic valve area, left ventricular dysfunction, aortic regurgitation, 
impaired functional status, abnormal exercise response on exercise testing, inactiv-
ity, elevated levels of serum cholesterol, calcium, creatinine, C-reactive protein, and 
natriuretic peptides, osteoporosis treatment, chronic renal failure, and hemodialy-
sis.8,30,33-51
As the basic concept of AS disease as a passive degenerative disease is now a 
concept of the past, and we are moving to the notion that it represents an active 
disease process with many similarities to atherosclerosis, the interest in potential 
medical treatments of AS disease is growing. The recent Working group of the 
National Heart Lung and Blood Institute/NIH, has defi ned the concept that calcifi c 
AS is not a passive degenerative process but an active biology.16 In this respect, 
fi ve randomized controlled trials on AS progression were developed to determine 
whether statins could reduce AS progression in adult patients with AS.32,52-55 These 
Figure 3. AS progression in observational studies. AS  =  aortic valve stenosis, PAGt  =  Peak aortic 
gradient at time t, SE = standard error, t = time. Interrupted lines = individual study estimates, solid 
line = pooled estimate (reprinted with permission)28.
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statin trials provide invaluable information into future trial design and also the 
eff ects of statins on the progression of AS in vastly diff erent patient populations. 
The TASS trial, the SALTIRE trial, the large SEAS trial, and the ASTRONOMER trial 
included patients with mild to severe AS, a mean age varying from 54 to 70 years 
with predominantly male patients and show an annual decrease in aortic valve 
area ranging from 0.03 to 0.08 cm2/year, an annual increase in maximum aortic 
jet velocity of 0.15 to 0.20 m/s/year, an annual increase in peak aortic gradient of 
2 to 7 mmHg/year, and an annual increase in mean aortic gradient of 1 to 4 mmHg/
year and showed no signifi cantly reduction in AS progression in patients receiving 
lipid-lowering therapy, in this range of patient population.28,32,52-54 Figure 4 displays 
the echocardiographic AS progression from a systematic review and meta-analysis 
of these published randomized controlled statin trials between 2005 and 2010.28 
Again there is some variability in the echo results as shown in Figure 4, but not 
as signifi cant as the progression study analysis in Figure  2 and 3. Recently, the 
hypothesis of lipid-lowering therapy on AS progression was tested in a congenital 
AS patient population, entitled the PROCAS trial. This trial included 63 patients 
with an age range of 18 to 45 years and no decrease in AS progression in patients 
randomized to rosuvastatin 10 mg for the duration of the trial.55 The results of these 
randomized trials can be possibly attributed to trial design, timing of treatment, 
and level of LDL lowering. Earlier initiation of therapy may be the key to success 
in the future clinical trials to treat this disease. The only study to demonstrate the 
Figure 4. AS progression in randomized controlled trials. AS = aortic valve stenosis, PAGt = Peak 
aortic gradient at time t, SE = standard error, t = time. Interrupted lines = individual study estimates, 
solid line = pooled estimate (reprinted with permission)28.
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positive eff ects of a statin in the treatment of calcifi c aortic valve disease is the 
RAAVE trial, Rosuvastatin Aff ecting Aortic Valve Endothelium in aortic stenosis.56 
This open label hypothesis driven study demonstrating slowing of progression of 
AS using Rosuvastatin 10 mg a day by measuring aortic valve area, mean gradient, 
and peak jet velocity. The retrospective and prospective studies and animal models 
are providing the foundation for the treatment of this disease in the future.
Several observational studies suggest that in particular age, baseline severity of AS 
disease, and aortic valve morphology like calcifi cation and the presence of a bicus-
pid valve, may aff ect AS progression rate.8,33,45 The ASTRONOMER trial sub-study 
identifi ed aortic valve calcifi cation as an independent factor associated with a faster 
AS progression after correcting for age, baseline AS severity, and tricuspid aortic 
valve morphology.52 It represents more severe and aggressive disease in bicuspid 
patients as compared to tricuspid patients, and therefore alerts the physician to 
careful clinical decision making for patients with bicuspid aortic valve disease.
These studies illustrate a wide variation in the observed progression of AS over 
time. As compared to observational studies, randomized controlled trials show 
smaller AS progression estimates which may be explained by selection bias and 
diff erent echocardiographic methods employed to monitor AS disease. Our obser-
vations of AS progression are biased in many ways. Another recent report shows 
that the hemodynamic criteria for AS severity are applied inconsistently for grading 
AS, even in patients with normal left ventricular function.57 If AS severity is assessed 
using the aortic valve area method, more patients are classifi ed as having severe AS 
compared to AS assessment with the mean aortic pressure or maximum aortic jet 
velocity method. These observations call for a universal classifi cation of AS severity, 
in order to optimize uniformity in assessment of AS disease. This textbook of val-
vular medicine provides further understanding into establishing criteria to include 
these novel fi ndings and clinical risk factors for this disease process.
CONCLUSIONS
This chapter aimed to provide insight in the natural history of AS over time and 
the complex nature of AS disease, especially to identify factors associated with AS 
progression and clinical outcome of AS disease in the aging population. We are only 
starting to understand the mechanisms underlying AS disease, and its complexity. 
From basic science to applied clinical studies, there are so many aspects of AS 
disease, which are under intense investigation. For example, there is increasing 
evidence that genetics may play a role in bicuspid valve disease and the calcifi cation 
of the tricuspid aortic valve.16 Improved insights into genetic factors associated 
CHAPTER 2
44
with AS disease may help clinicians to better diagnose and treat our patients. On 
a more general note, the emerging knowledge of the mechanisms underlying AS 
disease may provide us with drugs that prevent, reverse or slow down AS disease. 
Also, the tremendous development of diff erent non-invasive imaging techniques 
will help clinicians better diagnose disease severity, provided that a universal clas-
sifi cation of AS severity is achieved. Biomarkers that are at the horizon may also 
help prognostication.
Using the information obtained from emerging knowledge, the next step is to in-
tegrate this knowledge into clinical decision tools that can provide evidence-based 
estimates of outcome for individual patients, allowing optimal individualized treat-
ment in the natural history of AS.
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ABSTRACT
Background and aim of the study
Published reports on the progression of aortic valve stenosis (AS) over time are 
usually small, with widely varying AS progression rate estimates. Reliable estimates 
of AS progression are important for surveillance scheduling and optimal timing of 
surgical or interventional treatment. This systematic review presents an overview of 
published evidence on AS progression over time in adult patients with AS.
Methods
A systematic review using PubMed and Embase was performed to assess AS 
progression over time in adult patients with AS measured by echocardiography. A 
total of 27 reports (15 prospective, 12 retrospective, total 4,921 patients, pooled age 
69 years) was included in which the baseline and progression rates of the hemo-
dynamic variables were pooled. Subgroup analyses were performed to investigate 
factors associated with AS progression and sources of heterogeneity.
Results
Pooled annual AS progression was 3.70 mmHg per year (SE = 0.10) for randomized 
controlled trials, and 6.03 mmHg per year (SE = 0.10) for observational studies. A 
large variability in observed AS progression was found between studies, as well as 
a wide variety of methods employed to measure AS.
Conclusion
The observed large individual variability in measuring AS progression among the 
selected studies calls for the implementation of a universal method of AS assess-
ment. This will facilitate an insight into the determinants of AS progression and 
allow for an evidence-based tailoring of treatment.
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PROGRESSION AS: SYSTEMATIC REVIEW
Aortic valve stenosis (AS) is a common disease among the elderly, with a preva-
lence of 1-3% among American adults aged ≥65 years.1-5 In the same age group, the 
prevalence of aortic valve sclerosis is 25-29%, with 16% of cases deteriorating to AS 
within seven years.2,3,6 Mortality for patients with severe symptomatic AS is 56-83% 
within fi ve to seven years after diagnosis.7
According to the present American College of Cardiology/American Heart As-
sociation (ACC/AHA) and European Society of Cardiology (ESC) guidelines, aortic 
valve replacement is indicated in symptomatic patients with severe AS, whereas 
the indication remains debatable in asymptomatic patients with severe AS.8,9 As-
ymptomatic patients with mild to severe AS are monitored over time.8,9 In the past, 
several small studies have been conducted to investigate AS progression and its 
potential determinants although, due to their small sample size, it is diffi  cult to 
draw general conclusions. Thus, a systematic review and meta-analysis of available 
echocardiographic information on AS progression would allow for an improved 
insight into AS progression and its potential determinants. This may ultimately 
provide important clues for treatment optimization.
The aim of the present systematic literature review was to provide an overview 
of the published evidence on the progression of AS in adult patients, as measured 
using echocardiography.
MATERIALS AND METHODS
Search strategy
A literature search using the PubMed and Embase databases, with the key words 
‘aortic stenosis’ and ‘progression’, and their synonyms, was performed on July 
20th, 2010. The search was limited to English-language publications, human adults 
aged ≥18 years, and published between January 1st, 1989 and July 20th, 2010. Any 
duplicates were fi ltered out. All titles and abstracts were screened for study design 
(prospective and retrospective observational studies or randomized controlled 
trials; RCTs) and study population (patients with AS with none or only mild aortic 
regurgitation, who were not initially selected for coronary artery bypass grafting; 
CABG). A second independent reviewer (M. van G.) assessed whether the inclu-
sions and exclusions had been performed correctly. In case of any disagreement, an 
agreement was negotiated. The references of selected reports were crosschecked 
for other relevant studies. Authors were contacted when a publication could not be 
obtained, or when not all required information could be retrieved from a publica-
tion.
CHAPTER 3
52
Data extraction
The selected reports were reviewed and the patient characteristics and outcome 
variables tabulated using MS Excel for Windows and Review manager (version 5.0; 
Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008). 
The following patient characteristics were registered: gender (male), age (years), 
peak aortic gradient (PAG; mmHg), mean aortic gradient (MAG; mmHg), aortic 
jet velocity (Vmax, m/s), aortic valve area (AVA, cm2), left ventricular ejection fraction 
(%), aortic valve calcifi cation, prevalence of coronary artery disease (CAD), current 
smoking, hypertension, hyperlipidemia, and diabetes. Typically, CAD was defi ned 
as prior percutaneous transluminal coronary angioplasty, CABG or (symptoms of) 
myocardial infarction, and obstruction of the coronary arteries (i.e. stenosis ≥70%). 
Hyperlipidemia was defi ned as (a history of) hypercholesterolemia or hyperlipidemia.
Hemodynamic echocardiographic variables were registered according to the 
ACC/AHA guidelines for the clinical application of echocardiography.10 Outcome 
variables included baseline AVA, PAG, Vmax, and MAG, annual decrease in AVA, and 
annual increase in PAG, Vmax, and MAG.
For studies that compared statin users with non-statin users, these two sub-
groups were considered as separate study populations because overall estimates 
of the total study population were unavailable.11-20
Statistical analysis
The initial AS, as measured by PAG, MAG, Vmax, and AVA, and AS progression 
rate were pooled using the inverse variance method. If only Vmax was reported, the 
simplifi ed Bernoulli equation was used to calculate the PAG (see Appendix I). The 
AS progression rates were assumed constant over time, and annual AS progres-
sion rates were calculated using the formula described in Appendix I. Studies were 
divided by study design, namely RCTs versus observational studies. Heterogeneity 
among the studies was explored by the Q and I2-statistic, and by funnel plots. A 
subgroup analysis was carried out among observational studies to study factors 
that were potentially associated with the progression rate of PAG, employing cut-off  
points for classical risk factors. In the subgroup analyses, the following subgroups 
were compared: studies with mean age ≥70 years versus <70 years, with a mean 
CAD prevalence of ≥50% versus <50%, with a mean hypertension prevalence of 
≥50% versus <50%, with a mean hyperlipidemia prevalence of ≥50% versus <50%, 
with a mean smoking prevalence of ≥25% versus <25%, with a mean diabetes 
prevalence of ≥20% versus <20%, and with a mean PAG ≥40 mmHg versus <40 
mmHg. Any missing values in the independent variables were excluded test-by-test. 
All statistical analyses were performed using Review manager 5.0 and SPPS 15.0 
(SPSS, Chicago, IL, USA).
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RESULTS
Search results
The search identifi ed a total of 1,332 publications (Fig. 1). In addition, 1,305 reports 
were excluded, including those in which no serial hemodynamic measurements 
were described (n = 364 studies), patients underwent (percutaneous) aortic valve 
replacement, (balloon) valvuloplasty or revascularization (elective or percutaneous 
cardiac intervention) during hemodynamic measurements (n = 232, 100, and 6, 
respectively), age <18 years (n  =  142), specifi c patient subgroups (n  =  93), case 
reports (n = 108), reviews, letters or editorials (n = 72), focus on biological features 
of AS (n = 46), patients with low-gradient AS, poor left ventricular function (left ven-
tricular ejection fraction ≤30%) or congestive heart failure (n = 42), patients with 
concomitant valve pathology or root dissection (n = 61), supravalvular or subval-
vular AS (n = 25), experimental studies (n = 8), or focus on aortic sclerosis (n = 6). 
Finally, 27 Doppler echocardiography reports were used for the review.11-37 From 
these studies, eight study populations were obtained from four RCT reports,15,16,19,20 
and 29 study populations from 23 observational study reports.11-14,17,18,21-37
Figure 1. Flowchart of the search.
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Study characteristics
The eight study populations derived from the four RCTs (see Table I) included a 
total of 2,344 patients with a mean age of 67 years at inclusion (range: 58 to 70 
years), and 62% of these patients (age range: 54 to 72 years) were male. The mean 
follow up period was 49 months; hence, the total follow up was 9,506 patient-years 
(pt-yr).
The 29 study populations derived from the 23 observational studies (see Table II) 
included a total of 2,577 patients with a mean age of 71 years at inclusion (range: 
58 to 78 years), and 83% of these patients (age range: 33 to 99 years) were male. The 
mean follow up time was 30 months, and the total follow up 6,399 pt-yr. In total, 
there were 15 prospective and 14 retrospective cohorts.
Study outcome
The echocardiographic hemodynamic variables of the RCTs and observational 
studies are shown in Tables I and II, respectively. Details of individual studies and 
pooled AS progression over time are shown in Figure 2a and b.
Heterogeneity, subgroup analyses, and publication bias
Heterogeneity and subgroup analyses
Signifi cant heterogeneity was observed for all hemodynamic outcomes (see Tables 
I and II). Subgroup analyses of the observational studies showed that studies with 
a mean patient age ≥70 years had a slower AS progression rate compared to those 
with a mean patient age <70 years (p <0.00001). Studies with a higher smoking 
prevalence had a faster AS progression rate compared to those with a lower smok-
ing prevalence (p <0.00001).
Studies with a higher CAD prevalence had a slower progression rate compared to 
those with a lower CAD prevalence (p <0.00001); the same eff ect was apparent for 
the variables hypertension and diabetes, in which the high prevalence groups had a 
slower progression rate (p <0.00001).
Studies with a higher mean baseline PAG showed a faster AS progression rate 
compared to those with a lower mean baseline PAG (p <0.00001).
Publication bias
The funnel plot for baseline PAG was asymmetric. Smaller studies showed higher 
estimates of baseline PAG compared to larger studies (Fig. 3a), while the funnel 
plot for progression rate showed outliers in both small and large studies (Fig. 3b). 
Age, smoking, CAD, hyperlipidemia, hypertension, diabetes, and baseline PAG 
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were each considered as potential determinants for the large variability of both 
funnel plots, though none was detected.
A
B
Figure 2a. Aortic valve stenosis (AS) progression in randomized controlled trials. b. AS progression 
in observational studies. PAG = peak aortic gradient at time t; SE = standard error; t = time. Dotted 
lines indicate individual study estimates; solid lines indicate pooled estimates.
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DISCUSSION
This review is the fi rst to compile, systematically and as a comprehensive overview, 
the available evidence published during the past two decades relating to AS pro-
gression in adults. Clearly, the main fi ndings were the wide variability in observed 
AS progression between studies, and the wide variety of methods used to measure 
AS. Furthermore, the review fi ndings have confi rmed that AS progression is faster 
in those patients who have more severe AS at baseline.
A
B
Figure 3a. Funnel plot of baseline peak aortic gradient (PAG, mmHg) in randomized controlled tri-
als and observational studies. b. Funnel plot of AS progression in randomized controlled trials and 
observational studies. SE = standard error. The funnel indicates 95% confi dence intervals.
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Patient factors associated with AS progression
Although heterogeneity was considerable in this meta-analysis and may potentially 
lead to inaccurate results, a thorough examination of possible sources of hetero-
geneity was pursued. Consequently, patient age, CAD, hypertension, diabetes, and 
smoking were found to be potentially associated with AS progression. Most of 
these patient factors are in some way inter-related, and it is beyond the scope of this 
review to attempt to disentangle their potential individual role in AS progression. 
However, these observations may form the basis for future studies that focus on 
dissecting the determinants of AS progression.
Older patient age, which is thought to be the most important risk factor for the 
prevalence of AS,3 was in the present subgroup analysis associated with a slower 
annual AS progression. Potential explanations for this may lie in age-dependent 
infl ammatory and atherosclerotic pathways underlying AS pathogenesis,38,39 or the 
fact that the elderly patients - who typically have multiple comorbidities - are moni-
tored more carefully or have a higher death rate, which may have infl uenced the 
serial AS measurements. Nevertheless, these are all highly speculative suggestions 
that are yet to be confi rmed.
In the present review, smoking was found to be associated with a faster annual 
AS progression. A potential explanation for this may be found in the Cardiovascu-
lar Health Study, which showed that in elderly patients smoking was associated 
with a 35% higher risk for degenerative aortic valve disease.3 However, in another 
case-matched study of patients with severe AS, smoking was found to be sig-
nifi cantly associated with the presence of CAD, but was not more prevalent among 
patients with severe AS when compared to a control population without AS.40 These 
confl icting results highlight the need for further exploration of the potential associa-
tion between smoking and the progression of AS.
AS measurement methods
The present review confi rmed the current use of several diff erent classifi cations 
of AS severity, with guidelines employing AVA, Vmax, and MAG for grading AS.9 
However, Minners and colleagues showed these criteria to be inconsistent, even in 
patients with a normal left ventricular systolic function.41 In the present review, PAG 
was used to measure AS progression because this was the method most often used 
in the studies. Nonetheless, a universal classifi cation of AS severity would greatly 
enhance the comparability of diff erent reports and allow an enhanced estimation 
of AS progression.
In addition, a wide range of tests was employed to estimate aortic valve calci-
fi cation, though without any reference test to quantify the extent of calcifi cation. 
Although determined in only a few of the studies reviewed, aortic valve calcifi cation 
61
PROGRESSION AS: SYSTEMATIC REVIEW
was identifi ed on several occasions as a strong predictor for AS severity and out-
come, and described a close association with AS severity.42-44 Unfortunately, pooling 
of the data from calcifi cation studies was not possible because of the varying as-
sessment methods employed.
Study design
The meta-analysis of RCTs demonstrated smaller AS progression estimates com-
pared to the observational studies. This may be explained by diff erences in patient 
selection and monitoring methods over time.
Study limitations
The main limitation was that most of the included studies were retrospective, het-
erogenic, non-randomized and small, with a limited follow up duration and without 
registration of drug therapy. In addition, compared to RCTs, observational studies 
are more prone to publication bias.45
The primary aim of this systematic review was to provide an overview of AS 
progression, and for the subsequent subgroup analyses to provoke discussion. 
However, spurious results may emerge from the meta-analysis of observational 
data and must therefore be reproduced to be convincing. The included patients 
underwent serial measurements, which are most likely more frequently performed 
in more severe cases of AS. Attention was not focused on concomitant cardiac 
(valve) diseases, and this may have infl uenced the results. The reasons for patient 
referral (CAD or AS) were not retrievable, and may have hampered any analysis of 
the association between CAD and AS. Finally, disease severity at baseline potentially 
introduces bias. Most variables employed in this systematic review were continu-
ous, for which diff erent methods of analysis and cut-off  points were used, leading 
to a potential bias of the results obtained.
In conclusion, the present systematic review was the fi rst to include all published 
echocardiography data on AS progression in adult patients with the condition. The 
results demonstrated a wide variability in observed AS progression which was, most 
likely, due to the heterogeneous nature of AS and the various methods used for its 
monitoring. Indeed, an optimal and uniform monitoring of AS severity is the key to 
a better understanding of AS progression in adult patients, and these issues should 
be addressed in future clinical practice guidelines for the diagnosis and management 
of patients with this condition. This will eventually allow for a better assessment of 
the potential determinants of AS, the development of clinical decision tools that can 
predict disease progression, potential measures to reduce AS progression, and will ul-
timately also assist in an evidence-based tailoring of treatment for individual patients.
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APPENDIX
Statistical formula used for the different calculations
Simplifi ed Bernoulli equation:
4*Vmax2
Progression rate peak aortic gradient (PAG):
Progression ratei = ( PAGfi nal – PAGbaseline )/follow-upi
The 95% confi dence intervals (CI) of the individual studies:
95% CI = pooled mean ± tα,df=n-1*standard error, with α = 0.05 (if n < 30 patients)
95% CI = pooled mean ± 1.96*standard error (if n ≥ 30 patients)
The 95% confi dence intervals (CI) of the pooled outcomes:
Pooled standard error = 1/√(∑weights)
95% CI = pooled mean ± 1.96*pooled standard error
Bescheidenheid is een vorm van intelligentie.
E.M. Beunder
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ABSTRACT
Aortic valve stenosis (AS) is increasingly observed in the clinic. Although at present 
surgical valve replacement is the gold standard in patients with severe symptom-
atic AS, elderly patients experience higher morbidity and mortality compared with 
younger patients. The emergence of transcatheter aortic valve implantation off ers 
an alternative for high-risk or inoperable patients. However, mortality and morbidity 
is high and long-term outcome, particularly with respect to device durability, are 
not yet available. The life expectancy of patients with severe symptomatic AS who 
are not operated upon is reduced. Most of the reported data, however, date back 
to the presurgical and precatheterization era. The aim of this article is to outline 
the evidence of natural history with medical treatment to assist in optimal clinical 
decision-making in the high-risk elderly population with severe symptomatic AS.
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After hypertension and coronary artery disease, aortic valve stenosis (AS) is the 
most frequent cardiovascular disease. AS is increasingly observed in octogenarians 
and even in nonagenarians. The prevalence of AS is currently reported to be 2.5% at 
the age of 75 years and almost 8% at 85 years.1
Angina pectoris, syncope and congestive heart failure are the classic manifesta-
tions of severe AS. However, severe asymptomatic AS may manifest clinically in 
earlier stages with more subtle symptoms, such as decrease in exercise tolerance, 
fatigue or exertional dyspnea. The onset of symptoms is a critical point for making 
treatment decisions. It has been reported that only 50% of patients who present 
with angina survive for 5 years or more, whereas the average survival is 3 years for 
patients who present with syncope and 2 years in patients with congestive heart 
failure.2
At present, surgical aortic valve replacement is the gold standard for treatment of 
severe symptomatic AS and numerous reports document the safety and effi  cacy of 
this approach even in elderly patients. However, elderly patients experience higher 
morbidity and mortality compared with younger patients, with mortality rates rang-
ing from 5.7% to 13% (Table 1).3-9 Although consensus exists regarding the utility of 
aortic valve replacement for severe symptomatic AS, the decision to off er surgery to 
the elderly high-risk population is much more complex. Some patients are physically 
unfi t for surgery, or surgery is denied because of a treatment preference of either the 
patient or the physician. Certain comorbid factors, such as preoperative cerebro-
vascular accident, respiratory insuffi  ciency, renal failure and reduced left ventricular 
function, are independent predictors of in-hospital mortality in octogenarians.3,5,6
At present, patients who are high-risk candidates for surgical valve replacement 
may be off ered transcatheter aortic valve implantation (TAVI). Although promis-
ing, periprocedural complications and mortality rate are signifi cant (Table 2). The 
Table 1. Outcome of surgical aortic valve replacement in octogenarians
Author No. of 
patients
Patient characteristics Mortality Morbidity 5-year survival
CVA MI Respiratory 
failure
Thourani (2008) [3] 88 ≥ 80 years (Isolated AVR) 5.7% 3% 0% - 61%
De Vincentiis (2008) [5] 345 ≥ 80 years (70% CABG) 7.5% - - 5% 61%
Filsoufi  (2008) [6] 231 ≥ 80 years (48% CABG) 5.2% 4% 1% 13% 66%
Melby (2007) [7] 245 ≥ 80 years (57% CABG) 9.0% 3% 1% 22% 56%
Kolh (2007) [8] 220 ≥ 80 years (26% CABG) 13.0% 2% 4% 21% 75%
Bose (2007) [4] 68 ≥ 80 years (46% CABG) 13.0% 3% - - 78% at 2 years
Chiappini (2004) [9] 115 ≥ 80 years (38% CABG) 8.5% 1% 4% 5% 69%
CVA = cerebrovascular accident, MI = myocardial infarction.
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Table 2. Studies of the natural history of symptomatic patients with severe aortic valve stenosis
Author, year Period of 
study
Design No. of 
patients
Age (years) Survival (years) Defi nition severe 
stenosis
Bergeron 
(1954) [10]
1943 - 1952 Retrospective
Autopsy
82 Mean: 69 Angina: 3 year 45%
 5 year 15%
Syncope: 3 year 45%
 5 year 25%
CHF: 3 year 35%
 5 year 10%
Aortic valve 
admitting at most 
the tip of a fi nger
Mitchell (1954) 
[11]
1913 - 1952 Retrospective
Autopsy/
Follow-up
122 Mean: 65 Angina: mean 4.1
Syncope: mean 3.0
CHF: mean 2.0
Clinical fi ndings 
or autopsy
Olesen (1958) 
[29]
1933 - 1949 Retrospective
Autopsy/
Follow-up
42 Mean: 53 Angina: mean 4.7
Syncope: mean 3.2
Clinical fi ndings 
or autopsy
Anderson 
(1961) [38]
- Retrospective
Autopsy
49 Mean: 63 Angina: mean 3.5
CHF: mean 2.2
Not described
Takeda (1963) 
[27]
1948 - 1959 Retrospective
Follow-up
60 Mean: 57 Overall: mean 6.1
Angina: mean 6.3
Syncope: mean 6.4
CHF: mean 3.6
Not described
Ross (1968) [2] Review 
1968
Retrospective
Autopsy
- Not described Angina: mean 5.0
Syncope: mean 3.0
CHF: mean 2.0
Not described
Frank (1973) 
[12]
1954 - … Retrospective
Follow-up
15 Range: 32 - 59 Overall: 3 year 64%
 5 year 48%
Aortic valve area 
index
≤ 0.7 cm²
or maximum peak 
gradient ≥ 50 
mmHg
Chizner (1980) 
[13]
1966 - 1971 Retrospective
Follow-up
23 Mean: 56 Overall: 3 year 43%
 5 year 36%
Aortic valve area 
≤ 1.1 cm² or 
maximum peak 
gradient ≥ 40 
mmHg
Schwarz (1982) 
[30]
1975 - 1980 Retrospective
Follow-up
19 Mean: 56 Overall: 3 year 21% Clinical fi ndings
and maximum 
peak gradient ≥ 45 
mmHg
O’Keefe (1987) 
[31]
1978 - 1985 Retrospective
Follow-up
50 Mean: 77 Overall: 1 year 57%
 2 year 37%
 3 year 25%
Clinical fi ndings
Horstkotte 
(1988) [16]
1968 - 1976 Retrospective
Follow-up
35 Not described Angina: mean 4.5
Syncope: mean 2.6
CHF: mean 1.0
Aortic valve area ≤ 
0.8 cm²
71
NATURAL HISTORY OF SEVERE SYMPTOMATIC AS
Table 2. Studies of the natural history of symptomatic patients with severe aortic valve stenosis 
(Cont.)
Iivanainen 
(1996) [17]
1990 - 1991 Retrospective
Follow-up
13 Range: 75 - 86 Overall: 4 year 24% Aortic valve area 
≤ 0.8 cm² and 
velocity ratio ≤ 
0.35 (ratio of the 
peak outfl ow tract 
velocity to the 
peak transvalvular 
velocity)
Bouma (1) 
(2004) [18]
1991 - 1994 Retrospective
Follow-up
157 Range: 70 - 93 Overall: 1 year 60%
 5 year 28%
Aortic valve area 
≤ 1.0 cm² or 
maximum peak 
gradient ≥ 50 
mmHg
Iung (2005) [23] 2001 Retrospective
Follow-up
72 Mean: 82 Overall: 1 year 85% Aortic valve area 
index
≤ 0.6 cm²/m²
or mean gradient
≥ 50 mmHg
Charlson (2006) 
[39]
1995 - 1997 Retrospective
Follow-up
75 Mean: 85 Overall: 1 year 55%
 3 year 23%
 5 year 15%
Aortic valve area 
≤ 0.8 cm² or mean 
gradient
≥ 50 mmHg
Varadarajan 
(2006) [19]
1993 - 2003 Retrospective
Follow-up
453 Mean: 75 Overall: 1 year 62%
 5 year 32%
 10 year 18%
Aortic valve area ≤ 
0.8 cm²
van Geldorp 
(2009) [20]
2004 - 2007 Retrospective
Follow-up
101 Mean: 73 Overall: 1 year: 77%
 2 year: 69%
Aortic valve area 
< 1.0 cm² or 
maximum aortic 
jet velocity > 4.0 
m/s
or peak aortic 
gradient
> 64 mmHg
or mean aortic 
gradient
> 40 mmHg
Bakaeen (2010) 
[40]
1997 - 2008 Retrospective
Follow-up
140 Mean: 76 Overall: 1 year 65%
 3 year 29%
 5 year 16%
Aortic valve area < 
1.0 cm²
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prognosis is infl uenced by increased age (patient’s life expectancy) and various 
comorbidities. In this setting, the cardiologist and surgeons have to balance the 
mortality and morbidity associated with surgery or TAVI against the expected 
duration and quality of life with medical treatment, as life expectancy of elderly 
people is short, regardless of whether or not the patient has severe symptomatic AS 
(Figure 1). The benefi t of surgery or alternative treatment methods such as TAVI is 
uncertain because the majority of information about the outcome of medical treat-
ment dates back to the presurgical and precatheterization era.2 Therefore, the aim 
of this article is to outline the evidence of natural history with medical treatment to 
assist in optimal clinical decision-making in the high-risk elderly population with 
severe symptomatic AS.
NATURAL HISTORY: THE EVIDENCE
The fi rst report presenting survival data of patients treated conservatively for severe 
symptomatic AS was published in 1954. Bergeron et al. described the natural history 
outcome of 82 patients, mean age 69 years, with severe symptomatic AS who had 
been followed up over an 11-year period.10 All patients were examined at necropsy 
0
1
2
3
4
5
6
7
8
9
10
80 81 82 83 84 85 86 87 88 89 90 91 92
Age
Ex
pe
ct
ed
 y
ea
rs
Men Women
Figure 1. Expected gender-specifi c survival for octogenarians.
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at which severe AS was described as “an aortic valve admitting at most the tip of a 
fi nger”. In their analysis, 3-year survival was 45% in patients presenting with angina, 
45% in patients with syncope and 35% in patients with congestive heart failure 
(Table 2). In line with these observations, the next important contribution to the 
understanding of the natural history of severe symptomatic AS was also in 1954 by 
Mitchell et al..11 Over a 39-year period, they investigated the natural history outcome 
in 122 patients with severe symptomatic AS. Aortic stenosis was proven at autopsy, 
or the diagnosis was made clinically and verifi ed by the demonstration of calcium 
in the region of the aortic valve by x-ray and fl uoroscopic study. Mean survival in 
patients presenting with angina, syncope and congestive heart failure was 4.1, 3.0 
and 2.0 years, respectively.
In 1968, still before the era of hemodynamic assessment of AS severity, Ross and 
Braunwald summarized data from seven postmortem studies on the natural history 
of severe symptomatic AS.2 Most of these studies were retrospective and published 
before 1955. Based on their analysis, they observed that the average life expectancy 
after the onset of angina pectoris, syncope and congestive heart failure was 5, 3 
and 2 years, respectively. Ever since, these data have become commonly used to 
describe the natural history of severe symptomatic AS.
In the decade after this report, two studies assessed the hemodynamic conse-
quence of valvular obstruction in severe symptomatic patients with AS.12,13 In a re-
port by Frank et al. comprising 15 patients, the 5- and 10-year survival rates were 48 
and 10%, respectively.12 Among the 23 patients reported by Chizner et al., 26% were 
deceased 1 year after the onset of symptoms and 64% by 5 years.13 Not surprisingly, 
a prospective study examining the natural history of severe symptomatic AS has 
not been conducted since the introduction of aortic valve replacement. Because of 
the limited number of patients who were not operated for severe symptomatic AS, 
some studies retrospectively identifi ed the natural history of patients who refused 
or were denied aortic valve replacement.12-17 The natural history of this small subset 
of highly selected patients probably does not represent the natural history of all 
patients with severe symptomatic AS.
In 2004, Bouma et al. reported on a cohort of 280 elderly patients with severe 
symptomatic AS of which 120 were operated upon and 160 were treated conser-
vatively.18 The overall 1-year survival of these 160 patients was 60% and the 5-year 
survival was 28%. They found no diff erence in survival among patients ≥80 years 
with severe symptomatic AS and without cardiac comorbidity. One of the most 
recent series was published by Varadarajan et al. in 2006.19 In this study, the authors 
screened their echocardiographic database over a 10-year period for patients with 
severe AS (Doppler estimated aortic valve area (AVA) of 0.8 cm² or less). Seven 
hundred and forty patients were identifi ed, of whom 453 had no aortic valve re-
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placement through follow-up. These patients had a 1-, 5- and 10-year survival of 62, 
32 and 18%, respectively. In a recent series, van Geldorp et al. also screened the 
Erasmus MC echocardiographic database over a 3.5-year period for patients with 
severe symptomatic AS.20 One hundred and seventy-seven patients were identifi ed, 
of whom 101 were treated conservatively. These patients had a 1- and 2-year survival 
of 77 and 69%, respectively.
The most recent series was published in 2010 by Rajani et al..21 The authors 
published a series of 85 patients who were screened for TAVI. Of these patients, 
38 received TAVI and 47 patients (55%) were managed medically as these patients 
were deemed not suitable for a TAVI procedure. Survival was better for the TAVI 
group compared with the medically managed group. However, as medically treated 
patients were deemed not suitable for TAVI, these results are biased owing to selec-
tion bias.
DISCUSSION
Successful cardiac surgical therapy in the octogenarians and nonagenarians is 
increasingly performed and the number of procedures will increase even further 
over the coming years as healthcare in general improves and the population ages. 
Despite the high risk, surgical valve replacement is still the gold standard in those 
patients who are medically fi t and have severe symptomatic AS. The decision to 
proceed with aortic valve replacement depends on many factors, including the 
patient’s wishes and expectations. However, some patients are at high-risk due to 
several reasons and some will refuse surgery, even with a clear understanding of 
the risks and benefi ts.
The development of TAVI off ers a viable option for patients at high surgical risk. 
Recent studies have highlighted the underuse of aortic valve replacement ranging 
from 30 to 60% of elderly patients with severe symptomatic AS.22,23 As a result of 
the emergence of TAVI, some high-risk patients are now being referred because the 
strategy of the cardiologists is changing. The feasibility and immediate effi  cacy of 
the percutaneous devices have been demonstrated, while its long-term outcomes, 
particularly with respect to device durability, remains to be proven. However, the 
rates of serious periprocedural complications and major adverse cardiac and cere-
brovascular events rates within 30 days are of concern and need further improve-
ment.24-26
The hand drawn survival fi gure, based on data from seven postmortem studies on 
natural history of AS, published by Ross and Braunwald in 1968 is still being used in 
current clinical practice as the accepted clinical view regarding the natural history 
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of severe symptomatic AS.2 However, the natural history studies described in this 
article have signifi cant limitations when extrapolating fi ndings to current clinical 
decision-making. Studies in which prognosis is based only on postmortem cases 
are biased, because prognosis will appear better if living patients with symptoms 
are also included. For example, Takeda et al. reported an average survival of 4.4, 
3.8 and 2.8 years after angina, syncope and congestive heart failure, respectively.27 
However, they excluded living patients in their calculation. If living patients were 
included, mean survival calculations would be 6.3, 6.4 and 3.6 years after angina, 
syncope and congestive heart failure, respectively.
A problem that has arisen in clinical practise is the defi nition of ‘severe’ AS. Over 
recent years, echocardiography has evolved to become the major tool for evaluating 
patients with valvular AS. At present, severe AS is defi ned by the American College 
of Cardiology/American Heart Association Practice Guidelines as an AVA less than 
1.0 cm², mean gradient greater than 40 mm Hg or jet velocity greater than 4.0 m/s.28 
In the past, the severity of AS was based on clinical examination.11,27,29-31 As cardiac 
catheterization evolved and provided an objective measurement of the severity of 
AS by means of the AVA, the criterion for severe AS was fi rst set as an AVA less than 
0.7 cm² .32 However, the precise hemodynamic criterion for ‘severe’ AS has varied in 
the past (Table 3). As a consequence, the validity (patient generalizability) of earlier 
studies must be questioned.
Table 3. Success and outcome of transcatheter aortic valve implantation
Author No. of 
patients
Approach Procedure 
success
30-day 
mortality
30-day 
MACCE
Edwards-Sapien valve
Cribier (2006) [24] 34 Antegrade 
Retrograde
74% 17% 26%
Webb (2006) [41] 18 Retrograde 78% 11% -
Webb (2007) [42] 50 Retrograde 86% 12% 16%
Global update: Eltchaninoff (2008) [43] >270 Retrograde 86% 12% -
Ye (2009) [25] 26 Transapical 100% 23% 31%
Thomas (SOURCE Registry) (2010) [44] 1038 Transfemoral
Transapical
94% 9% 30%
Walther (2007) [45] 59 Transapical 90% 14% -
Core valve
Grube (2006) [26] 25 Retrograde 84% 20% 32%
Grube (2007) [46] 86 Retrograde 88% 12% 22%
Global update: Grube (2008) [47] 175 Retrograde 92% 15% -
MACCE = major adverse cardiac and cerebrovascular events.
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Coronary angiography was not performed in most of the published series, al-
though the presence of coronary artery disease is clearly a major risk factor for 
mortality. In a study by Turina et. al., 50% of patients with severe symptomatic AS 
with additional coronary artery disease died within the fi rst year of follow-up, while 
only 16% of patients without coronary artery disease died.33 Therefore, survival and 
symptoms may even be improved if medically treated patients undergo percutane-
ous coronary intervention of signifi cant coronary lesions.
Furthermore, treatment decisions made in the past diff er greatly from those 
of today. For example, today an impaired left ventricular function would be an 
indication for operation,34 whereas in the past it would be considered a relative 
contraindication. In addition, the aetiology of AS and the characteristics of the 
patient population have changed markedly during the past decades, and it can be 
questioned whether the course of AS in middle-aged patients of the 1960s should 
guide the management of today’s octogenarians and nonagenarians with severe 
symptomatic AS.
Moreover, studies have involved few elderly patients and have reported on com-
bined end points (e.g., a combination of death and cardiac surgery), which makes 
their results diffi  cult to interpret.16,35,36
Important 1-year data of the randomized trial in the USA, PARTNER-US, in which 
TAVI is compared with standard therapy in a group of patients unsuitable for surgi-
cal aortic valve replacement have recently been published.37 At 1 year, the rate of 
death was 31% with TAVI, as compared with 50% with standard therapy (p<0.001). 
However, the incidence of major strokes at 30 days (5.0 vs. 1.1%; p=0.06) and major 
vascular complications (16.2 vs. 1.1%; p<0.001) was higher with TAVI as compared 
with standard therapy. These data must be interpret with caution as patients in the 
TAVI group compared with the standard therapy group had a signifi cantly lower 
incidence of prognostic factors which have an eff ect on outcome, such as a lower 
EuroSCORE, lower rate of chronic obstructive pulmonary disease and lower rate of 
atrial fi brillation. Moreover, only 12% of those patients considered not be suitable 
candidates for surgery were considered suitable for TAVI and underwent randomiza-
tion. An important issue in the future will be the cost-benefi t of TAVI versus medical 
therapy, since after 1 year 31% of the TAVI patients are death and 20% have severe 
symptoms (New York Heart Association Class 3 or 4), resulting in a 1-year asymp-
tomatic or mild symptomatic survival of only 50%. Nevertheless, recently Reynolds 
et al. showed that among selected inoperable patients with severe symptomastic 
AS, compared with standard therapy, TAVI resulted in signifi cant improvements in 
health-related quality of life.38
Management decision in elderly high-risk patients with severe symptomatic AS 
must be taken thoughtfully and should be made on an individual basis, taking into 
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account patients’ life expectancy and quality of life, patients’ wishes and cardiac 
and non-cardiac comorbid factors. Once coronary disease, other valvular heart 
disease, neurological defi cits, renal failure and other comorbidities are added to 
the clinical setting, outcome worsens and these factors must be taken into consid-
eration when deciding whether to correct AS in elderly patients. As life expectancy 
in the octogenarian is short and the main aim in the elderly is to improve quality 
of life rather than to increase the duration of life, surgeons and cardiologists have 
to question whether they do their patients a favour or a disservice with the chosen 
therapy. Based on the available data, TAVI promises signifi cantly improved 1-year 
survival when compared with medical management. Nevertheless, the technology 
of TAVI is still in its infancy and rigorous evaluation of transcatheter technology with 
adequate follow-up is needed. In addition, the natural history of medically managed 
patients with severe symptomatic AS in the modern era is still unclear, as most 
published data is outdated or biased. In this regard, much remains to be learned 
about the current natural history of severe symptomatic AS, especially in high-risk 
elderly patients.
FUTURE PERSPECTIVE
At present, surgical aortic valve replacement is still the gold standard for treatment 
of severe symptomatic AS. However, TAVI has been proven to be a feasible treat-
ment option to treat high-risk inoperable elderly patients with severe symptomatic 
AS. An assessment of the durability and long-term clinical safety and eff ectiveness 
of the bioprosthetic valves will require more prolonged follow-up of patients who 
participate in clinical trials of TAVI.
The key issue in the future is to adequately select those elderly patients who 
will benefi t from TAVI and select those who will benefi t from medical treatment. 
For example, treatment options could be diff erent in an 85-year-old patients with 
severe AS, mild angina and comorbidity (medical treatment could be a better op-
tion) compared with an 85-year-old patients with severe AS, congestive heart failure 
and no further comorbidity (TAVI could be a better option). Additional randomized 
trials on specifi c patient populations with certain symptoms and comorbidity is 
necessary to determine the best treatment option in those groups of patients. In 
addition, a clinical course of patients who are denied TAVI (which was 88% in the 
PARTNER-US trial) should be documented.
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EXECUTIVE SUMMARY
• Surgical aortic valve replacement is still the gold standard for treatment of 
severe symptomatic aortic valve stenosis.
• Patients who are inoperable of high-risk candidates may be off ered transcatheter 
aortic valve implantation.
• The feasibility and immediate effi  cacy of transcateheter aortic valve implantation 
has been demonstrated, while its long-term outcome, particularly with respect 
to device durability, remains to be proven.
• The majority of published series describing the natural history of severe 
symptomatic aortic valve stenosis are biased because most reported series are 
post-mortem studies and date back to the presurgical and precatheterization 
era, or are biased due to highly selected patient populations.
• The fi rst randomized trial (PARTNER-US) comparing transcatheter aortic valve 
implantation with medical therapy in a group of inoperable patients with severe 
symptomatic aortic valve stenosis clearly demonstrates an improved 1-year 
survival in the transcatheter group. However, data cannot be extrsapolated to all 
inoperable patients since the study population was higly selected (only 12% of 
inoperable patients were included in the study).
• The natural history of medically treated patients with severe symptomatic aortic 
valve stenosis in the modern era is still unclear. Additional randomized trials in 
specifi c patient populations with certain symptoms and comorbidity is neces-
sary. The clinical course of patients who are denied transcatheter aortic valve 
implantation should be documented.
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ABSTRACT
Background
To optimally exploit the potential added diagnostic and prognostic value of new left 
ventricular (LV) deformation parameters, better understanding of LV mechanics in 
aortic stenosis (AS) is warranted. We sought to determine a broad spectrum of LV 
rotation parameters in AS patients and age-matched healthy controls, in order to 
gain insight into the mechanical properties of the LV in AS.
Methods
The study comprised 48 AS patients with an aortic valve area <2.0 cm2 and LV ejec-
tion fraction >50%, and 24 healthy – for age and gender matched – control subjects.
LV peak systolic rotation (Rotmax), LV peak systolic twist (Twistmax), untwisting 
rate (mean diastolic untwisting velocity from Twistmax to mitral valve opening), peak 
diastolic untwisting velocity, and time-to-peak diastolic untwisting velocity were 
determined by speckle tracking echocardiography.
Results
AS patients had normal basal Rotmax and increased apical Rotmax, resulting in in-
creased Twistmax (13.4 ± 4.0° versus 11.4 ± 2.7°, P <0.05). Apical Rotmax and Twistmax 
correlated signifi cantly to echo-Doppler indicators of AS severity. Time-to-peak 
diastolic untwisting velocity was increased (20 ± 10 % versus 15 ± 9 %, P <0.05) 
and untwisting rate was decreased (-38 ± 21°/s versus -50 ± 28°/s, P <0.01) in AS 
patients.
Conclusions
Twistmax increases proportionally to the severity of AS, which might serve as a com-
pensatory mechanism to maintain systolic LV function. LV diastolic untwisting is 
delayed and the untwisting rate is reduced in AS.
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INTRODUCTION
The timing of aortic valve replacement in patients with severe aortic stenosis (AS) is 
based on symptoms and left ventricular (LV) ejection fraction.1 Newer LV deforma-
tion parameters, such as strain and rotation, may serve as better estimates of LV 
function.2 However, to optimally exploit the added value of these new parameters, 
better understanding of LV mechanics in AS is warranted. In previous tagged 
magnetic resonance imaging (MRI) studies changes in LV rotation parameters in 
AS patients have been described.3-6 However, these studies were limited by small 
numbers of patients3-6 and not for age matched control subjects.4-6 Since LV rota-
tion parameters are known to be infl uenced by age,7,8 this latter is a serious limita-
tion. Speckle tracking echocardiography (STE) is a new imaging modality that is 
able to assess LV rotation.9,10 The purpose of the current study was to determine 
a broad spectrum of LV rotation parameters in a large group of AS patients com-
pared to age-matched healthy controls, in order to gain insight into the mechanical 
properties of the LV in AS. In addition, LV rotation parameters were correlated to 
echocardiographic indicators of AS severity.
METHODS
Study participants
The study population consisted of 46 consecutive patients (mean age 65 ± 14 
years, 26 men) referred for echocardiography because of a murmur or follow-up 
of known AS, in sinus rhythm, with an aortic valve area <2.0 cm2, normal LV ejec-
tion fraction (>50%), and good echocardiographic image quality that allowed for 
complete segmental assessment of LV rotation at both the basal and apical LV 
level, and without moderate to severe mitral regurgitation. During the enrolment 
of these 46 patients, 26 other patients (36%) were excluded because of suboptimal 
echocardiographic image quality not fulfi lling this criterion or the presence of atrial 
fi brillation. Of the 46 included patients, 33 (72%) were symptomatic (dyspnoea in 
23 (50%), angina in 12 (26%), and collapse in 1 (2%)). Mild mitral regurgitation was 
present in 14 patients (30%). The AS patients were compared to 23 healthy – for 
age and gender matched – control subjects in sinus rhythm, without hypertension, 
diabetes, or regular use of medication for cardiovascular disease, and with normal 
left atrial dimensions, LV dimensions, LV ejection fraction and LV diastolic function 
for age (in elderly subjects >60 years an impaired relaxation pattern (grade 1 dia-
stolic dysfunction, defi ned as: E/A ratio <0.75 and E-wave velocity deceleration time 
>240 ms) was not considered abnormal). Control subjects were recruited from our 
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department (personnel) or were family members or friends. The study protocol 
conformed to the ethical guidelines of the 1975 Declaration of Helsinki as refl ected 
in a priori approval by the institution’s review board and all subjects gave informed 
consent.
Echocardiography
Two-dimensional grayscale harmonic images were obtained in the left lateral de-
cubitus position using a commercially available ultrasound system (iE33, Philips, 
Best, The Netherlands), equipped with a broadband (1-5 MHz) S5-1 transducer 
(frequency transmitted 1.7 MHz, received 3.4 MHz). All echocardiographic mea-
surements were averaged from three heartbeats. From the M-mode recordings 
the following data were acquired: left atrial size, LV end-diastolic anteroseptal and 
inferolateral wall thickness, and LV end-diastolic and end-systolic dimension. LV 
mass was assessed with the two-dimensional area–length method.11 LV ejection 
fraction was calculated from LV volumes by the modifi ed biplane Simpson rule in 
accordance with the guidelines.11 From the mitral-infl ow pattern, peak early (E) and 
late (A) fi lling velocities, E/A ratio, and E-velocity deceleration time were measured. 
Tissue Doppler was applied end-expiratory in the pulsed-wave Doppler mode at 
the level of the inferoseptal side of the mitral annulus from an apical 4-chamber 
view. To acquire the highest wall tissue velocities, the angle between the Doppler 
beam and the longitudinal motion of the investigated structure was adjusted to a 
minimal level. The spectral pulsed-wave Doppler velocity range was adjusted to 
obtain an appropriate scale. The timing of the beginning and ending of the iso-
volumic relaxation time were determined using pulsed wave Doppler. Aortic valve 
areas were calculated by the continuity equation and also indexed by body surface 
areas, calculated using the Mosteller formula.12 The severity of aortic and mitral 
regurgitation was determined according to the guidelines.13
To optimize STE, images were obtained at a frame rate of 60 to 80 frames/s. 
Parasternal short-axis images at the LV basal level (showing the tips of the mitral 
valve leafl ets) with the cross section as circular as possible were obtained from the 
standard parasternal position, defi ned as the long-axis position in which the LV 
and aorta were most in-line with the mitral valve tips in the middle of the sector. 
To obtain a short-axis image at the LV apical level (just proximal to the level with 
end-systolic LV luminal obliteration) the transducer was positioned 1 or 2 intercos-
tal spaces more caudal as previously described by us.14 From each short-axis image, 
three consecutive end-expiratory cardiac cycles were acquired and transferred to a 
QLAB workstation (Philips, Best, The Netherlands) for off -line analysis.
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Speckle tracking analysis
Analysis of the datasets was performed using QLAB Advanced Quantifi cation 
Software version 6.0 (Philips, Best, The Netherlands), which was recently vali-
dated against MRI for assessment of LV twist.10 To assess LV rotation, six tracking 
points were placed manually (after gain correction) on the mid-myocardium on 
an end-diastolic frame in each parasternal short-axis image. Tracking points were 
separated about 60° from each other and placed on 1 (30°, anteroseptal insertion 
into the LV of the right ventricle), 3 (90°), 5 (150°), 7 (210°), 9 (270°, inferoseptal 
insertion into the LV of the right ventricle), and 11 (330°) o’clock to fi t the total LV 
circumference (Figure 1).
Data were exported to a spreadsheet program (Excel, Microsoft Corporation, 
Redmond, WA) to determine LV peak systolic rotation during ejection (Rotmax), time 
to Rotmax (from R wave to Rotmax), instantaneous LV peak systolic twist (Twistmax, 
defi ned as the maximal value of instantaneous apical systolic rotation − basal 
systolic rotation), time to Twistmax (from R wave to Twistmax), and LV untwisting 
at 5%, 10%, 15%, and 50% of diastole. The degree of untwisting was expressed as 
a percentage of maximum systolic twist: untwisting = (Twistmax − Twistt)/ Twistmax 
x 100%, where Twistt is twist at time t. Furthermore, peak systolic rotation velocity 
a
b
Figure 1a. Positioning of the tracking points at the left ventricular apical level. b. Left ventricular rota-
tion–time curve (x-axis: time in ms; y-axis: left ventricular apical rotation in degrees). The grey line 
represents left ventricular apical rotation (peak systolic rotation 8.2°), and the white line recruitment, 
which was not activated in this example. The electrocardiogram is displayed at the bottom.
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and peak diastolic de-rotation velocity, peak systolic twist velocity and peak diastolic 
untwist velocity, and the timing of these parameters were assessed. Normalized 
velocities were determined by correcting for Rotmax or Twistmax. Finally, untwisting 
rate was defi ned as the mean diastolic untwisting velocity from peak systolic twist to 
mitral valve opening and calculated as: (twist at mitral valve opening − peak systolic 
twist) / time interval from peak systolic twist to mitral valve opening. To adjust for 
intra- and intersubject diff erences in heart rate, the time sequence of systolic and 
diastolic events was normalized to the percentage of systolic and diastolic duration, 
respectively. End-systole was defi ned as the point of aortic valve closure. In each 
study it was verifi ed that heart rate for the cardiac cycle in which the timing of aortic 
valve closure was assessed, was the same as the cardiac cycle used for analysis of 
LV rotation parameters.
Statistical Analysis
Matching of controls and AS patients was achieved by randomly matching each 
control with two AS patients with the same sex and age ± 5 years. Measurements 
are presented as mean ± SD. Variables were compared using Student’s t test, or 
Chi-square test when appropriate. Kolmogorov-Smirnov test with Lilliefors signifi -
cance correction was used for testing normality of distribution. The homogeneity of 
variance in the data for AS patients and control subjects was checked with Levene’s 
test. Relations between parameters were assessed using Pearson’s and Spearman’s 
test for parametric and nonparametric correlations. A P value <.05 was considered 
statistically signifi cant. Intraobserver and interobserver variability for LV twist in our 
center are 6% ± 6% and 9% ± 5%, respectively.15
RESULTS
Characteristics of the study population
In Table 1, the clinical and echocardiographic characteristics of the study population 
are shown. On average, AS was moderate-to-severe with a mean jet velocity of 3.9 
± 0.9 m/s, a mean gradient of 41 ± 20 mmHg, an aortic valve area of 1.0 ± 0.5 
cm2, and an aortic valve area indexed by body surface area of 0.45 ± 0.27 cm2/m2. 
Heart rate, left atrial size and LV mass were increased in AS patients as compared 
to control subjects. E-wave and A-wave velocities, the E-wave velocity deceleration 
time, and the E/Em ratio were increased in AS patients as well, whereas the E/A 
ratio was comparable.
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Systolic LV rotation parameters
AS patients had normal basal Rotmax, and increased apical Rotmax, resulting in in-
creased Twistmax (Figure 2). Apical peak systolic rotation velocity and peak systolic 
twist velocity were increased in AS patients, although these diff erences were lost 
when the velocities were normalized for apical Rotmax and Twistmax, respectively. The 
time-to-peak systolic twist velocity was decreased in AS patients (Table 2).
Diastolic LV rotation parameters
AS patients had decreased untwisting at 10% and 15% of diastole. Furthermore, AS 
patients had normal basal peak diastolic de-rotation velocity, and increased apical 
Table 1. Clinical and echocardiographic characteristics of the study population
Control subjects (n = 23) Aortic stenosis patients (n = 46) p-value
Clinical characteristics
Age, year 61 ± 7 65 ± 14 0.117
Male, n (%) 12 (54) 25 (54) 0.330
Heart rate, beats/minute 60 ± 11 67 ± 11 0.015
Hypertension, n (%) 0 9 (20) 0.054
Diabetes, n (%) 0 5 (11) 0.245
Coronary artery disease, n (%) 0 18 (39) 0.002
Echocardiographic characteristics
Left atrial size, cm 3.8 ± 0.5 4.4 ± 0.9 0.004
Left ventricular mass, g 162 ± 54 236 ± 112 0.004
Left ventricular ejection fraction, % 60 ± 8 56 ± 8 0.054
E, cm/s 60 ± 11 81 ± 30 0.002
A, cm/s 69 ± 17 89 ± 30 <0.001
E/A ratio 1.1 ± 0.3 1.0 ± 0.5 0.381
Deceleration time, ms 185 ± 29 239 ± 85 0.004
Em septal, cm/s 8.0 ± 1.9 5.3 ± 2.5 <0.001
E/Em ratio 8.4 ± 2.2 17.4 ± 9.4 <0.001
Aortic valve
Velocity, m/s 1.3 ± 0.3 3.9 ± 0.9 <0.001
Mean gradient, mmHg 4 ± 2 41 ± 20 <0.001
Valve area, cm2 3.0 ± 0.4 1.0 ± 0.5 <0.001
Valve area indexed by BSA, cm2/m2 1.60 ± 0.23 0.45 ± 0.27 <0.001
Regurgitation grade (1-4), mean 0.0 ± 0.0 1.1 ± 0.9 <0.001
E = peak early phase fi lling velocity, A = peak atrial phase fi lling velocity, Em = peak early diastolic wave velocity, BSA = body 
surface area. Values are means ± SD.
CHAPTER 6
102
peak diastolic de-rotation velocity, resulting in increased peak diastolic untwisting 
velocity. However, again these diff erences were lost when apical peak diastolic 
de-rotation velocity and peak diastolic untwisting velocity were normalized for api-
cal Rotmax and Twistmax, respectively. The time-to-peak apical diastolic de-rotation 
velocity and time-to-peak diastolic untwisting velocity were increased in AS patients. 
Untwisting rate was decreased in AS patients (Table 3).
Relations of LV rotation parameters to echocardiographic indicators of AS 
severity
Apical Rotmax and Twistmax correlated positively to aortic valve jet velocity (R2 = 0.22, 
and R2 = 0.21, respectively, both P = 0.006) and mean gradient (R2 = 0.19, and 
R2 = 0.20, respectively, both P = 0.005), negatively to aortic valve area (R2 = 0.30, 
and R2 = 0.27, respectively, both P <0.001), and aortic valve area indexed by body 
surface area (R2 = 0.34, and R2 = 0.30, respectively, both P <0.001) (Figure 3). To 
investigate the infl uence of the bimodally distributed patients group (relatively 
many patients had either severe or very mild AS) on these correlations, a separate 
analysis was performed in AS patients with an aortic valve area <1.5 cm2. In this 
subgroup, all relationships remained identifi able (apical Rotmax and Twistmax corre-
lated positively to aortic valve jet velocity (R2 = 0.14, P = 0.01 and R2 = 0.13, P = 0.02, 
respectively) and mean gradient (both R2  =  0.12, P  =  0.02), negatively to aortic 
valve area (R2 = 0.20, P = 0.006 and R2 = 0.17, P = 0.008), and aortic valve area 
indexed by body surface area (R2 = 0.20 and R2 = 0.19, both P = 0.006)). The only 
velocity parameter that was related to echocardiographic indicators of AS severity, 
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Figure 2. Peak systolic left ventricular rotation and twist.
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was the time-to-peak apical de-rotation velocity (positively to aortic valve jet velocity 
(R2 = 0.24, P = 0.008), and aortic valve mean gradient (R2 = 0.18, P = 0.02), and 
negatively to aortic valve area (R2 = 0.20, P = 0.007) and aortic valve area indexed 
by body surface area (R2 = 0.22, P = 0.009)). LV mass was not related to any of the 
LV rotation parameters.
Mutual relations of LV rotation parameters
Basal and apical Rotmax correlated positively to basal (R2 = 0.61, P <0.001) and api-
cal (R2 = 0.46, P <0.001) peak systolic rotation velocity, respectively, and to basal 
(R2 = 0.34, P = 0.003) and apical (R2 = 0.24, P <0.009) peak diastolic de-rotation 
velocity, respectively. Twistmax correlated positively to peak systolic twist velocity 
(R2 = 0.63, P <0.001) and peak diastolic untwisting velocity (R2 = 0.45, P <0.001).
Table 2. Systolic left ventricular rotation parameters in aortic stenosis patients and control subjects
Control subjects (n = 23) Aortic stenosis patients 
(n = 46)
p-value
Left ventricular basal level
Rotmax, degree -3.9 ± 1.6 -3.8 ± 2.3 0.852
Peak systolic rotation velocity, degree/sec -42 ± 10 -46 ± 15 0.252
Normalized peak systolic rotation velocity, 
sec-1
11.4 ± 2.4 10.7 ± 5.0 0.528
Time to Rotmax, % 94 ± 12 92 ± 12 0.516
Time-to-peak systolic rotation velocity, % 47 ± 10 46 ± 18 0.805
Left ventricular apical level
Rotmax, degree 7.5 ± 2.2 9.7 ± 2.5 <0.001
Peak systolic rotation velocity, degree/sec 52 ± 11 67 ± 18 <0.001
Normalized peak systolic rotation velocity, 
sec-1
7.9 ± 3.0 7.4 ± 3.2 0.535
Time to Rotmax, % 95 ± 5 95 ± 8 1.000
Time-to-peak systolic rotation velocity, % 51 ± 14 47 ± 18 0.354
Left ventricular twist
Twistmax, degree 11.4 ± 2.7 13.4 ± 4.0 0.034
Peak systolic twist velocity, degree/sec 69 ± 17 81 ± 22 0.025
Normalized peak systolic twist velocity, sec-1 6.4 ± 1.0 6.7 ± 1.7 0.438
Time to Twistmax, % 96 ± 5 97 ± 6 0.494
Time-to-peak systolic twist velocity, % 56 ± 11 45 ± 14 0.002
Normalized rotation and twist velocities adjusted for Rotmax and Twistmax, respectively. Time to peak as a percentage of 
duration of systole. Rotmax = left ventricular peak systolic rotation during ejection, Twistmax = instantaneous left ventricular peak 
systolic twist. Values are means ± SD.
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DISCUSSION
This study sought to assess a broad spectrum of LV rotation parameters in a large 
group of AS patients compared to age-matched healthy controls and to correlate 
these parameters to echocardiographic indicators of AS severity. The main fi ndings 
of this study are, 1) Twistmax is increased in AS, driven by increased apical Rotmax, 
2) this increased Twistmax may facilitate maintenance of peak diastolic untwisting 
velocity, although overall untwisting is delayed and untwisting rate is decreased, 
and 3) apical Rotmax and Twistmax are related to the severity of AS.
Systolic LV rotation in AS
LV twist is caused by the dynamic interaction between oppositely oriented subepi-
cardial and subendocardial myocardial fi bre helices and has an important role in LV 
ejection.16 The direction of LV twist is governed by the subepicardial fi bres, mainly 
owing to their longer arm of movement.17 Subendocardial ischemia has long been 
recognized as an early sign of myocardial suff ering from pressure overload caused 
by AS.18,19 Apical Rotmax and Twistmax were increased in AS patients, possibly because 
Table 3. Diastolic left ventricular rotation parameters in aortic stenosis patients and control subjects
Control subjects 
(n = 23)
Aortic stenosis patients 
(n = 46)
p-value
Left ventricular basal level
Peak diastolic de-rotation velocity, degree/sec 50 ± 13 56 ± 19 0.178
Normalized peak diastolic de-rotation velocity, sec-1 -12.6 ± 4.3 -12.5 ± 10.3 0.965
Time-to-peak diastolic de-rotation velocity, % 17 ± 11 23 ± 14 0.077
Left ventricular apical level
Peak diastolic de-rotation velocity, degree/sec -62 ± 23 -81 ± 26 0.004
Normalized peak diastolic de-rotation velocity, sec-1 -9.1 ± 3.6 -9.4 ± 5.2 0.805
Time-to-peak diastolic de-rotation velocity, % 11 ± 7 22 ± 13 <0.001
Left ventricular untwist
Untwisting at 5% of diastole, % 14 ± 6 12 ± 8 0.294
Untwisting at 10% of diastole, % 30 ± 13 22 ± 15 0.033
Untwisting at 15% of diastole, % 43 ± 17 32 ± 18 0.017
Untwisting at 50% of diastole, % 70 ± 10 68 ± 14 0.544
Peak diastolic untwisting velocity, degree/sec -89 ± 22 -103 ± 27 0.035
Normalized peak diastolic untwisting velocity, sec-1 -8.7 ± 2.4 -8.3 ± 2.9 0.570
Time-to-peak diastolic untwisting velocity, % 15 ± 9 20 ± 10 0.042
Untwisting rate, degree/sec -50 ± 27 -37 ± 21 0.031
Normalized de-rotation and untwist velocities adjusted for Rotmax and Twistmax, respectively. Time-to-peak as a percentage of 
the duration of diastole. Values are means ± SD.
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subendocardial ischemia diminishes the counteraction of the subendocardial 
myofi bres. Another potential mechanism may be LV hypertrophy with an increased 
arm of force over which the subepicardial fi bres work, although LV mass was not 
related to any of the LV rotation parameters in the current study. Nevertheless, 
both mechanisms may be expected to lead to increased basal Rotmax as well, sup-
ported by fi ndings in a previous study in which increased basal Rotmax was found in 
hypertrophic cardiomyopathy patients.20 The lack of increased basal Rotmax in the 
current study may be explained by stiff ening of the atrioventricular valvular plane 
that might prevent basal Rotmax to increase.
The current study is the fi rst to relate LV rotation parameters to echocardio-
graphic indicators of AS severity. Apical Rotmax and Twistmax correlated positively to 
aortic valve jet velocity and mean gradient, and negatively to aortic valve area and 
aortic valve area indexed by body surface area. This underlines the potential role of 
subendocardial ischemia as the cause of increased apical Rotmax and Twistmax in AS 
since the severity of subendocardial ischemia is known to be related to the severity 
of AS.21 We have previously shown that septal and lateral mitral annular velocities 
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Figure 3. Linear regressions between aortic valve area and aortic valve area indexed by body surface 
area and left ventricular peak systolic apical rotation and twist.
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are reduced in patients with severe AS and normal LV ejection fraction.22 Increased 
Twistmax may serve as a compensatory mechanism to balance loss of LV myocardial 
contraction in other directions due to subendocardial ischemia. LV apical rotation, 
and in particular changes within one patient, may therefore provide an easy as-
sessable marker of subendocardial ischemia. However, before large-scale clinical 
studies will be started, the relation between increased Twistmax and subendocardial 
ischemia should be investigated in more detail, perhaps by using more objective 
measures of subendocardial ischemia, such as provided by contrast perfusion 
echocardiography.
In previous tagged MRI studies increased Twistmax in AS patients has also been 
described.3-6 However, these studies were limited by small numbers of patients3-6 
and not for age-matched control subjects.4-6 It is well known that LV rotation pa-
rameters are infl uenced by age,7,8 so this latter is a serious limitation not present 
in our study. In other small tagged MRI studies, LV rotation parameters before and 
after aortic valve replacement were investigated.23,24 Sandstede et al.23 found that 
the compensating increased Twistmax in AS patients declined with increasing LV 
hypertrophy and dilatation, and that aortic valve replacement led to normalization 
of Twistmax. The former may be a surprising fi nding since increasing LV hypertrophy 
would be expected to be accompanied by increasing subendocardial ischemia and a 
larger diff erence in lever arms between the subendocardial and subepicardial fi bres, 
leading to a further increase in Twistmax. Sandstede et al. explained their fi nding 
by suggesting a reverse mechanism in which a smaller degree of compensating 
increased Twistmax might result in more LV hypertrophy and dilatation. Biederman 
et al.24 investigated the role of coronary artery disease and found that independent 
of the presence of concomitant coronary artery disease, Twistmax decreased after 
aortic valve replacement. Finally, Tzemos et al.25 studied women with congenital 
aortic stenosis and found that Twistmax was increased in this population as well. Fur-
thermore, during pregnancy, LV twist further increased in the antepartum period, 
except in those women who experienced functional deterioration requiring urgent 
aortic balloon valvuloplasty.
Diastolic LV rotation in AS
The LV myocardium adapts to increased pressure overload due to AS by hypertrophy 
of individual myocytes. In addition, this pathological hypertrophy is accompanied 
by interstitial and perivascular fi brosis, and thickening of the media of intramyo-
cardial coronary arteries.26 Each of these factors in turn contributes to diastolic 
dysfunction commonly seen in AS patients.27,28 In our study, LV untwist was delayed 
and the untwisting rate was reduced.
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Normally, over 40% of diastolic LV untwisting has been completed after the 
fi rst 15% of diastole, which contributes to the large pressure decrease during the 
isovolumic relaxation phase.29,30 This early, rapid LV untwisting process may be 
supported by active and passive mechanisms. There is a temporal dispersion in 
endocardial and epicardial repolarization, with in early diastole still depolarized 
endocardial fi bres (as opposite to the already repolarized epicardial fi bres) that may 
actively untwist the LV (normally the action of these fi bres are, as mentioned in the 
previous section, overruled by the epicardial fi bres). However, the eff ective force of 
contraction of myocardial fi bres is expected to be minimal during this part of the 
cardiac cycle. Nevertheless, dissimilarities of apparent stiff ness of the endocardium 
and epicardium caused by diff erences in breakdown of actin-myosin cross-bridges 
may be of infl uence. Furthermore, high levels of stored potential energy from the 
active systolic twist are transformed into kinetic energy, adding a passive component 
to rapid early diastolic untwisting.31 Subendocardial ischemia in AS patients may 
lead to loss of the active part of diastolic untwisting and the relaxation abnormality 
seen in AS patients may further compromise LV untwisting, evidenced by delayed 
and reduced early (and thus overall) LV untwisting. Surprisingly, peak diastolic un-
twisting velocity was higher in AS patients. This may be explained by the increased 
potential energy stored in the more twisted LV that will be released after all. This 
may lead to increased, but delayed, peak diastolic untwisting velocity, that may 
serve as a compensatory mechanism to help LV fi lling.
Conclusions
Twistmax is increased in AS patients, proportionally to the severity of LV outfl ow 
obstruction. This increased Twistmax might serve as a compensatory mechanism to 
maintain systolic function in the pressure overloaded LV. Conversely, LV untwist is 
delayed and the untwisting rate is reduced. However, the increase in Twistmax may 
cause an (although delayed) increase in peak diastolic untwisting velocity that may 
partially compensate for the decrease in untwisting rate.
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ABSTRACT
Objective
To prospectively evaluate the clinical course of patients with severe aortic stenosis 
(AS) and identify factors associated with treatment selection and patient outcome.
Methods
Patients diagnosed with severe AS in the Rotterdam area were included between 
June 2006 and May 2009. Patient characteristics, echocardiogram, brain natriuretic 
peptide (NT-proBNP), and treatment strategy were assessed at baseline, and after 
6, 12, and 24 months. Endpoints were aortic valve replacement (AVR) / transcath-
eter aortic valve implantation (TAVI) and death.
Results
The study population comprised 191 patients, 132 were symptomatic and 59 asymp-
tomatic at study entry. Two-year cumulative survival of symptomatic patients was 
89.8% (95% CI 79.8-95.0%) after AVR/TAVI and 72.6% (95% CI 59.7-82.0%) with 
conservative treatment. Two-year cumulative survival of asymptomatic patients was 
91.5% (95% CI 80.8-96.4%). Two-year cumulative incidence of AVR/TAVI was 55.9% 
(95% CI 47.5-63.5%) in symptomatic patients. Sixty-eight percent of asymptomatic 
patients developed symptoms, median time to symptoms was 13 months; AVR/
TAVI cumulative incidence was 38.3% (95% CI 23.1-53.3%). Elderly symptomatic 
patients with multiple comorbidities were more likely to receive conservative treat-
ment.
Conclusions
In contemporary Dutch practice many symptomatic patients do not receive invasive 
treatment of severe AS. Two-thirds of asymptomatic patients develop symptoms 
within 2 years, illustrating the progressive nature of severe AS. Treatment optimisa-
tion may be achieved through careful individualised assessment in a multidisci-
plinary setting.
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INTRODUCTION
The prevalence of calcifi ed aortic stenosis (AS) increases with the ageing of the 
population, and represents a growing health burden.1,2 According to the current Eu-
ropean Society of Cardiology and American College of Cardiology/American Heart 
Association guidelines, aortic valve replacement (AVR) is indicated in patients with 
severe symptomatic AS.3,4 Even elderly patients with multiple comorbidities are 
usually eligible for AVR, and if surgery is not an option, transcatheter aortic valve 
implantation (TAVI) is often feasible.5,6 Nevertheless, at least one third of patients 
with symptomatic AS do not undergo AVR although they have a clear indication.7-10 
Advanced age, poor left ventricular function, and comorbidities are common rea-
sons for non-referral for AVR.8,9,11-13
The aim of this study was to prospectively evaluate the clinical course of patients 
with severe AS in contemporary Dutch practice and identify factors associated with 
treatment selection and patient outcome. This information may facilitate treatment 
optimisation.
METHODS
Patient population
The Aortic Valve RIJNmond (AVARIJN) Study is a multicentre prospective cohort 
study of patients diagnosed with severe AS in seven Cardiology clinics in the wider 
Rijnmond area between June 2006 and May 2009. Patients 18 years and older were 
included if they met one of the following echocardiographic criteria: aortic valve 
area (AVA) ≤1 cm2, peak transaortic jet velocity (Vmax) ≥4 m/s, or aortic valve / 
left ventricular outfl ow tract velocity time integral ratio ≥4. The study protocol was 
approved by the medical ethics committee of Erasmus University Medical Center 
(MEC 2006-066); all patients provided written informed consent.
Patient characteristics, i.e. medical history, cardiovascular risk factors, symp-
tomatic status defi ned as presence of dyspnoea, angina, and/or syncope at study 
entry,3,4 echocardiographic data including Vmax, peak and mean aortic gradient, 
AVA, left ventricular ejection fraction, and low-fl ow/low-gradient AS (mean aortic 
gradient <30 mmHg and an AVA <1.0 cm2), brain natriuretic peptide (NT-proBNP), 
and treatment strategy (conservative or either AVR or TAVI) were assessed at base-
line, and after 6, 12, and 24 months. Expected operative risk was calculated using 
the logistic EuroSCORE and the Society of Thoracic Surgeons’ risk model (www.
euroscore.org; www.sts.org). Asymptomatic patients were invited for exercise test-
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ing at baseline; a positive exercise test outcome was defi ned according to the ACC/
AHA guidelines.14 Patients with a positive test stayed in the asymptomatic group.
Treatment strategies were retrieved from the patients’ medical charts. Study 
endpoints were AVR or TAVI and all-cause death, which were documented using 
the hospital information systems or information obtained through the treating 
physicians.
Statistical analysis
Continuous data are presented as mean (SD) or median (interquartile range) and 
for comparison between groups the unpaired t-test or Mann-Whitney U test was 
used. Categorical data are presented as counts and proportions, and comparison 
was done with the Chi-square test.
Kaplan-Meier analysis was used to assess patient survival and cumulative in-
cidence of AVR/TAVI. Patient follow-up started at enrolment and ended at time 
of death (event), completion of study, or when the patient was lost to follow-up 
(censoring).
Logistic regression was used to evaluate the association between baseline char-
acteristics and conservative treatment strategy. Cox proportional hazards analysis 
was used to analyse time-related events. Missing values were imputed by the mean. 
Univariable predictors with a p-value ≤ 0.05 were entered into the multivariable 
model using the enter method. In case of correlation between potential predictors, 
the potential predictor that was considered clinically most relevant was selected 
for the multivariable model. Age, male gender, smoking, hypertension, diabetes, 
dyslipidaemia, chronic obstructive pulmonary disease, carotid disease, stroke, 
peripheral arterial disease, previous myocardial infarction, coronary artery disease, 
renal failure, symptomatic status, body mass index, body surface area, systolic 
and diastolic blood pressure, NT-proBNP, Vmax, AVAi (indexed by body surface 
area), left ventricular ejection fraction, left ventricular hypertrophy (on electrocar-
diography), ischaemia (on electrocardiography), and aortic and mitral regurgita-
tion ≥grade II were considered as co-variables in the models (defi nitions in the 
Appendix). All statistical tests were two-sided and a p-value ≤0.05 was considered 
signifi cant. Statistical analyses were performed using SPSS for Windows, version 
15 (SPSS Inc, Chicago, Illinois) and GraphPad Prism 5 for Windows (GraphPad 
Software, San Diego, California).
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RESULTS
The study population consisted of 191 patients with severe AS, of whom 132 were 
symptomatic and 59 were asymptomatic at study entry (Table 1).
Forty-seven of the 59 patients who were asymptomatic underwent an exercise 
test at baseline. Of these 47 patients, 15 (32%) tested positive (ST depression ≥2 
mm (N=10), no increase blood pressure (N=2), collapse (N=1), angina (N=1), and 
Table 1. Patient characteristics at baseline diff erentiated by symptomatic status
All
N=191
Symptomatic
N=132
Asymptomatic
N=59
p-value
Age (yrs) 72.6 (63.7-78.6) 74.0 (64.4-79.2) 69.9 (61.6-76.4) 0.034
Male gender (%) 62 56 76 0.008
Previous valve surgery (%) 1 2 0 0.343
Previous CABG (%) 6 8 3 0.272
Smoking (%) 61 56 71 0.049
Hypertension (%) 52 54 49 0.554
Diabetes (%) 20 19 22 0.622
Dyslipidemia (%) 49 49 47 0.820
COPD (%) 17 20 10 0.083
PAD (%) 13 15 7 0.108
History of MI (%) 13 15 8 0.207
Stroke (%) 19 18 20 0.725
Vmax (m/s) 4.3 ± 0.8 4.3 ± 0.8 4.2 ± 0.7 0.693
AVA (cm2) 0.74 (0.59-0.91) 0.72 (0.54-0.85) 0.80 (0.63-0.96) 0.026
LVEF (%) 61 ± 7 61 ± 7 62 ± 6 0.129
Low fl ow/low gradient AS (%) 13 15 8 0.207
AR grade ≥ II (%) 17 18 14 0.494
MR grade ≥ II (%) 11 15 4 0.025
LVH (%) 27 28 24 0.445
NT-proBNP (pmol/l) 50 (22-153) 89 (29-180) 31 (13-74) <0.001
Logistic EuroSCORE (%) 5.4 (3.1-8.2) 6.2 (3.9-9.6) 4.0 (2.1-6.9) <0.001
STS score (%) 4.5 (2.8-7.6) 5.1 (3.3-8.0) 3.8 (2.0-6.0) 0.002
CABG = coronary artery bypass graft, COPD = chronic obstructive pulmonary disease, PAD = periph-
eral arterial disease, MI = myocardial infarction, Vmax = peak transaortic jet velocity, AVA = aortic 
valve area, LVEF = left ventricular ejection fraction, AS = aortic stenosis, AR = aortic regurgitation, 
MR = mitral regurgitation, LVH = left ventricular hypertrophy, NT-proBNP = N-terminal pro-brain na-
triuretic peptide, STS = Society of Thoracic Surgeons. Normal distributed variables: mean ± standard 
deviation; skewed distributed variables: median (interquartile range 25 and 75%).
CHAPTER 8
128
dyspnoea (N=2)), 25 (53%) patients tested negative, and in 7 (15%) patients the test 
was inconclusive. Twelve patients were unable to perform the exercise test due to 
impaired mobility, logistic reasons, or refusal.
Figure  1 displays the fl ow chart of patients during the study. Completeness of 
follow-up was 99%; 2 patients had emigrated.
Clinical course of symptomatic patients
Of the 132 symptomatic patients at baseline, 24 patients (18%) died during 
follow-up of whom 7 patients after AVR/TAVI due to: pneumonia (N=3), sudden 
unexpected unexplained death (N=1), subdural haematoma (N=1), mediastinitis 
(N=1), and unknown reason (N=1). Causes of death in the non-operated patients 
were congestive heart failure (N=11), sudden unexpected unexplained death (N=3), 
ruptured abdominal aortic aneurysm (N=1), pneumonia (N=1), and intestinal 
bleeding (N=1).
Sixty-four patients (48%) underwent AVR, 5 (4%) TAVI, and 63 (48%) were treated 
conservatively (Figure 1). Reasons for TAVI were informed patient preference in 1 
patient (age 53 years) and inoperability due to comorbidities in the other 4 patients 
(age >70 years).
Overall cumulative survival at 2 years was 81.7% (73.9-87.3%). For patients receiv-
ing AVR/TAVI, 2-year cumulative survival was 89.8% (95% CI 79.8-95.0%) and for 
patients who were treated conservatively 72.6% (95% CI 59.7-82.0%) (Figure 2). 
Older patient age (HR 1.05; 95% CI 1.001-1.101; p=0.046), previous myocardial 
Figure 1. Flowchart of patient distribution during the study.
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infarction (HR 2.75; 95% CI 1.14-6.60; p=0.024), and a higher baseline NT-proBNP 
(HR 1.002; 95% CI 1.001-1.003; p<0.001) were independently associated with 
increased mortality rates. Although in the univariable model AVR/TAVI was associ-
ated with decreased mortality rates (HR 0.30; 95% CI 0.13-0.67; p=0.004), in the 
multivariable model it was no longer a signifi cant factor (HR 0.69; 95% CI 0.27-1.75; 
p=0.430).
Figure 2. Patient survival for symptomatic patients diff erentiated by treatment strategy.
Figure 3. Cumulative incidence of AVR/TAVI diff erentiated by symptom status.
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Cumulative incidence of AVR/TAVI at 2 years was 55.9% (95% CI 47.5-63.5%) 
(Figure 3). Factors associated with a conservative treatment strategy are displayed 
in Table 2. Logistic EuroSCORE in symptomatic patients was 5.1% for those who 
underwent AVR/TAVI and 7.2% for symptomatic patients who were treated conser-
vatively (p<0.001). Low-fl ow/low-gradient AS was more common in symptomatic 
patients who were conservatively treated compared with those who underwent 
AVR/TAVI (22% versus 9%; p=0.013).
Clinical course of asymptomatic patients
Of the 59 asymptomatic patients at baseline, 5 patients died during follow-up. Three 
patients died after AVR due to congestive heart failure (N=2: 1 < 30 days postop-
erative) and malignancy (N=1). One patient died of a pulmonary embolism and 1 
patient died of unknown cause.
Forty patients (68%) became symptomatic, median time to symptom develop-
ment was 13 months (range 1-24 months); 19 underwent AVR. In addition, 3 asymp-
tomatic patients underwent AVR for rapidly progressing very severe AS (n=2) and 1 
for subvalvular AS with a gradient of 61 mmHg.
Overall cumulative survival at 2 years was 91.5% (80.8-96.4%). Of the 19 patients 
who became symptomatic and underwent AVR/TAVI, 2-year cumulative survival was 
89.5% (95% CI 64.1-97.3%). For the 21 patients who became symptomatic during 
follow-up but were treated conservatively, survival was 90.5% (95% CI 67.0-97.5%), 
for the 16 patients who remained asymptomatic and were treated conservatively 
100%, and for the 3 patients who remained asymptomatic but nevertheless under-
went AVR, survival was 66.7% (95% CI 5.4-94.5%).
Table 2. Logistic regression analysis for conservative treatment in symptomatic patients at baseline
Odds ratio
Univariable p-value* Multivariable p-value
Age (yrs) 1.09 (1.05-1.14) <0.001 1.10 (1.04-1.15) 0.001
PAD (%) 8.77 (2.42-31.25) 0.001 10.99 (2.32-52.63) 0.003
Vmax (m/s) 0.37 (0.22-0.63) <0.001 0.46 (0.25-0.85) 0.013
Previous MI (%) 5.95 (1.87-18.87) 0.003 5.26 (1.30-21.28) 0.020
Hypertension (%) 3.21 (1.56-6.58) 0.002 2.72 (1.11-6.67) 0.029
MR (%) 2.93 (1.04-8.26) 0.042 0.64 (0.17-2.34) 0.495
Low flow/low gradient AS (%)** 3.23 (1.15-9.01) 0.025
EuroSCORE (%)** 1.11 (1.04-1.19) 0.002
PAD = peripheral arterial disease, Vmax = peak transaortic jet velocity, MI = myocardial infarction, 
MR = mitral regurgitation, AS = aortic valve stenosis, () = 95% confi dence interval. Univariable p-val-
ues ≤ 0.05 were included in multivariable model. * Enter method. **Low fl ow/low gradient AS and 
EuroSCORE were highly correlated with ≥ 1 other co-variables and not entered in multivariable model.
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Symptom development rate was faster in patients with a higher Vmax at baseline 
(HR 2.06; 95% CI 1.29-3.27; p=0.002), those with CAD (HR 4.73; 95% CI 1.20-18.73; 
p=0.027), and prior myocardial infarction (HR 3.47; 95% CI 1.14-10.54; p=0.028).
Cumulative incidence of AVR/TAVI at 2 years was 38.3% (95% CI 23.1-53.3%) 
(Figure 3).
DISCUSSION
This study refl ects current clinical practice for adult patients with severe AS in sev-
eral ways. First, a signifi cant proportion of asymptomatic patients have a positive 
exercise test, underlining the importance of exercise testing in asymptomatic severe 
AS patients. Secondly, a considerable proportion of symptomatic patients do not 
undergo AVR/TAVI. In particular, elderly symptomatic patients with multiple comor-
bidities and a relatively low peak transaortic gradient are not likely to undergo AVR, 
and have a poor survival. Finally, the majority of asymptomatic patients become 
symptomatic over a 2-year period of time. This illustrates the progressive nature of 
severe AS and the need for careful and frequent ‘watchful waiting’ if a conservative 
strategy in the asymptomatic patients is pursued.
Challenges at diagnosis
A signifi cant proportion of asymptomatic patients have a positive exercise test.13,15 
The gradual decrease in physical functioning in the elderly can be attributed to 
advanced age, multiple comorbidities or to the worsening of AS, which might 
sometimes be diffi  cult to diff erentiate. If it is not clear whether a patient with severe 
AS is symptomatic, exercise testing and/or measuring BNP can play an important 
role.16 Unfortunately, the European Heart Survey shows that exercise testing is 
underutilised and the true number of symptomatic patients may be much higher 
than is currently observed.17
Symptomatic patients
This study shows that symptomatic patients are usually older, more often female, 
and have more severe AS, more often concomitant mitral regurgitation, a higher 
NT-proBNP, and higher surgical risk scores compared with asymptomatic patients. 
Almost half of the symptomatic patients at study entry, as well as half of the asymp-
tomatic patients who develop symptoms, are treated conservatively. Confi rming 
previous reports, in particular older patients with a lower Vmax and multiple comor-
bidities are more likely to be treated conservatively.8,12,13 Low-fl ow/low-gradient AS 
may possibly explain the association between lower Vmax and conservative treat-
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ment.18 Although a higher EuroSCORE is associated with conservative treatment, 
the average EuroSCORE of conservatively treated patients in our study was only 
7.2%. However, EuroSCORE and other operative risk stratifi cation models do not 
consider patient factors related to ageing, such as frailty, which become increasingly 
important in determining short- and long-term outcome with advancing age.19,20 In 
this respect, there is a need for risk stratifi cation models that better fi t this elderly 
population.
We previously showed that important reasons for conservative treatment of 
symptomatic AS patients include misclassifi cation of AS severity and symptoms, 
overestimation of operative risk, and patient preferences.13 Given the survival benefi t 
of TAVI for inoperable patients,10 patients with severe symptomatic AS should be 
referred for multidisciplinary heart team discussion to assess individual feasibility 
of invasive treatment approaches.21
Although survival appears better in symptomatic patients who undergo AVR/TAVI 
versus those treated conservatively, this survival benefi t disappears when corrected 
for patient age, NT-proBNP, and previous myocardial infarction. This suggests that 
patient survival is mainly driven by patient characteristics and to a lesser extent 
by treatment strategy. Our fi nding that NT-proBNP is associated with increased 
mortality confi rms a previous report.22 Although treatment strategy may not aff ect 
survival, it does infl uence quality of life23.In elderly patients with severe AS, quality 
of life should play a key role in optimising treatment strategies. With the steadily 
increasing application of TAVI it is expected that more elderly symptomatic AS 
patients will receive invasive treatment, and hopefully an improved quality of life.
Asymptomatic patients
Asymptomatic severe AS has a progressive course, evidenced by the fact that no less 
than two-thirds of asymptomatic patients in our study became symptomatic within 
2 years. This is higher compared with a previous report in which only one third 
became symptomatic and may be explained by the higher prevalence of classical 
risk factors, more left ventricular hypertrophy, and smaller aortic valve areas in our 
study patients.24 AS severity was predictive of symptom development in our study, 
and underlines the importance of frequent monitoring of asymptomatic patients 
with more severe AS. Of all asymptomatic patients who became symptomatic, 
less than half undergo invasive treatment, while there are also a few patients who 
remain asymptomatic, but actually receive AVR. This illustrates the ongoing debate 
on the timing of AVR in asymptomatic patients with very severe AS.
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Limitations
Some elderly patients refused participation which has undoubtedly resulted in a 
selection bias toward younger patients with milder symptoms and less comorbidity. 
The 15 patients who tested positive during exercise testing remained assigned to 
the asymptomatic group during data analysis. Exercise test results were sent to the 
treating cardiologists and may have infl uenced treatment strategy.
CONCLUSIONS
In contemporary practice in the Rotterdam Rijnmond area nearly half of the patients 
with symptomatic severe AS, in particular elderly patients with multiple comorbidi-
ties, do not undergo invasive treatment. In addition, our observation that more that 
two-thirds of asymptomatic patients develop symptoms during a two-year period 
underlines the progressive nature of severe AS and the need for stringent and 
frequent watchful waiting.
A systematic evidence-based multidisciplinary team approach is recommended 
to optimise treatment selection for symptomatic patients with severe AS. There 
is an urgent need to optimise patient treatment strategy by taking into account 
clinical factors related to AS and comorbidities, costs and benefi ts of treatment 
strategies, patient preferences, quality of life, and anticipated life expectancy.
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APPENDIX
Definitions
• Body surface area: calculated with DuBois and DuBois formula.
• Carotid disease: stenosis >50%, or previous or planned surgery.
• Chronic obstructive pulmonary disease: diagnosis previously made by physician, 
or receiving bronchodilators.
• Congestive heart failure: hospital stay with clinical sign(s) of congestive heart 
failure.
• Coronary artery disease: >50% stenosis in at least one coronary artery proved by 
coronary angiography, or previously coronary artery bypass grafting.
• Diabetes: diagnosis previously made by physician, or receiving blood glucose 
lowering medication.
• Dyslipidemia: diagnosis previously made by physician, or receiving lipid lowering 
medication.
• Hypertension: diagnosis previously made by physician, or known blood pressure 
of ≥ 140 mmHg systolic or ≥ 90 mmHg diastolic on at least two measurements, 
or receiving blood pressure lowering medication.
• Ischemia: ST-depression ≥ 1 mm at J+60 ms in at least two electrocardiographic 
leads.
• Left ventricular hypertrophy: S in V1 plus R in V5/V6 > 35 mm, R in V6 > R in V5, R 
in I and/or aVL > 12 mm on electrocardiography at J+60 ms.
• Myocardial infarction: diagnosis previously made by physician.
• Peripheral arterial disease: claudication, or previous or planned surgery of the 
lower limbs.
• Renal failure: diagnosis previously made by physician or creatinin ≥ 200 μmol/L.
• Smoking: smoking cigarette or cigar during ≥ 5 years in the past.
• Stroke: diagnosis ‘transient ischemic attack’ or ‘cerebrovascular accident’ previ-
ously made by physician, or neurological disease severely aff ecting ambulation 
or day-to-day functioning.
Let’s go!
Y.A. Gagarin
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ABSTRACT
Background
The disease burden of patients with severe aortic stenosis is not often explored, 
while the incidence is increasing and many patients who have an indication for 
aortic valve replacement are not referred for surgery. We studied the quality of life of 
191 patients with severe aortic stenosis, hypothesising that symptomatic patients 
have a far worse quality of life than the general population, which could enforce the 
indication for surgery.
Methods
The SF-36v2 Health Survey was completed by 191 consecutive patients with symp-
tomatic or asymptomatic severe aortic stenosis.
Results
Asymptomatic patients (n = 59) had health scores comparable with the general 
Dutch population but symptomatic patients (n = 132) scored signifi cantly lower 
across diff erent age categories. Physical functioning, general health and vitality 
were impaired, as well as social functioning and emotional well-being. There was 
no relation between degree of stenosis and physical or mental health scores.
Conclusions
Both physical and emotional problems have a major impact on normal daily life and 
social functioning of symptomatic patients with severe aortic stenosis, regardless 
of age. If the aortic stenosis is above the ‘severe’ threshold, the degree of stenosis 
does not predict disease burden. These results encourage to reconsider a conser-
vative approach in symptomatic patients with severe aortic stenosis. Using the 
SF-36v2 Health Survey together with this study, an individual patient’s quality of life 
profi le can be assessed and compared with the patient group or with the general 
population. This can assist in decision making for the individual patient.
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INTRODUCTION
Degenerative aortic stenosis is the most common valvular heart disease in devel-
oped countries and represents a growing health problem. Medical therapy does not 
slow the progression of severe aortic stenosis nor has it proven to reduce major 
adverse cardiac events, the only eff ective treatment is replacement of the aortic 
valve.1-3 Surgical techniques and postoperative care have improved over the years 
and even patients with advanced age and comorbidities can be operated relatively 
safely.4,5 Recently, the indications of transcatheter valve implantations have been 
evaluated, which now form a treatment option in patients with high operative risk.6,7
The guidelines of both the American Heart Association / American College of 
Cardiology and the European Society of Cardiology on the management of patients 
with valvular heart disease, recommend prompt aortic valve replacement (AVR) 
once symptoms occur in patients with severe aortic stenosis.6,8,9 Nonetheless, 
several studies show that for various reasons many patients who have an indication 
for aortic valve replacement are denied surgery.10-13
Although some literature is available on the functional status and quality of life 
(QoL) of (elderly) patients after AVR, more high-quality studies are needed.14,15 Even 
less is known about the QoL of patients in whom the decision to operate is yet 
to be considered. Classical symptoms of aortic stenosis are dyspnea, angina and 
syncope, and although the severity of symptoms can be used as a rough surrogate 
for the QoL, the impact of symptoms on daily life and the resulting disease burden 
remain unknown. The New York Heart Association (NYHA) classifi cation is a func-
tional measurement of physical performance or pain. It does not take social and 
emotional aspects into account and only roughly refl ects one’s current health status 
but certainly not one’s desired health status or disease burden. Furthermore, physi-
cians sometimes fail to recognize the functional disability of their patients.16 An 
underestimation by the treating physician of the impact of symptoms on a patient’s 
QoL might be one of the reasons why so many symptomatic patients with severe 
aortic stenosis are not referred for surgery. If these patients indeed present with a 
low QoL and better evidence about this burden of disease could be presented, there 
would be an additional argument to follow the clinical guidelines more strictly.
This paper presents the results of the Short Form-36v2™ Health Survey 
(SF-36v2™) in patients with severe aortic stenosis compared with the general popu-
lation in order to investigate if, and to what extent, patients experience impairment 
of their daily life. We hypothesized that in symptomatic patients QoL is far worse 
than in the general population, both in younger and elderly patients, which could 
enforce the indication for surgery. Further we hypothesized that echocardiographic 
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parameters are not good indicators of disease burden, at least not in our patient 
group in whom the degree of stenosis is severe.
METHODS
Patients
This study is part of a recently published multicentre prospective cohort study 
among patients with severe aortic stenosis in the Rotterdam area (the Netherlands) 
between July 2006 and April 2009.17 In short, patients with severe aortic stenosis 
were recruited from the echocardiography laboratories of the outpatient clinics of 
seven local hospitals and all consecutive patients who provided written informed 
consent were included, regardless of whether they were referred for surgery or 
not. The study protocol was approved by the institutional ethical committee (MEC 
2006-066).
Methods
Patients were invited for a personal assessment by the principal investigators (MvG, 
HH). This assessment included an echocardiogram according to a specifi c study 
protocol focused on the aortic valve, recording of patient characteristics, NYHA 
class, medication and a calculation of anticipated operative mortality -for descrip-
tive purposes only- using both the EuroSCORE model and the STS risk model (www.
euroscore.org, www.sts.org). While establishing NYHA class, the investigators were 
blinded for the results of the health survey.
The QoL assessment was made by means of the SF-36v2™ Health Survey ac-
cording to the instructions given by Ware et al. regarding data collection, scoring, 
interpretation and validation.18 To allow for comparison of burden between the study 
patients and the general population we used the paper presented by Aaronson et 
al. in 1998.19 They took a sample of the general Dutch population, subdivided in 
diff erent age-categories and generated normative SF-36® Health Survey data for 
use in the Netherlands. Our study population was therefore subdivided in the same 
age categories.
The SF-36v2™ Health Survey is an evolution of the SF-36® Health Survey and 
consists of 36 scale-rated health-related questions, grouped into eight multi-item 
domains which are not disease-specifi c and which measure functioning in diff er-
ent aspects of daily life: ‘Physical Functioning’, physical health related to age- and 
role-specifi c activities termed ’Role-Physical’, ‘Bodily Pain’, ‘General Health’, ‘Vital-
ity’, ‘Social Functioning’, personal feelings of performance in age- and role-specifi c 
activities termed ’Role-Emotional’, and ‘Mental Health’. The eight domains form 
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two main components: the ‘Physical-’ and ‘Mental Component Summary’. The raw 
SF-36 scores given by Aaronson et al. are converted into a norm-based score from 
0 to 100 in which 50 represents the mean score of the general population and 10 
points on the scale correspond to 1 standard deviation (SD).19
Table 1. Patient characteristics
Patient characteristics Total patient group Symptomatic patients
N=191 N=132
Age (median, interquartile range, in years) 72.6 (63.7-78.6) 74.0 (64.4-79.2)
Age category
≤40 4 (2%) 3 (2%)
41-60 28 (15%) 18 (14%)
61-70 44 (23%) 25 (19%)
>70 115 (60%) 86 (65%)
Male sex 119 (62%) 75 (57%)
NYHA class
I 59 (31%) Not applicable
II 73 (38%) 73 (55%)
III 49 (26%) 49 (37%)
IV 10 (5%) 10 (8%)
Sort of symptom (%)
Only dyspnea 46.2
Only angina 4.5
Only syncope 3.8
Combination 45.5
Cardiovascular history (%)
Diabetes Mellitus 20 19
Hypertension 52 54
Dyslipidaemia 49 49
Chronic obstructive pulmonary disease 17 20
Renal failure 7 9
Peripheral vascular disease 13 15
Cerebro vascular accident (residual neurological defi cit) 19 18
Previous coronary artery bypass grafting 6 8
Logistic EuroSCORE (median, interquartile range) 5.4 (3.1-8.2) 6.2 (3.9-9.6)
STS score (median, interquartile range) 4.5 (2.8-7.6) 5.1 (3.3-8.0)
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Statistical analyses
For the statistical analyses SPSS 13.0.1 software was used (SPSS Inc. 2001). Con-
tinuous variables are displayed as means ± SD if normally distributed, skewed 
distributed variables as median with interquartile range. Categorical variables are 
displayed as proportions. One-sided Student’s T tests were used for comparisons 
of health scores of patient groups to the general population. A p-value below 0.05 
was considered signifi cant.
RESULTS
We identifi ed 459 patients with severe aortic stenosis; 268 of these patients (mean 
age 76±14 years) declined participation (n=185), had an operation scheduled (n=65) 
or died (n=18) before they could participate in the study. Reasons to refuse partici-
pation were most often high age and severe disability resulting in personal logistic 
problems or perceived high burden (data not shown). A total of 191 patients (mean 
age 70.6 years) agreed to participate. Table 1 shows their characteristics.
Figures 1a, b and c display the results for the symptomatic patients versus the 
general Dutch population in three age groups. In each age category almost all health 
domains were scored signifi cantly lower than the general Dutch population except 
‘Bodily Pain’. More importantly, in most health domains the diff erences compared 
to the general population were considerable. Table 2 gives the exact norm-based 
scores and standard deviations of each group compared with the general Dutch 
population.
Figure 2 shows that QoL outcomes in all domains are related to the NYHA clas-
sifi cation. Asymptomatic patients showed a trend towards high scores in most 
domains compared to the general population, certainly given the higher mean age 
of the patients (71 versus 47 yrs). Patients in NYHA class II had lower scores on the 
‘Physical Function’, ‘Role Physical’, ‘General Health’ and ‘Role Emotional’ scales. 
Patients in NYHA class III and IV had lower scores on all scales, and the diff erences 
compared with the general population were large.
Echocardiographic measurements indicating stenosis severity were not related to 
either physical or mental health scores (data not shown).
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Figure 1a. Quality of life of symptomatic patients with severe aortic stenosis (AS) aged 41-60 years 
(n=18) versus the general Dutch population aged 41-60 years. * p<0.05
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General Dutch populaƟon 61-70 yrs 44,1 53,2 44,4 45,9 47,9 44,8 53,2 49,3 49,9 51,1
SymptomaƟc paƟents 61-70 yrs (n=25) 36,2 47,8 34,8 34,3 46,7 36,0 47,0 41,6 36,1 46,6
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Figure 1b. Quality of life of symptomatic patients with severe aortic stenosis (AS) aged 61-70 years 
(n=25) versus the general Dutch population aged 61-70 years. * p<0.05
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Table 2. Norm-based scores of symptomatic patients with severe aortic stenosis and the general 
Dutch population
Health Domain Norm-Based Score
Symptomatic patients with severe aortic 
stenosis
Norm-Based Score
General Dutch population *
41-60 yrs
n=18
61-70 yrs
n=25
>70 yrs
n=86
41-60 yrs 61-70 yrs >70 yrs
Physical Component Summary 41.2 ± 9.9 36.2 ± 9.7 36.5 ± 9.8 48.4 44.1 40.7
Mental Component Summary 48.5 ± 9.9 47.8 ± 10.2 47.3 ± 12.7 51.6 53.2 51.6
Physical Function 41.1 ± 10.1 34.8 ± 10.1 34.6 ± 11.6 49.8 44.4 38.8
Role Physical 40.7 ± 10.5 34.3 ± 10.9 34.2 ± 11.1 48.0 45.9 42.8
Bodily Pain 48.1 ± 10.8 46.7 ± 12.3 45.4 ± 12.3 48.4 47.9 46.9
General Health 40.1 ± 8.1 36.0 ± 8.6 37.9 ± 9.0 48.8 44.8 43.4
Vitality 47.9 ± 10.2 47.0 ± 9.7 45.9 ± 12.1 53.6 53.2 50.4
Social Function 43.5 ± 10.6 41.6 ± 12.1 42.9 ± 13.7 50.0 49.3 46.4
Role Emotional 44.0 ± 13.9 36.1 ± 15.0 35.9 ± 15.3 50.1 49.9 47.9
Mental Health 46.7 ± 9.8 46.6 ± 11.1 45.2 ± 14.4 50.4 51.1 49.0
* Norm-Based Score calculated based on the paper by Aaronson et al [19].
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Figure 1c. Quality of life of symptomatic patients with severe aortic stenosis (AS) aged >70 years 
(n=86) versus the general Dutch population aged >70 years.* p<0.05
147
QUALITY OF LIFE OF SEVERE AS
DISCUSSION
Interpretation and discussion of main results
Quality of life decreases with increasing age both in the general population and 
in the symptomatic severe AS patients (Figures 1a, b and c). However, the key 
point is that the diff erences between the general population and the symptomatic 
patients are large and remain signifi cant for most health domains across all three 
age groups we studied.
While angina is one of the classical symptoms of aortic stenosis, it is notable 
that ‘Bodily Pain’ was scored almost normal, suggesting that pain itself only plays 
a modest role. The low scores on the ‘Role Physical’ domain indicate that patients 
do have severe physical constraints by dyspnea or fatigue.
Not only the physical domains but also the mental health scores show large dif-
ferences compared with normal. Figure 1b and 1c show that among patients aged 
over 60 years, the largest diff erence with the general population is observed in the 
‘Role Emotional’ scale, meaning patients suff er from anxiety or a depressed state 
of mind aff ecting daily activities. Also the ‘Social Function’, ‘Vitality’ and ‘General 
Health’ scores indicate patients lack energy and have a negative view on their health, 
hampering social contact.
There was no relation between stenosis severity and physical or mental QoL in our 
patient cohort. Thus, whenever the aortic stenosis is above the ‘severe’ threshold, 
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Severe AS paƟents NYHA class 1 (n=59) 47,8 54,9 49,4 47,5 53,4 46,3 57,6 51,5 48,6 54,8
Severe AS paƟents NYHA class 2 (n=73) 43,0 50,2 42,8 41,3 50,0 41,3 51,8 48,0 41,9 48,3
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Figure 2. Quality of life of patients with severe aortic stenosis (AS) according to symptomatic status.
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‘objective’ measures of valve function do not correlate to disease burden. Since we 
only studied the ‘severe’ category, a relation between disease burden and stenosis 
severity in mild or moderate aortic stenosis cannot be ruled out.
We did demonstrate that scores of the SF-36v2™ correspond well with the severity 
of symptoms according to NYHA classifi cation (Figure 2). Although asymptomatic 
patients have a normal health perception, patients in NYHA class II -thus having 
only ‘mild’ symptoms- clearly experience a lower QoL. With the increase of the 
severity of the symptoms, scores are lower on both the physical and mental part of 
the survey. This is what one would expect and indicates that the SF-36v2™ is a valid 
measure of QoL in this patient population.
Policy implication
AVR is recommended both by American and European guidelines in symptomatic 
patients with severe aortic stenosis because even elderly patients can be operated 
on with acceptable risks and can expect improvement in functional class and sur-
vival compared to non-operated patients.4-6,8,9,14,20-22 Still, 30 to 60% of them do not 
undergo AVR.10,12,20,23,24 Exercise testing is highly underused and downgraded from a 
class 2a to a 2b recommendation in the ACC/AHA guidelines although it is reported 
to elicit symptoms in approximately 37% of patients with aortic stenosis who were 
previously regarded as ‘asymptomatic’.8,25,26 Therefore, the proportion of patients 
who would deserve operative treatment could even be underestimated. Years ago 
it has already been shown that doctors have diffi  culty to recognize functional dis-
ability in patients -not so much the symptoms themselves- and one could speculate 
this is even more true for emotional impairment.16 Although we are unable to draw 
any conclusions based on the results of the current study, one could hypothesize 
that underestimating the impact of symptoms represents another cause to under-
estimate the need for treatment. Given the highly conservative approach towards 
patients with symptomatic severe aortic stenosis, we feel that this burden should 
receive more attention.
Quality of life is of utmost importance for a patient, yet there is hardly any literature 
on this subject in patients with severe aortic stenosis. Although some retrospective 
studies report on functional status and QoL in patients after AVR, they are often 
troubled by several limitations.5,14,15,27 Furthermore, these studies used patients with 
aortic stenosis who were referred (selected) for surgery. The eff ect of AVR on QoL 
among patients with severe aortic stenosis is discussed in the companion paper.28 
Importantly, in our current study we focussed not on the QoL of AVR selected pa-
tients before or after surgery, but on the quality of life when the decision to operate 
or not is yet to be made. Therefore these results can also be used for decision 
making in the individual patient. A patient could fi ll in a survey -online or on paper 
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(www.qualitymetric.com)- and the cardiologist or heart team could then compare 
these results with the general population or with similar patients (Figure 2), and 
use this information in deciding whether or not to advise AVR.
Limitations
Although enrolment from the outpatient cardiology echocardiography departments 
was encouraged, some patients may not have been identifi ed and also a substantial 
number of patients declined participation. Mostly these patients were the elderly, or 
the more sick patients for whom an extra study-trip to the hospital was unfeasible. 
Therefore, it is likely that we even underestimated the magnitude of quality of life 
impairment in the total patient population with symptomatic severe aortic stenosis 
and are only able to present the tip of the iceberg.
A limitation of using the SF-36v2™ survey could be the number of questions. This 
problem may be improved by easier, but often less specifi c, surveys, such as the 
EuroQOL survey (www.euroqol.org).
CONCLUSIONS
Our results encourage to reconsider a conservative approach in symptomatic pa-
tients with severe aortic stenosis. If the aortic stenosis is above the ‘severe’ thresh-
old, the degree of stenosis does not predict disease burden. This study provides a 
quantifi cation of this burden, especially in symptomatic patients: even minor symp-
toms have major impact on patient well-being and result in a strongly impaired 
QoL compared to the general population. Not only do physical complaints aff ect 
daily life to a great extent, patients also suff er from emotional problems hampering 
normal daily activities and social functioning.
When considering to send a patient for AVR or to treat conservatively, one should 
not only consider the operative risks and the lifespan gained after AVR, but also 
the current state of the patient both physically and mentally. Using the SF-36v2™ 
Health Survey together with this study, an individual patient’s QoL profi le can be 
assessed and compared with the patient group or with the general population. This 
can assist in decision making for the individual patient.
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ABSTRACT
Objective
Although symptomatic patients with severe aortic stenosis have a high disease 
burden and guidelines recommend aortic valve replacement, many are treated con-
servatively. This study describes to what extent quality of life is changed by aortic 
valve replacement relative to conservative treatment.
Methods
This observational study followed 132 symptomatic patients with severe aortic 
stenosis who were subjected to an SF-36v2™ Health Survey.
Results
At baseline 84 patients were treated conservatively, 48 were referred for aortic 
valve replacement. In the conservatively treated group 15 patients died during a 
mean follow-up of 18 months (Kaplan-Meier survival was 85 % and 72 % at one 
and 2 years respectively) and 22 patients crossed over to the surgical group. Of the 
resulting 70 patients in the surgical group 3 patients died during a mean follow-up 
of 11 months (survival 95 % at 1 year). Physical functioning, vitality and general 
health improved signifi cantly 1 year after aortic valve replacement. In conservatively 
treated patients physical quality of life deteriorated over time while general health, 
vitality and social functioning showed a declining trend. Mental health remained 
stable in both groups.
Conclusions
Aortic valve replacement improves physical quality of life, general health and vitality 
in patients with symptomatic severe aortic stenosis. Besides having a low life expec-
tancy, conservatively treated patients experience deterioration of physical quality of 
life. Health surveys such as the SF-36v2™ can be valuable tools in monitoring the 
burden of disease for an individual patient and off er additional help in treatment 
decisions.
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EFFECT AVR ON QUALITY OF LIFE
INTRODUCTION
Prognosis of symptomatic patients with severe aortic stenosis (AS) is poor when 
treated conservatively, and according to the American College of Cardiology/
American Heart Association and European Society of Cardiology guidelines pa-
tients should be referred for aortic valve replacement (AVR) without delay when 
they become symptomatic.1-3 However, in daily practice many symptomatic patients 
do not receive operative treatment.4-6 Underestimation of disease burden and the 
eff ect of AVR on quality of life (QoL) could in part be responsible for the observed 
under-treatment, yet there is hardly any literature on this subject.7
Previously we compared the QoL of patients with severe AS to the general 
age-matched population and found it is much lower in symptomatic patients: even 
‘mild’ symptoms result in both physical and emotional problems which have a ma-
jor impact on normal daily life and social functioning.8 The objective of our current 
study is to investigate if -and to what extent- AVR improves this disease burden, and 
to compare these outcomes with the QoL of conservatively treated patients during 
follow-up. This is a novel approach compared to other studies, which only describe 
subgroups of patients selected for surgery.9-11
METHODS
Patients
This study is part of a recently published multicentre prospective cohort study 
among patients with severe AS in the Rotterdam area (the Netherlands) between 
July 2006 and April 2009.12 Patients with severe AS were recruited from the out-
patient clinics of seven local hospitals and were invited to our hospital for sev-
eral clinical investigations, an echocardiogram and a QoL assessment. Based on 
patient characteristics and medical history -and for descriptive purposes only- an 
anticipated operative mortality was calculated using the EuroSCORE model (www.
euroscore.org).
After the baseline measurements, patients were followed to register treatment 
selection, major adverse cardiac events, QoL and survival. Since the design of this 
study was strictly observational, the investigators did not interfere with treatment 
selection. Follow-up of the entire patient cohort continued until May 1st 2011.
The current study concerns only the QoL of the symptomatic patients. For ob-
servational and analysis purposes we registered symptomatic patients into two 
groups: an AVR group and a conservatively/medically treated group. Medically 
treated patients were re-invited to our hospital after six, 12 and 24 months. Patients 
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who were referred for AVR (by their treating cardiologist) were re-invited only once, 1 
year after AVR. Patients who were initially treated conservatively but referred for AVR 
later on, were accounted for in the conservative group and crossed over to the AVR 
group at the time of operation (and therefore accounted for in both groups). In the 
patients who crossed to the AVR group, the measurements of earlier ‘conservative’ 
visits were carried forward as ‘pre-AVR measurements’. By doing so all AVR patients 
had recent pre-operative QoL data, instead of data collected at the start of the study.
AVR patients generally had conventional AVR through a median sternotomy using 
extra corporal circulation, cold crystalloid cardioplegia and mild hypothermia. A mi-
nority of AVR patients had a percutaneous valve implantation, using the retrograde 
transfemoral approach and a Core Valve® device. Transapical valve implantations 
were performed through a small intercostal incision. All procedures were performed 
electively.
The study protocol was approved by the institutional ethical committee (MEC 
2006-066) and all patients provided written informed consent.
Quality of life measurement
The SF-36v2™ Health Survey is a validated and widely used questionnaire originat-
ing from the Medical Outcomes Study.13 The survey consists of 36 multiple-choice 
health-related questions, grouped into eight multi-item domains measuring quality in 
diff erent aspects of daily life: ‘Physical Functioning’, physical health related to age- and 
role-specifi c activities termed ’Role-Physical’, ‘Bodily Pain’, ‘General Health’, ‘Vitality’, 
‘Social Functioning’, personal feelings of performance in age- and role-specifi c activi-
ties termed ’Role-Emotional’, and ‘Mental Health’. The eight domains form two main 
components: the ‘Physical-’ and ‘Mental Component Summary’.
Comparing QoL results of long-term survivors with the results of all patients alive 
at baseline, constitutes a bias since a selection of the healthier patients takes place 
over time. Therefore patients who died or refused to participate in a certain time 
interval –either in the AVR or in the conservative group- were withdrawn.
Statistics
For the statistical analyses SPSS 17.0 software was used (SPSS Inc.). Continuous 
variables with a normal distribution are displayed as means ± standard deviation 
(SD). If data were not normally distributed the median and interquartile ranges are 
given. Categorical variables are displayed as percentages.
Previously, Dutch norms have been established by Aaronson et al. using the fi rst 
version of the SF-36 Health Survey.14 To allow for useful comparison these raw SF-36 
scores have been transformed to norm-based scores from 0 to 100 in which 50 
represents the mean score of the general population and 10 points on the scale 
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correspond to 1 SD.15,16 A detailed explanation regarding data collection, scoring, 
interpretation and validation of the SF-36v2™ is given by Ware et al.15
Paired t-test analyses were used to compare QoL outcomes between diff erent 
points in time within each group. P values lower than 0.05 were considered statisti-
cally signifi cant.
Survival was explored using Kaplan-Meier analysis in patients who had AVR 
during follow-up and separately in conservatively treated patients. Because the 
distinction between the two groups is based on selection, we deliberately chose not 
to compare baseline characteristics or survival between both groups and therefore 
no p-values or log-rank tests are given.
RESULTS
Of 191 participating patients with severe AS, 132 were symptomatic and formed 
the current study group (fl owchart is given in Figure 1, baseline characteristics in 
Table 1).
The baseline QoL in the AVR group was slightly worse over all health domains 
compared to the baseline of the conservative group (Figure 2). Figure 2 also shows 
that QoL in both groups was much worse over almost all health domains compared 
to the general age-matched Dutch population.
Conservative group
Initially 84 symptomatic patients were treated medically. In this group 15 patients 
died during a mean follow-up of 18 months. A total of 22 patients were referred for 
AVR after initial conservative treatment; therefore, these patients crossed over to 
the AVR group (Figure 1). Sixty-seven patients completed the SF-36v2™ Health Sur-
vey after 6 months and 30 after two years of conservative treatment. Kaplan-Meier 
survival in the conservative group was 85% at 1 year and 72% at 2 years.
In medically treated patients physical health worsened signifi cantly (Figure 3b). 
‘Bodily Pain’, ‘General Health’, ‘Vitality’ and ‘Social Function’ only showed a ten-
dency to worsen yet not signifi cant and ‘Mental Health’ remained stable.
AVR patients
Initially 48 patients were referred for AVR within 6 months and during follow-up 
another 22 patients (Figure 1). Thirty-day mortality was zero but three patients died 
within one year after AVR. The mean follow-up in the AVR group was 11 months. 
Kaplan-Meier survival was 95% at 1 year.
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Figure 1. Flow chart.
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Not only the physical QoL components improved, but also ‘Vitality’ and ‘General 
Health’ were signifi cantly better than pre-operatively and approached the scores of 
the general Dutch population (Figure 4).
DISCUSSION
Quality of life in symptomatic patients with severe AS is lower in almost all health 
domains than in the age-matched general Dutch population, both in patients se-
lected for surgery as well as in conservatively treated patients. In a previous paper 
Table 1. Patient characteristics
Conservative
(n=84)
AVR
(n=70)
Mean age (years) 73.2 (± 10.9) 67.8 (± 12.2)
Male gender (%) 61 49
NYHA class (%)
II 62 45
III 32 45
IV 6 9
Mean NYHA class 2.4 (± 0.6) 2.6 (± 0.7)
Logistic EuroSCORE 8.2 (± 6.3) 6.0 (± 6.0)
Echocardiography
Aortic jet velocity Vmax (m/s) 4.1 (± 0.7) 4.6 (± 0.8)
Peak gradient (mmHg) 68.0 (± 23.7) 88.3 (± 32.5)
Mean gradient (mmHg) 38.5 (± 13.6) 50.8 (± 20.1)
Aortic Valve Area (cm2) 0.76 (± 0.25) 0.74 (± 0.31)
Aortic valve/Left ventricular outfl ow tract velocity time integral ratio 4.5 (± 1.4) 4.7 (± 1.7)
Ejection Fraction (%) 52.2 (± 12.8) 48.3 (± 11.5)
Medical history (%)
Smoking (current or past) 60.0 53.0
Diabetes Mellitus 18.8 15.1
Renal failure / dialysis 11.8 / 2.4 6.1 / 0
Hypertension 60.0 43.9
Dyslipidaemia 51.8 48.5
Chronic Obstructive Pulmonary Disease 20.0 19.7
Cerebro Vascular Accident (infarction/bleeding) 4.7 7.6
Open Heart Surgery previously 7.1 6.1
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EmoƟonal
Mental 
Health
Baseline 39,1 49,3 38,1 37,3 48,1 39,0 48,0 45,0 40,0 47,5
6 months  37,0 48,4 36,4 35,9 45,3 37,1 47,0 43,5 37,4 46,9
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* p< 0.05
Figure 3a. Quality of life of conservative group: baseline versus 6 months.
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Figure 2. Baseline quality of life of AVR and conservative groups versus general Dutch population.
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Summary
Physical 
FuncƟoning Role Physical Bodily Pain
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EmoƟonal
Mental 
Health
Baseline 40,3 49,3 38,6 39,1 48,4 40,4 49,1 46,7 39,6 47,0
24 months   35,9 49,6 34,1 33,8 46,3 38,2 48,1 43,8 37,5 47,3
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Figure 3b. Quality of life of conservative group: baseline versus 24 months.
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Mental 
Health
Before AVR 37,7 48,9 36,8 36,2 46,6 38,0 46,5 45,1 38,5 47,0
12 months aŌer AVR   44,3 47,2 43,5 41,4 48,6 43,6 50,6 45,0 41,3 45,0
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* p< 0.05
Figure 4. Quality of life of AVR group: baseline versus 12 months.
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we also showed a clear association between New York Heart Association (NYHA) 
class and the SF-36v2™ outcomes.8
Conservative group
The conservatively treated patients who survived two years showed a slight deterio-
ration of their physical health status after two years. Yet the degree of deterioration 
seems to be less than what might be expected based on the low life expectancy of 
symptomatic AS patients reported in literature.17,18 However, besides a higher mor-
tality also the number of patients who were not capable to complete the subsequent 
questionnaires is larger in the conservative group compared with the AVR group. 
The baseline QoL of these withdrawn patients was lower than that of the rest of the 
group (data not shown). Therefore the observed QoL in our study overestimates 
the real QoL over time in the total conservative group.
AVR group
Although patients in the conservative group are older, the QoL of the AVR patients 
seems slightly lower at baseline (Figure 2). This is a refl ection of clinical practice in 
which patients with severe symptoms are more likely to be referred for surgery than 
the ones who have only mild symptoms.
The patients who had AVR and were alive at 1 year follow-up showed a markedly 
improved QoL after 1 year compared with pre-operatively, except in ‘Mental Health’. 
The improvement is quite large in the physical domains and, although not signifi cant, 
a positive trend is clearly visible in the ‘Bodily Pain’ and ‘Role Emotional’ scales.
We assumed a period of 1 year after AVR would be enough to eliminate most direct 
postoperative problems and assumed a relatively stable health after that period. It is 
interesting to see that ‘Mental health’ does not improve after AVR, and remains much 
lower than in the age-matched general population. Whether concentration, memory, 
emotional or other cognitive problems form the basis of this observation and whether 
this could be explained by the operation or postoperative recovery remains speculative.
Implications
Whether the improved QoL in operated patients can be extrapolated to the total 
symptomatic population with severe AS still remains a matter of debate. The gain of 
surgery in the operated group might be higher than it would be in patients who are 
currently treated conservatively. In reality, some (elderly) patients are not surgical 
candidates or simply refuse to be operated upon. From these data it cannot be 
determined how the outcomes, both in terms of survival and QoL, would have been 
supposed all patients would have had AVR. Therefore projection of the study results 
to the entire symptomatic patient population is only speculative.
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One could argue that current treatment selection seems good: in selected pa-
tients, QoL generally improves after AVR. Compared with other reports the observed 
mortality in the conservative group is less high and the presented QoL outcomes 
in the surviving patients show only a slowly and borderline signifi cant worsening 
over time.17,18 On the other hand these fi ndings could be a refl ection of a somewhat 
conservative approach among the studied population.
Timing of surgery in patients with AS is an important and continuing issue of de-
bate. An underestimation of the impact of symptoms on a patient’s QoL might be 
one of the reasons why many symptomatic patients with severe AS are not referred 
for surgery. Based on our previous study and the current paper, we argue in favour 
of using QoL survey’s in the pre-operative assessment when the choice between 
surgery or conservative treatment has to be made.8
Literature
Although other studies describe QoL in cardiac surgery patients,9-11,19-24 quality of life 
studies by objective survey’s such as the SF-36v2™ have, to our knowledge, not been 
performed in patients who have (symptomatic) AS and in whom the decision to oper-
ate or not is yet to be made. Most studies we found did not study QoL in patients 
with AS, but QoL in patients with AS who were referred (selected) for surgery. Some 
of them describe QoL only in long-term survivors after intervention and do not have a 
baseline (pre-operative) value. Such analyses constitute a selection bias in which only 
the healthier patients are subjected to a survey: ‘survival of the fi ttest’.7,19,20,22,24
Some studies only concern selective subgroups, others use NYHA classifi cations as 
a raw refl ection of QoL rather than objective health surveys.19,23,24 The SF-36v2™ Health 
Survey describes multiple physical and emotional aspects and is therefore a better and 
more objective refl ection of one’s (desired) health status than the NYHA classifi cation.
Limitations
For adequate functional and echocardiographic assessment we believed it to be 
necessary to invite the patients to our hospital each time a quality of life assess-
ment was done, resulting in substantial number of patients denying participation 
because of perceived high burden. Often these were the elderly, more sick patients 
for whom an extra study-trip to the hospital was unfeasible. Therefore it is likely that 
we underestimated the magnitude of QoL impairment in the total patient popula-
tion with symptomatic severe aortic stenosis.
An obvious limitation is the fact that some of the patients –and most likely those 
with low quality of life- died or refused further cooperation over time which pre-
cluded further observations.
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CONCLUSIONS
AVR off ers improved quality of life in selected symptomatic patients with severe AS. 
The benefi cial eff ect is most evident in the physical components, but also general 
health perception, vitality and emotional aspects improve after AVR to the level of 
the general age-matched population in contrast to conservatively treated patients.
Besides considering life-expectancy and anticipated risks with either conservative 
or operative treatment, QoL should be taken into account when making treatment 
decisions in patients with severe AS. A health survey like the SF-36v2™ could be a 
valuable tool in monitoring the burden of disease for an individual patient and off er 
additional help in this decision.
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ABSTRACT
Aims
DSS is often diagnosed early in life and known for its sometimes rapid hemody-
namic progression in childhood and strong association with AR. However, data 
about the evolution of DSS in adulthood are scarce. Therefore we aimed to evaluate 
the natural history of discrete subaortic stenosis (DSS), and identify risk factors for 
progression of DSS, aortic regurgitation (AR) and intervention-free survival.
Methods and Results
Conservatively managed adult DSS patients were included in this retrospective 
multicentre cohort study. Mixed-eff ects and joint models were used to assess pro-
gression of DSS and AR, and intervention-free survival.
Longitudinal natural history data were available for 149 patients (age 20 (IQR 
18-34) years, 48% male). Sixty patients (40.3%) had associated congenital heart 
defects (CHD). Median follow-up duration was 6.3 (IQR 3.0-12.4) years. Baseline 
peak left ventricular outfl ow tract (LVOT) gradient was 32.3±17.0 mmHg and in-
creased with 0.8±0.1 mmHg/year. While baseline LVOT gradient (p=0.891) or age 
(p=0.421) did not infl uence progression rate, presence of associated CHD was 
associated with faster progression (p=0.005). Mild AR was common (58%), but did 
not signifi cantly progress over time (p=0.701). Median intervention-free survival 
was 16 years and associated with baseline LVOT gradient (HR=3.9 (95%CI 2.0-7.6)), 
DSS progression (HR=2.6 (95%CI 2.0-3.5)) and AR (HR=6.4 (95%CI 2.6-15.6)).
Conclusions
In contrast to children, DSS progresses slowly in adulthood. In particular patients 
with associated CHD are at risk for faster progression and should be monitored 
cautiously. DSS progression is not infl uenced by baseline LVOT gradient or age. 
Mild AR is common, but nonprogressive over time.
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INTRODUCTION
Fibromuscular discrete subaortic stenosis (DSS) is often diagnosed early in life 
and notable for its unpredictable, but sometimes rapid hemodynamic progression 
during childhood.1-4 Aortic regurgitation (AR) is present in 30-80% of patients and 
thought to develop secondary to aortic valve damage caused by the high velocity 
subvalvular jet.1-11 In children, natural history is well established and several predic-
tors for hemodynamic progression have been identifi ed such as younger age or a 
higher gradient at diagnosis.1,12-14 Despite the fact that DSS is a relatively frequent 
abnormality (6.5%) in adults with congenital heart defects (CHD), data about 
DSS in adulthood are scarce.7,8,15-18 In contrast to infants and children, adults with 
DSS seem to have a slower progression rate.7 However, there is a lack in studies 
focusing on the elucidation of factors that predict DSS or AR progression in adults. 
Therefore, the main purpose of this study was to evaluate the natural history of 
DSS in a large cohort of adults and identify risk factors for DSS progression, AR 
progression, and the need for surgery.
METHODS
All adult patients (18 years or older) with a pre-existing diagnosis of fi bromuscular 
DSS seen between January 1980 and October 2011 at the Congenital Cardiac Centre 
for Adults of one of the participating centres (Erasmus University Medical Centre, 
Rotterdam, The Netherlands; University Hospital Gasthuisberg, Leuven, Belgium; 
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; To-
ronto Congenital Cardiac Centre for Adults located at Peter Munk Cardiac Centre, 
Toronto, Canada) were evaluated for eligibility. Fibromuscular DSS was defi ned 
as: ‘encirclement of the left ventricular outfl ow tract (LVOT) by a membrane or 
short-segment stenosis consisting of fi brous or fi bromuscular tissue’. Eligible 
patients were selected from the CONCOR database,19 the Dutch registry for adult 
patients with CHD, and the Leuven and Toronto database for adults with CHD.
Exclusion criteria were: prior surgical resection of subaortic tissue, lack of se-
rial echocardiographic examinations, predominant dynamic subaortic obstruction 
due to hypertrophic cardiomyopathy, subvalvular obstruction caused by accessory 
mitral valve tissue or the support system of mitral valve prosthesis, complex LVOT 
obstruction (tunnel-like subaortic narrowing), concomitant moderate-to-severe 
valvular aortic stenosis, transposition of the great arteries, or univentricular con-
nections. This retrospective study was approved by the institutional review board 
and ethical committee of the participating centres. Informed consent was waived.
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Demographic, clinical, and surgical data were obtained from medical charts and 
electronic health records. All available transthoracic echocardiograms, electrocar-
diograms and exercise tests were collected. Baseline was defi ned as entry of the 
study (fi rst available echocardiogram in adulthood). Follow-up was defi ned as the 
time between the fi rst and last available echocardiogram. Peak systolic instanta-
neous LVOT gradient was derived from the continuous wave Doppler LVOT peak 
fl ow velocity from the apical three- or fi ve-chamber views. The degree of AR was 
graded by experienced echocardiographers and cardiologists as mild, moderate, 
or severe.20 Left ventricular (LV) mass was calculated using the modifi ed Devereux 
formula.21 The aorto-septal angle was measured in the parasternal long-axis view at 
end-diastole, as previously described.22,23
Statistical analysis
The Statistical Package for Social Sciences, version 19.0 (SPSS, Inc., Chicago, IL, 
USA) was used for descriptive data analysis. Normally distributed continuous vari-
ables were summarized using the mean ± standard deviation (SD). Non-normally 
distributed continuous variables were summarized using the median and inter-
quartile range (IQR). Categorical variables were summarized using the frequency 
and percentage. Group diff erences in baseline variables were assessed using the 
2-sample t test, chi-square test, or Mann-Whitney U test. All statistical tests were 
2-sided; a p-value <0.05 was considered statistically signifi cant.
For advanced statistical analyses of the longitudinal and survival data, the R 
statistical software (version 2.15.0, available at: www.r-project.org) was used. To 
assess changes in echocardiographic measurements over time while accounting 
mfor the correlation between repeated follow-up measurements in each patient, 
mixed-eff ects models analyses were used. In particular, for the LVOT gradient pro-
gression rate a linear mixed-eff ects model was used, whereas for AR progression a 
mixed-eff ects continuation ratio model was employed.24 The following factors were 
included in the models as covariates: age at baseline, age at diagnosis, gender, prior 
intracardiac surgery, additional CHDs, baseline LVOT gradient (< or ≥ 50 mmHg), 
aortic valve morphology, LV mass, ventricular septal defect (VSD), AR, aorto-septal 
angle, and smoking. For each of the covariates in the model, its main eff ect and 
interaction with time was added, allowing for diff erent average longitudinal evolu-
tions per covariate. Residual plots were used to validate the models’ assumption, 
and when appropriate, transformations of the outcome variables were used in the 
analysis. Furthermore, to account for missing covariate data a multiple imputation 
approach was used. Wald tests were used to assess which prognostic factors were 
most associated with the progression of LVOT gradient and AR.
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Probabilities of intervention-free survival from baseline were obtained by the 
Kaplan-Meier method. Survival of DSS patients was compared to the expected sur-
vival of the normal Dutch population.25 Patients were censored at end of follow-up 
or classifi ed as event (surgery for DSS or death). A penalized likelihood approach 
was employed for the Cox regression model with baseline data, to account for the 
low number of events compared to the number of covariates. A joint modelling 
approach and time-dependent Cox model were respectively used to investigate the 
eff ect of LVOT gradient and AR on the hazard ratio (HR).26
RESULTS
Out of 427 identifi ed patients with fi bromuscular DSS, longitudinal natural history 
data were available for 149 patients (Figure  1). Baseline characteristics are sum-
marized in Table 1. Sixty patients (40.3%) had associated CHD (Table 1). Median 
Figure 1. Flowchart of patient inclusion. DSS = discrete subaortic stenosis, HOCM = hypertrophic 
obstructive cardiomyopathy, LVOT = left ventricular outfl ow tract.
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Table 1. Baseline characteristics
Discrete subaortic 
stenosis patients
(n=149)
Intervention-free 
survival group
(n=106)
Patients with an 
event (surgery or 
death)
(n=43)
p-value
Male 72 (48.3) 52 (49.1) 20 (46.5) 0.778
Age at baseline, years 20.4 (17.6-33.8) 20.2 (17.5-33.6) 20.5 (17.8-34.2) 0.701
Age at DSS diagnosis, years 17.0 (7.5-30.5) 18.8 (7.4-31.8) 16.7 (5.9-29.0) 0.810
Body mass index, kg/m2 25.4 ± 5.5 25.8 ± 6.1 24.6 ± 3.9 0.251
Systolic blood pressure, mmHg 125.6 ± 16.6 125.9 ± 16.6 125.1 ± 16.6 0.787
Diastolic blood pressure, mmHg 74.9 ± 10.3 75.5 ± 10.2 73.5 ± 10.6 0.282
Peak systolic instantaneous LVOT gradient, 
mmHg
32.3 ± 17.0 28.4 ± 14.1 41.9 ± 19.9 < 0.001
≤30 mmHg 76 (51.0) 64 (60.4) 12 (27.9) <0.001
30-50 mmHg 51 (34.2) 33 (31.1) 18 (41.9)
≥50 mmHg 22 (14.8) 9 (8.5) 13 (30.2)
Aortic regurgitation
None / trivial 57 (38.3) 44 (41.5) 13 (30.2) 0.085
Mild 86 (57.8) 61 (57.5) 25 (58.1)
Moderate 5 (3.4) 1 (9.4) 4 (9.3)
Severe 1 (0.7) 0 (0.0) 1 (2.3)
Associated CHD / repaired *
None 89 (59.7) 63 (59.4) 26 (60.5) 0.961
Ventricular septal defect 24 (16.1) / 7 (4.7) 17 (16.0) / 5 (4.7) 7 (16.3) / 2 (4.7) 0.971
Atrial septal defect 11 (7.4) / 6 (4.0) 9 (8.5) / 5 (4.7) 2 (4.7) / 1 (2.3) 0.417
Valvular aortic stenosis (< 3 m/s) 7 (4.7) / 0 (0.0) 2 (1.9) / 0 (0.0) 5 (11.6) / 0 (0.0) 0.011
Coarctation of the aorta 15 (10.1) / 6 (4.0) 10 (9.4) / 4 (3.8) 5 (11.6) / 2 (4.7) 0.687
Persistent ductus arteriosus 6 (4.0) / 4 (2.7) 4 (3.8) / 3 (2.8) 2 (4.7) / 1 (2.3) 0.805
Shone’s complex 2 (1.3) / 0 (0.0) 0 (0.0) / 0 (0.0) 2 (4.7) / 0 (0.0) 0.025
Aorto-septal angle, º # 138.2 ± 16.2 138.8 ± 16.8 133.6 ± 11.0 0.423
Left atrial diameter, mm
 Indexed for BSA, mm/m2
36.6 ± 8.4
20.1 ± 5.2
35.9 ± 7.7
19.5 ± 4.8
40.1 ± 10.8
22.6 ± 6.4
0.058
0.028
LV mass, gram
 Indexed for BSA, gram/m2
174.0 ± 65.0
94.6 ± 35.1
164.9 ± 55.8
88.6 ± 27.9
215.6 ± 86.8
121.5 ± 49.8
0.003
<0.001
LVOT diameter, mm 16.5 ± 3.3 16.4 ± 3.4 17.0 ± 3.0 0.640
LV end-diastolic diameter, mm (IQR)
 Indexed for BSA, mm/m2
46.8 ± 6.7 (41.0 ± 51.0)
25.8 ± 4.3
46.1 ± 6.2 (40.0-50.0)
25.2 ± 3.9
50.1 ± 8.0 (46.5-56.3)
28.4 ± 5.3
0.059
0.004
LV end-systolic diameter, mm (IQR)
 Indexed for BSA, mm/m2
28.3 ± 5.6 (25.0 ± 32.0)
15.6 ± 3.5
27.8 ± 5.3 (24.3-31.0)
15.2 ± 3.1
30.6 ± 6.8 (24.8-35.0)
17.4 ± 4.6
0.053
0.013
Fractional shortening, % 39.7 ± 7.2 39.8 ± 7.1 38.9 ± 7.9 0.641
Maximum exercise capacity, % from norm 86.3 ± 22.3 86.6 ± 21.8 85.8 ± 23.4 0.256
Sinus rhythm 146 (98.0) 104 (98.1) 42 (97.7) 0.283
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follow-up duration was 6.3 (IQR 3.0-12.4) years, yielding a total of 1191 patient-years. 
On average 2.7 ± 0.9 (range 2-9) echocardiographic studies were available for each 
patient.
Progression of LVOT gradient over time
Peak systolic instantaneous LVOT gradient was 32.3 ± 17.0 mmHg at baseline and 
linearly increased over time with a rate of 0.8 ± 0.1 mmHg per year. Six patients dem-
onstrated a progression rate >5 mmHg/year. The presence of an associated CHD 
was associated with faster progression of the LVOT gradient (p=0.005; Figure 2), in 
particular a VSD (p=0.035). The LVOT gradient progression rate was not infl uenced 
by age at baseline (p=0.421), age at time of diagnosis (p=0.273), gender (p=0.960), 
prior intracardiac surgery (p=0.162), baseline LVOT gradient ≥50 mmHg (p=0.891; 
Figure 2), current smoking (p=0.282), or aortic valve morphology (p=0.240) (see 
Supplementary material online, Table S1).
Progression of AR over time
A LVOT gradient ≥50 mmHg (p=0.007) was independently associated with a higher 
probability of having AR (see Supplementary material online, Table S2). Although 
Figure 3 demonstrates that over 10 years time the probability of not having AR decreases 
from approximately 40% to approximately 20%, progression to moderate-to-severe 
AR was rare. Overall, AR severity did not signifi cantly progress over time (p=0.747). 
A baseline peak LVOT gradient ≥50 mmHg did not infl uence the progression of AR 
(p=0.999).There were no factors signifi cantly associated with progression from mild 
to moderate-to-severe AR (see Supplementary material online, Table S2).
Table 1. Baseline characteristics (Continued)
Heart frequency, beats per minute 71.9 ± 14.5 72.5 ± 14.6 70.3 ± 14.5 0.487
QRS duration, ms 101.8 ± 20.8 98.7 ± 17.5 110.8 ± 26.6 0.005
PR time, ms 154.6 ± 34.3 153.6 ± 35.8 157.0 ± 30.3 0.640
NYHA class I 144 (96.6) 104 (98.1) 40 (93.0) 0.118
Smoking
Never 112 (75.2) 84 (79.2) 28 (65.1) 0.323
Former 11 (7.4) 6 (5.7) 5 (11.6)
Current 26 (17.4) 16 (15.1) 10 (23.3)
BSA = body surface area, CHD = congenital heart defects, DSS = discrete subaortic stenosis, IQR = in-
terquartile range, LV = left ventricular, LVOT = left ventricular outfl ow tract, NYHA = New York Heart 
Association.
*Diagnoses are not mutually exclusive (one patient could have multiple associated CHD).
# This variable was only available for 82 patients.
Values are expressed as n(%), median (IQR) or mean ± SD.
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Clinical outcome
Two patients died suddenly 4 and 16 years after entry in the study (37 and 39 years 
old, LVOT gradients before death 63 and 85 mmHg, respectively, no associated 
CHD, no left ventricular hypertrophy). The cause of death was unknown in both 
Figure 3. Evolution of aortic regurgitation over time. No signifi cant progression the severity of in 
aortic regurgitation over time (p = 0.747).
Figure 2. Evolution of discrete subaortic stenosis over time. Progression of the left ventricular outfl ow 
tract gradient over time by the baseline left ventricular outfl ow tract gradient (<50 and ≥50 mmHg; 
p = 0.891) and by the presence or absence of an associated congenital heart defect (p = 0.005). The 
dashed lines denote 95% confi dence intervals. LVOT = left ventricular outfl ow tract, CHD = congeni-
tal heart defect.
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patients (no autopsy). The cumulative survival was 94% at 20 years (0.17% per 
patient-year; Figure 4a). One patient was successfully resuscitated after an episode 
of ventricular fi brillation (36 years old, LVOT gradient before event 49 mmHg, as-
sociated repaired VSD and left ventricular hypertrophy). Two patients (22-year old 
male and 52-year-old female, LVOT gradient 21 and 64 mmHg, respectively, both 
Figure 4. Kaplan–Meier plots. a. Cumulative Kaplan–Meier survival and intervention-free survival 
for discrete subaortic stenosis patients and expected survival for the normal Dutch population. b. 
Cumulative Kaplan–Meier intervention-free survival for discrete subaortic stenosis patients with a 
baseline peak systolic instantaneous left ventricular outfl ow tract gradient <50 mmHg compared 
with ≥50 mmHg (p <0.001). DSS = discrete subaortic stenosis, LVOT = left ventricular outfl ow tract.
CHAPTER 11
180
had an associated unrepaired VSD and mild AR) had an episode of endocarditis 
(0.17% per patient-year).
During follow-up 41 patients required surgery for DSS according to the clinical 
practice guidelines (5.9% per patient-year). Median intervention-free survival was 
16 years (Figure 4a). The mean age at time of DSS surgery was 35.1 ± 14.0 years. 
The pre-operative LVOT gradient was 75.3 ± 3.6 mmHg and 17 of the 41 patients 
(41.5%) had moderate-to-severe AR. Type of DSS surgery was enucleation in 20 
patients (48.8%) and enucleation with additional myectomy in 21 patients (51.2%). 
Nineteen patients (46.3%) underwent concomitant surgery: aortic valve replace-
ment or repair (n=16) or VSD closure (n=3). Post-operative complications included 
bleeding requiring rethoracotomy (n=1), atrial fi brillation (n=4), complete AV block 
requiring permanent pacemaker implantation (n=3), and heart failure (n=1).
Independent predictors for impaired intervention-free survival were the baseline 
LVOT gradient ≥50 mmHg (HR 3.9 (95%CI 2.0-7.6); Figure  4b), LVOT gradient 
progression over time (HR 2.6 (95%CI 2.0-3.5)) and moderate-to-severe AR (HR 6.4 
(95%CI 2.6-15.6)) (see Supplementary material online, Table S3).
DISCUSSION
This study is the fi rst large longitudinal study focusing on the natural course of 
DSS over time and risk factors infl uencing clinical outcome in adult patients. Given 
the scarcity of data about the natural evolution of DSS in adults, these results will 
contribute to our understanding of the clinical course of DSS in adulthood and 
guide clinical management.
Progression of DSS
Interestingly, the present study demonstrates that DSS in adulthood progresses very 
slowly, with less than 1 mmHg gradient increase per year. These results confi rm the 
fi ndings of a series published by Oliver et al. that showed a similar slow progression 
rate in only 25 patients with sequential echocardiographic studies.7 Remarkably, the 
slow progression rate along several decades in adults contrasts to the progressive 
nature of DSS described in children.1-4 This phenomenon might be explained by 
the fact that adults who survived into adulthood without an intervention compile a 
highly selected subgroup and represent a mild phenotype within the spectrum of 
DSS.
The study by Oliver et al. suggested that age infl uences DSS evolution, since they 
found signifi cant correlations between age and LVOT gradient and progression.7 
To evaluate if age was not only correlated but could actually signifi cantly predict 
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DSS disease progression, we explored age as a covariate in longitudinal echocar-
diographic models in this large population. However, neither age at study baseline 
nor age at time of diagnosis signifi cantly infl uenced LVOT progression over time. 
Furthermore, in contrast to paediatric populations, we did not fi nd an association 
between DSS severity at baseline and the progression rate in adults who naturally 
survived into adulthood.1,12-14 Thus, patients with LVOT gradients ≥50 mmHg were 
not at risk for faster progression of the LVOT obstruction.
With respect to the prevalence of associated CHD, our population was compa-
rable to those described in other studies.7,8,15 Notably, the presence of an associated 
CHD, particularly a VSD, was the only independent predictor for DSS progression. 
Many previous studies have tried to elucidate the poorly understood aetiology of 
DSS.3,27,28 It has been demonstrated that abnormal geometric arrangements in the 
LVOT, such as steepened aorto-septal angle, malaligned VSD and mitral-aortic 
separation, may induce increased shear stress.22,23,29-31 Cellular fl ow studies have 
shown that increased shear stress triggers growth factors and cellular proliferation, 
eventually stimulating development of the subaortic membrane and progression 
of the LVOT obstruction.11 Our fi ndings suggest that adult DSS patients with as-
sociated CHD and those without additional CHD compile two diff erent subgroups 
within the DSS spectrum. We hypothesize that the presence of associated CHD, 
particularly a VSD, causes more abnormal hemodynamic forces at the LVOT level, 
which could be caused either by the CHD itself or by prior intracardiac surgery for 
that defect. The abnormal hemodynamic forces might cause increased shear stress, 
thereby evoking a more intense response on a cellular level and faster progres-
sion of the LVOT obstruction. We tried to elucidate whether the aorto-septal angle 
infl uenced LVOT progression over time, but unfortunately there were too many 
missing values for this covariate. Future rheological studies in adult DSS patients 
are certainly warranted to test this hypothesis.
Aortic regurgitation
The most commonly described hemodynamic sequel in DSS patients is AR, which 
is thought to evolve secondary to the high velocity subvalvular jet produced by the 
LVOT obstruction.5-11 In an attempt to prevent damage to the aortic valve, early 
surgical resection of the subaortic membrane has been advocated.32,33 However, 
Oliver et al. demonstrated in 25 adults that AR is common, and usually mild, and 
nonprogressive over time.7 Similarly, our study clearly showed that AR is only 
haemodynamically relevant (moderate-to-severe) in a minority of patients although 
mild AR is found in the majority of adult DSS patients. More importantly, while 
approximately 20% of patients developed mild AR during the study period, progres-
sion to moderate-to-severe is rare. In the total group, the AR progression was not 
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statistically signifi cant and we could not identify a subgroup of patients at higher 
risk for progression. Therefore, the fear of development of progressive AR seems to 
be overestimated and early surgical repair of DSS in adult patients with a low LVOT 
gradient and no/mild AR is not justifi ed.
Survival
Overall, the cumulative 20-year survival of patients with DSS is comparable with the 
survival of the age-matched normal Dutch population.25 Since the life expectancy 
of Canada, the Netherlands and Belgium is comparable; this probably does not 
infl uence our survival results at young adult age.34 However, the rate of (near) sud-
den death (0.17-0.25% per patient-year) in our study of young adult patients with 
DSS is worrisome. This seems to be higher than the generally estimated 0.09% 
per patient-year in adult patients with any type of CHD.35,36 Moreover, it represents 
a 30-125 times increased risk of sudden death compared to the general population 
with a similar age range.37-41 Unfortunately the absolute number of events was too 
small to identify any risk factors for sudden death in patients with DSS.
Clinical implications
DSS progresses very slowly in adulthood; however, patients with associated con-
genital lesions, particularly a VSD, are at risk for faster disease progression and 
should be monitored cautiously. Furthermore, this large study shows that AR is 
usually mild and does not progress over time; thereby rejecting the hypothesis that 
early repair is required to prevent development of progressive AR.
According to the present study, prophylactic surgery in asymptomatic adult DSS 
patients is not indicated solely to prevent rapid progression of the LVOT obstruction 
or progressive AR. Our data do not support the current North American guidelines 
that state that surgical intervention should be recommended in any DSS patient 
with a peak LVOT gradient ≥50 mmHg, but are more in line with the European and 
Canadian guidelines.42-44 However, the timing of surgical intervention is a highly 
complex issue compiling various factors in an individual patient based approach: 
the peak LVOT gradient, progression rate of the LVOT gradient, severity and pro-
gression of AR, presence of associated CHD, LV diameter and function, and risk 
of sudden death. Postponing surgery to higher LVOT gradients might increase the 
chance of requirement of concomitant aortic valve repair or replacement and in-
crease the risk of sudden death. On the other hand, up till now it is unclear whether 
surgery will prevent or at least minimize the risk of sudden death. Unfortunately, 
the optimal timing of surgical intervention in adult patients with DSS cannot yet be 
derived from the present study.
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Since endocarditis only occurred in two patients with a concomitant unrepaired 
VSD, it is likely that these cases were related to the unrepaired VSD rather than 
DSS. Thus, the risk of endocarditis in patients with isolated DSS seems to be low 
and endocarditis prophylaxis should only be indicated in high risk patients.44
Since the LVOT gradient progression is generally slow and AR is usually mild, 
echocardiographic follow-up can probably be limited to 3-5-year intervals for the 
majority of patients. However, for patients with associated congenital lesions (par-
ticularly a VSD), peak LVOT gradient ≥50 mmHg, or moderate-to-severe AR more 
frequent echocardiographic follow-up evaluations seem reasonable, for example 
every 1-2 years.
Study limitations
This retrospective study inheriting all limitations of a retrospective study design 
included patients monitored in adult congenital clinics at tertiary care centre, and 
therefore referral bias may exist. Inclusion of deceased patients from the databases 
limited survival bias. Unfortunately, some echocardiographic parameters could not 
be retrieved for all patients, but this was dealt with by using the multiple imputation 
approach for missing values. The fact that echocardiography was not performed 
precisely every year, was accounted for by the use of mixed-eff ects models that 
take diff erent lengths of follow-up into account. Furthermore, by using the joint 
modelling approach we allowed for the dependency and association between the 
longitudinal echocardiographic data and survival data. Finally, we have to acknowl-
edge that the median follow-up duration of 6.3 years was relatively short. For defi ni-
tive conclusions regarding the long-term outcome of DSS in adulthood, a longer 
follow-up period is required.
CONCLUSIONS
Conservatively (non-surgically) managed DSS progresses slowly in adulthood, 
though patients with associated congenital lesions, especially a VSD, are at risk for 
faster DSS progression and should be monitored cautiously. Baseline LVOT gradi-
ent does not infl uence DSS progression over time, and thus should not be used as 
sole indication to proceed to surgery. AR is usually mild and does not progress over 
time, indicating that prophylactic surgery to prevent AR progression is not justifi ed.
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ABSTRACT
Background
DSS is notable for its unpredictable hemodynamic progression in childhood and 
high reoperation rate; however, data about adulthood are scarce.
Methods and results
Adult patients who previously underwent surgery for DSS were included in this 
retrospective multicenter cohort study. Mixed-eff ects and joint models were used 
to assess postoperative progression of discrete subaortic stenosis and aortic regur-
gitation, as well as reoperation.
A total of 313 patients at 4 centers were included (age at baseline, 20.2 years 
(25th–75th percentile, 18.4–31.0 years), 52% male). Median follow-up duration was 
12.9 years (25th–75th percentile, 6.2–20.1 years), yielding 5617 patient-years. The 
peak instantaneous left ventricular outfl ow tract gradient decreased from 75.7 ± 
28.0 mmHg preoperatively to 15.1 ± 14.1 mmHg postoperatively (p<0.001) and 
thereafter increased over time at a rate of 1.31 ± 0.16 mmHg/y (p=0.001). Mild 
aortic regurgitation was present in 68%, but generally did not progress over time 
(p=0.76). A preoperative left ventricular outfl ow tract gradient ≥80 mmHg was a 
predictor for progression to moderate aortic regurgitation postoperatively. Eighty 
patients required at least one reoperation (1.8% per patient-year). Predictors for 
re-operation included female gender (hazard ratio, 1.53; 95% confi dence interval, 
1.02-2.30) and left ventricular outfl ow tract gradient progression (hazard ratio, 1.45; 
95% confi dence interval, 1.31–1.62). Additional myectomy did not reduce the risk for 
reoperation (p=0.92), but signifi cantly increased the risk of a complete heart block 
requiring pacemaker implantation (8.1% versus 1.7%; p=0.005).
Conclusions
Survival is excellent after surgery for discrete subaortic stenosis; however, reopera-
tion for recurrent discrete subaortic stenosis is not uncommon. Over time, the left 
ventricular outfl ow tract gradient slowly increases and mild aortic regurgitation is 
common, although generally nonprogressive over time. Myectomy does not show 
additional advantages and as it is associated with an increased risk of complete 
heart block, it should not be performed routinely.
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INTRODUCTION
Discrete subaortic stenosis (DSS) is notable for its unpredictable and sometimes 
rapid hemodynamic progression in childhood and its association with aortic regur-
gitation (AR), which is found in 30 to 80% of patients.1-7 Diff erent strategies exist 
for the timing of surgical treatment, ranging from early (mild to moderate obstruc-
tion) to late (severe or symptomatic) repair. Early repair has been advocated to 
prevent aortic valve damage and thus AR progression.5-12 Nevertheless, it remains 
unclear whether surgery can actually alter the course of progressive AR. Further-
more, surgery is associated with a high recurrence risk and need for reoperation 
(8-34%).12-18 A major factor in DSS recurrence is believed to be inadequate relief of 
the obstruction.19 Therefore some groups advocate concomitant selective myec-
tomy to achieve complete relief of the left ventricular outfl ow obstruction (LVOT) 
obstruction,8,18-21 whereas others have reported that the addition of myectomy does 
not reduce the number of recurrences.16,17,22-27
Although postoperative outcome and risk factors for reoperation in children 
are well established, postoperative data for the adult population are limited.15,27,28 
Therefore, the aim of this study was to identify risk factors for postoperative DSS 
recurrence, AR progression and reoperation in a large cohort of adult patients who 
previously underwent surgical treatment for DSS.
METHODS
All adult patients who previously underwent surgery for fi bromuscular DSS and 
were seen between January 1980 and October 2011 at the Congenital Cardiac 
Center for Adults of one of the participating centers (Erasmus University Medical 
Center, Rotterdam, and Radboud University Nijmegen Medical Center, Nijmegen, 
The Netherlands; University Hospital Gasthuisberg, Leuven, Belgium; and Toronto 
Congenital Cardiac Centre for Adults located at Peter Munk Cardiac Centre, Toronto, 
Canada) were evaluated for eligibility for this study.
Fibromuscular DSS was defi ned as a complete or incomplete encirclement of 
the LVOT by a membrane or short-segment stenosis consisting of fi brous or fi -
bromuscular tissue. The baseline of this study was defi ned as time of fi rst adult 
outpatient clinic visit. Eligible patients were selected from the CONgenital CORvitia 
(CONCOR) database (the Dutch registry for adult patients with congenital heart 
disease (CHD)),29 and from the Leuven and Toronto local database for adults with 
CHD. Although all patients followed in Congenital Cardiac Centers for Adults were 
≥17 years old, the fi rst surgery for DSS could have been performed in childhood. Ex-
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clusion criteria were: lack of serial echocardiograms, non-DSS causes for subaortic 
obstruction (tunnel-like subaortic narrowing, hypertrophic cardiomyopathy, acces-
sory mitral valve tissue, or mitral valve prosthesis), concomitant moderate-to-severe 
valvular aortic stenosis, transposition of the great arteries, and univentricular con-
nections. This retrospective study was approved by the institutional review board 
and ethical committee of participating centers. Informed consent was waived.
Demographic, clinical, and surgical data were obtained from medical charts 
and electronic health records. All available transthoracic echocardiograms, ECGs, 
and exercise tests were collected. Peak systolic instantaneous LVOT gradient was 
derived from the continuous-wave Doppler LVOT peak fl ow velocity. The degree 
of AR was graded by experienced echocardiographers and cardiologists as mild, 
moderate, or severe.30 Left ventricular mass was calculated using the modifi ed-De-
vereux-formula.31 In the parasternal long-axis view at end-diastole, we measured the 
aorto-septal angle, which is the angle formed by the plane of the ventricular septum 
and the ascending aorta, as previously described.32,33
Statistical analysis
The Statistical Package for Social Sciences, version 19.0 (SPSS, Inc, Chicago, IL) 
was used for descriptive data-analysis. Continuous variables were summarized 
using the mean±SD or median and 25th and 75th percentile. Categorical variables 
were summarized by use of frequency and percentage. The paired t-test, paired Wil-
coxon, and McNemar tests were used to compare preoperative and postoperative 
measurements. All statistical tests with a p-value <0.05 were considered signifi cant.
For advanced statistical analyses of the longitudinal and survival data, the R 
statistical software (version 2.15.0; www.r-project.org) was used. To assess changes 
in echocardiographic measurements over time while accounting for the correlation 
between repeated follow-up measurements in each patient, mixed-eff ects models 
analyses were used. In particular, for the postoperative LVOT gradient progres-
sion rate, a linear mixed-eff ects model was used, whereas for postoperative AR 
progression a mixed-eff ects continuation ratio model was used.34 To allow fl exibility 
in the modeling of the patientspecifi c longitudinal trajectories, we used natural 
cubic splines of time in the specifi cation of the mixed-eff ects models, in both the 
fi xed- and random-eff ect parts of the models. The following variables were included 
in the models as covariates: age at the time of surgery, age at diagnosis, gender, 
preoperative peak instantaneous LVOT gradient, diff erence between preoperative 
and postoperative gradient (delta), type of surgery (isolated enucleation or addi-
tional myectomy), associated CHD, and smoking. For each of the covariates in the 
model, its main eff ect and interaction with time was added, allowing for diff erent 
average longitudinal evolutions per covariate. Residual plots were used to validate 
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the model assumptions, and when appropriate, transformations of the outcome 
variables were used in the analysis. Furthermore, to account for missing covariate 
data, a multiple imputation approach was used for the preoperative and postop-
erative LVOT gradient covariates (missing for 42 patients). Five generations of 
complete data sets were realized. Wald tests were used to assess which prognostic 
factors were most associated with the progression of peak instantaneous LVOT 
gradient and AR.
Probabilities of intervention-free survival from baseline were obtained by the 
Kaplan-Meier method. Survival of DSS patients was compared to the expected 
survival of the age-matched normal Dutch population.35 Patients were censored 
at end of follow-up or classifi ed as event (surgery for DSS or death). A penalized 
likelihood approach was employed for the Cox regression model with baseline data, 
to account for the low number of events compared to the number of covariates. A 
joint longitudinal and survival model and the timedependent Cox model were used 
to investigate the eff ect of peak instantaneous LVOT gradient and AR, respectively, 
on the hazard ratio for intervention-free survival.36
RESULTS
A total of 737 patients were assessed for eligibility to participate in this study. Inclu-
sion criteria were met by 313 patients. A total of 424 patients were excluded, mainly 
due to LVOT obstruction resulting from another cause (n=145), no history of DSS 
surgery (n=149), or lack of serial echocardiography examinations (n=74).
Baseline characteristics of the 313 patients are summarized in Table 1. Of the 313 
patients, 163 patients (52.1%) had ≥1 associated CHD. Baseline LVOT diameter was 
14.5 ± 3.8 mm in women and 15.7 ± 4.2 mm in men (p=0.19). Follow-up ranged 
from 1 to 31 years (median, 12.9 years; 25th–75th percentile, 6.2–20.1 years), yielding 
a total of 5617 patient-years. On average, 2.3 ± 1.4 (minimum, 2; maximum, 8) 
echocardiographic studies were available for each patient.
Operative outcomes
The 313 included patients underwent a total of 412 operations for DSS. The peak 
instantaneous LVOT gradient decreased from 75.7 ± 28.0 mmHg pre-operatively to 
15.1 ± 14.1 mmHg postoperatively (p<0.001). The LVOT diameter increased from 
14.5 ± 3.8 mm to 19.0 ± 3.7 mm (p<0.001). In 251 patients (61%), the fi rst surgery 
was performed in childhood (mean age, 12.9 ± 6.7 years). Table 2 shows the sur-
gical details, including concomitant surgery and postoperative complications. In 
those patients who did not undergo concomitant aortic valve repair or replacement 
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Table 1. Baseline characteristics
Operated DSS patients
Male 163 (52.1)
Age at baseline, years 20.2 (18.4-31.0)
Age at DSS diagnosis, years 8.0 (4.0-15.0)
Body surface area, m2 1.8 ± 0.2
Body mass index, kg/m2 25.9 ± 5.4
Systolic blood pressure, mmHg 125.6 ± 19.4
Diastolic blood pressure, mmHg 72.6 ± 10.9
Associated CHD anomalies; previously repaired *
None 150 (47.9)
Ventricular septal defect 72 (23.0); 15 (4.8)
Atrial septal defect 18 (5.8); 4 (1.3)
Valvular aortic stenosis 29 (9.3); 2 (0.6)
Coarctation of the aorta 48 (15.3); 10 (3.2)
Persistent ductus arteriosus 20 (6.4); 8 (2.6)
Shone complex 10 (3.2); 0 (0.0)
Aortoseptal angle, º 124.7 ± 15.9
Left atrial diameter, mm (indexed for BSA, mm/m2) 42.4 ± 11.7 (22.8 ± 5.3)
Left ventricular mass, gram (indexed for BSA, mm/m2) 222.0 ± 86.3 (120.1 ± 42.8)
LV end-diastolic diameter, mm (indexed for BSA, mm/m2) 49.1 ± 7.5 (27.1 ± 4.4)
LV end-systolic diameter, mm (indexed for BSA, mm/m2) 29.5 ± 7.4 (16.3 ± 4.3)
LV fractional shortening, % 40.3 ± 9.0
E/A ratio 1.5 ± 0.6
E/E’ ratio 11.9 ± 6.0
Maximum exercise capacity, % from norm 82.1 ± 20.4
Sinus rhythm 295 (94.2)
Heart frequency, beats per minute 72.5 ± 14.5
QRS duration, ms 114.9 ± 28.9
PR time, ms 160.5 ± 30.9
NYHA class I 290 (92.9)
Smoking
Never 211 (67.4)
Former 26 (8.3)
Current 64 (20.4)
Unknown 12 (3.8)
BSA = body surface area, CHD = congenital heart disease, DSS = discrete subaortic stenosis, LV = left 
ventricular, LVOT = left ventricular outfl ow tract, NYHA = New York Heart Association.
* Diagnoses are not mutually exclusive.
Values are n(%), median (IQR) or mean ± SD.
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during surgery for DSS, the severity of AR was unchanged postoperatively (p=0.60). 
Seventeen patients (4.4%) suff ered from a complete heart block postoperatively, re-
quiring pacemaker implantation. Patients who underwent an additional myectomy 
more frequently developed a complete heart block than patients who underwent 
isolated enucleation (respectively 8.1% versus 1.7%; p=0.005).
Mortality and morbidity
One death occurred within 30 days after surgery for DSS resulting from heart fail-
ure. Ten patients (mean age, 49.1 ± 16.5 years) died during follow-up (0.18% per 
patient-year; Figure 1a). Five deaths were for cardiac reasons (4 heart failure and 1 
septic shock after endocarditis). In 2 patients the cause of death was metastasized 
cancer. Three patients died suddenly during follow-up (unknown cause of death, 
no autopsy; age 19, 30, and 48 years old; all had an LVOT gradient <30 mmHg at 
last follow-up visit, 2 had an associated ventricular septal defect, no left ventricular 
hypertrophy). The cumulative survival of DSS patients after surgery was 97% at 20 
years.
During follow-up 34 patients (age, 29.9 ± 15.1 years) were hospitalized for 
various reasons (0.61% per patient-year): heart failure (n=13), endocarditis (n=12), 
ventricular fi brillation followed by successful resuscitation (n=2), cardioversion for 
atrial fi brillation (n=5), stroke (n=1), and pericarditis (n=1).
Reoperations
During follow-up, 80 patients (25.6%) underwent at least 1 reoperation for recur-
rent DSS; 19 of these patients required a third operation (reoperation rate 1.76% 
per patient-year; Table  2). The mean time interval between initial operation and 
reoperation was 12.0 ± 7.6 years. Median intervention-free survival was 17 years 
(Figure  1a). Independent predictors for impaired intervention-free survival were 
female sex (hazard ratio, 1.531; 95% confi dence interval, 1.018–2.302; Figure  1b), 
peak instantaneous LVOT gradient progression over time (hazard ratio, 1.454; 95% 
confi dence interval, 1.308–1.616), preoperative peak instantaneous LVOT gradient 
≥80 mm Hg (hazard ratio, 1.016; 95% confi dence interval, 1.004–1.028), and diff er-
ence between preoperative and postoperative peak instantaneous LVOT gradients 
(hazard ratio, 1.021; 95% confi dence interval, 1.007–1.035; Table I in the online-only 
Data Supplement).
Recurrence of LVOT gradient postoperatively
Postoperative peak instantaneous LVOT gradient was 15.1 ± 14.1 mmHg, which 
linearly increased over time at a rate of 1.31 ± 0.16 mmHg per year (p=0.001). Inde-
pendent risk factors for faster postoperative peak instantaneous LVOT gradient pro-
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Table 2. Surgical details for 412 DSS operations
First operation
(n=313)
Second operation
(n=80)
Third operation
(n=19)
Age at time of surgery, years 17.1 ± 14.9 22.9 ± 13.9 32.1 ± 10.4
Pre-operative peak LVOT gradient, mmHg 74.7 ± 28.9* 79.3 ± 22.2 76.6 ± 36.3
Postoperative peak LVOT gradient, mmHg 14.6 ± 13.8* 17.6 ± 16.2 10.9 ± 9.2
Pre-operative aortic regurgitation
None 84 (26.8) 15 (18.8) 1 (5.3)
Mild 173 (55.3) 26 (32.5) 5 (26.3)
Moderate 44 (14.1) 15 (18.8) 4 (21.0)
Severe 12 (3.8) 24 (30.0) 9 (47.4)
Postoperative aortic regurgitation
None 87 (27.8) 18 (22.5) 5 (26.3)
Mild 208 (66.4) 59 (73.8) 13 (68.4)
Moderate 18 (5.8) 3 (3.8) 1 (5.3)
Severe 0 (0.0) 0 (0.0) 0 (0.0)
Type of surgery
Isolated enucleation 189 (60.4) 31 (38.8) 8 (42.1)
Additional myectomy 122 (39) 43 (53.8) 9 (47.4)
Unknown 2 (0.6) 6 (7.5) 2 (10.5)
Concomitant surgery † 8 (2.5) 7 (8.8) 2 (10.5)
Aortic valve bioprosthesis 10 (3.2) 12 (15.1) 8 (42.1)
Aortic valve mechanical prosthesis 18 (5.8) 7 (8.8) 2 (10.5)
Aortic valve repair 2 (0.6) 12 (15.0) 2 (10.5)
Ross procedure 4 (1.3) 0 (0.0) 0 (0.0)
Coarctation repair 3 (1.0) 1 (1.3) 1 (5.3)
Supravalvular aortic repair 9 (2.9) 0 (0.0) 0 (0.0)
Persistent ductus arteriosus ligation 8 (2.5) 3 (3.8) 0 (0.0)
Mitral valve replacement or repair 46 (14.7) 1 (1.3) 0 (0.0)
Ventricular septal defect closure 6 (1.9) 0 (0.0) 0 (0.0)
Atrial septal defect closure
Postoperative complications †
New left bundle branch block 36 (3.2) 8 (10) 0 (0.0)
New right bundle branch block 33 (3.2) 3 (3.8) 1 (5.3)
New complete heart block requiring pacemaker 12 (3.8) 3 (3.8) 2 (10.5)
Atrial fi brillation 6 (1.9) 2 (2.5) 2 (10.5)
Heart failure 3 (1.0) 1 (1.3) 0 (0.0)
Mortality 1 (0.3) 0 (0.0) 0 (0.0)
Neurological complication (stroke or neuropathy) 1 (0.3) 2 (2.5) 0 (0.0)
DSS = discrete subaortic stenosis, LVOT = left ventricular outfl ow tract obstruction.
*Only available for 298 patients.
† Overlapping categories.
Values are n(%) or mean ± SD.
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gression were increased age at the time of DSS diagnosis (p=0.048) and female sex 
(p=0.059 for trend; Figure 2). A higher preoperative LVOT gradient was associated 
with an overall higher residual postoperative peak instantaneous LVOT gradient 
(p<0.001) but did not signifi cantly infl uence the postoperative peak instantaneous 
LVOT gradient progression rate (p=0.74). Peak instantaneous LVOT gradient pro-
gression rate was not infl uenced by type of surgery (enucleation with or without 
myectomy; p=0.85), age at the time of surgery (p=0.21), presence of associated 
CHD (p=0.12), or smoking (p=0.24; Table II in the onlineonly Data Supplement).
Figure 1. Kaplan-Meier plots. a. Survival and intervention-free survival for patients with discrete sub-
aortic stenosis (DSS) and expected survival for the normal age-matched Dutch population. b. By sex.
Figure 2. Discrete subaortic stenosis over time. Evolution of discrete subaortic stenosis over time 
postoperatively by age at time of diagnosis (p = 0.048) and sex (p =0.059). LVOT = left ventricular 
outfl ow tract.
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Progression of AR postoperatively
Immediately postoperatively, mild AR was present in 68% of patients and moderate 
AR in 5%; no patients exhibited severe AR. Over time, AR severity did not signifi cantly 
progress in the total study population (p=0.76; Figure 3). However, approximately 
10% of patients progressed from having no AR to mild AR, and another 10% of 
patients developed moderate AR during the fi rst 8 years after surgery (Figure 3). 
None of the patients progressed to severe AR. A preoperative peak instantaneous 
LVOT gradient ≥80 mmHg was an independent risk factor for development of 
moderate AR postoperatively (p=0.008; Figure 4). We could not identify any other 
factor that was signifi cantly associated with postoperative development of mild AR 
or progressive AR (Table III in the online-only Data Supplement).
Figure 3. Aortic regurgitation over time. Probability of postoperative aortic regurgitation over time.
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DISCUSSION
In this multicenter study, we have analyzed data on a large cohort of adult patients 
who underwent surgical DSS resection with 13 years postoperative follow-up 
(range, 1-31 years) to determine predictors for DSS recurrence, AR worsening, and 
re-operation. The results of the present study may be the basis for modifi cation of 
the current strategies for management of DSS patients.
DSS recurrence and reoperations
In the total study population, postoperatively, the peak instantaneous LVOT gra-
dient increased slowly but signifi cantly over time at 1.3 mmHg/year. This fi nding 
confi rms a smaller study that previously reported a slight increase in postoperative 
gradient at late follow-up.27 Surprisingly, increased age at the time of diagnosis (>30 
years old) was a risk factor for faster postoperative LVOT gradient progression. This 
phenomenon might be explained by the fact that when DSS was discovered late in 
adulthood, patients were more likely to present with symptoms and thus might 
be in an advanced stage of the disease. Another hypothesis is that aging itself is 
related to faster postoperative progression.
In this study we used reoperation as an objective clinically relevant outcome, 
rather than recurrence only because of the lack of a universal defi nition for recur-
rence. We do acknowledge that the indication for reoperation is also not concrete 
and universal. Our reoperation rate for recurrent DSS (1.8% per patient-year) was 
Figure 4. Preoperative left ventricular outfl ow tract (LVOT) gradient vs postoperative aortic regur-
gitation. Association between various levels of preoperative peak LVOT gradient and probability of 
postoperative aortic regurgitation progression over time.
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comparable to two other adult surgical series, which reported reoperation rates of 
0.5% and 2.6% per patient-year.15,27 As reported in several studies in children with 
DSS, a higher peak instantaneous gradient across the LVOT at the fi nal preoperative 
echocardiogram was an independent predictor for reoperation in our adult patient 
population.10,12,16,17,24 Testing various cutoff  points, we found that a peak instanta-
neous LVOT gradient ≥80 mmHg is most predictive for the need of reoperation. 
In addition, incomplete removal of the LVOT obstruction, refl ected in a smaller 
diff erence between preoperative and postoperative gradients, was found to be a risk 
factor for reoperation. This has previously been demonstrated in several previous 
studies.12,15,20,22,26,37 Furthermore, as expected, LVOT gradient progression postop-
eratively is a strong predictor for reoperation. In addition to the echocardiographic 
parameters to monitor and predict LVOT gradient progression, perhaps biomarkers 
might be useful to identify those with more rapidly progressing disease. Further 
research in this area is warranted.
Surprisingly, women carry a 1.5-times elevated risk for reoperation compared to 
men. In addition, female patients tended to have a more rapid postoperative LVOT 
gradient progression rate than male patients. These sex diff erences in reoperation 
or recurrence risk have not been reported previously. This phenomenon might be 
explained by the fact that women are likely to have a smaller LVOT. In our cohort the 
LVOT diameter tended to be smaller in women compared to men, although not sta-
tistically signifi cant. Perhaps pregnancy might have been a confounding factor, but 
unfortunately we did not collect information about pregnancies during follow-up, 
and there is a lack of studies investigating the consequences of pregnancy in DSS 
patients. Furthermore, transcriptional regulation of genes related to myocardial hy-
pertrophy and fi brosis might be sex dependent, as has been shown after aortic valve 
replacement for valvular aortic stenosis.38 Pathophysiological studies are required 
to explore the underlying mechanisms for these sex diff erences.
Isolated enucleation versus additional myectomy
Several hypotheses regarding DSS recurrence have been proposed. Recurrence may 
result from regeneration of tissue from the same region or from scar formation in 
the subvalvular area during healing.19,39 Furthermore, turbulence due to incomplete 
removal of the LVOT obstruction has been postulated to promote fi brosis and subse-
quent restenosis.12 Although some previous studies have suggested that additional 
myectomy during the fi rst operation reduces the incidence of recurrence, other 
authors have questioned this fi nding.8,16-27 Our results do not support the benefi t of 
additional myectomy for either the risk of reoperation or LVOT gradient progression 
rate postoperatively. A tradeoff  when performing aggressive surgical resection to 
potentially lower the recurrence rate is the risk of a complete atrioventricular block, 
201
SURGICAL OUTCOME OF DSS
which was signifi cantly higher in the patients who underwent additional myectomy 
compared to those who underwent isolated enucleation (8% versus 2%). In previ-
ous studies the risk of a postoperative complete atrioventricular block is typically 
1% to 5%, however this might be up to 14% when a more aggressive surgical ap-
proach is performed.6,7,12,17,20 Of course, the results of a myectomy and risk of heart 
block are operator dependent, but this study included patients from four diff erent 
centers over a time span of 30 years, making it impossible to study this factor 
adequately. Therefore, from our study we conclude that an additional myectomy 
may be justifi ed when a substantial degree of septal hypertrophy is detected but 
should be discouraged in most patients.
AR after DSS surgery
Although most DSS patients exhibited mild (non hemodynamically relevant) AR 
both preoperatively and postoperatively, our study shows that in most patients AR 
is not progressive over time. Approximately 10% of patients who did not have AR 
before surgery, however, developed mild AR relatively shortly after surgery. Further-
more, another 10% of patients progressed from mild to moderate AR, but progres-
sion to severe AR was very rare. We identifi ed a preoperative peak instantaneous 
LVOT gradient ≥80 mmHg as a risk factor for progressive AR after surgery. Previous 
studies in children with DSS have also demonstrated the association between a 
high preoperative LVOT gradient and progressive AR postoperatively.40,41 In order 
to prevent progressive AR postoperatively, it may be wise to reoperate before the 
peak LVOT gradient reaches 80 mmHg. In conclusion, we agree with the statement 
made by Stassano et al. that resection of the subaortic membrane cannot improve 
AR, but we disagree with their suggestion that resection can entirely “stabilize” the 
grade of regurgitation.27
Clinical implications
Postoperative long-term survival after surgical treatment of DSS is excellent and 
comparable to that of the normal population. However, the rate of reoperation is 
considerable (approximately 2%/year), and given the excellent survival of these 
young adult patients, most patients will require a reoperation for recurrent DSS at 
some point in their lifetime. Postoperatively, the peak instantaneous LVOT gradi-
ent progresses slowly but steadily over time in adults. Therefore, lifelong regular 
follow-up, including echocardiography, is required after surgery. However, because 
the LVOT progression is generally slow, follow-up can probably be limited to 2- to 
4-year intervals in most patients. Women and patients >30 years old at time of 
diagnosis are at risk for faster LVOT gradient progression after surgery and should 
thus be monitored more frequently. Of course, patients with decreased LV function 
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or severe/progressive AR should also be followed more frequently. Additional myec-
tomy did not reduce DSS recurrence or reoperation risk and signifi cantly increased 
the risk of a complete heart block. Therefore, myectomy should not be encouraged 
in most patients and should only be performed in case of marked LV hypertrophy. 
Postoperative AR is common but generally mild and non-progressive over time in 
most patients. Patients with a preoperative Doppler derived peak instantaneous 
LVOT gradient ≥80 mmHg, however, are at increased risk for development of mod-
erate AR, but progression to severe AR is rare.
Study limitations
Several limitations of this study merit attention. This retrospective study included 
patients monitored in adult congenital clinics; therefore, referral bias may exist. One 
of the major study limitations was the fact that indications for (re)operation were 
not standardized because of the multicenter approach and broad time period. By 
using prospective databases to identify eligible patients and therefore also includ-
ing deceased patients, we aimed to limit survival bias. Unfortunately, some echo-
cardiographic parameters could not be retrieved for all patients, but this was dealt 
with through the use of the multiple imputation approach for missing values. The 
fact that echocardiography was not performed precisely every year was accounted 
for by the use of mixed-eff ects models that take diff erent lengths of follow-up into 
account. Furthermore, by using the joint modeling approach, we allowed for the 
dependency and association between the longitudinal echocardiographic data and 
survival data. Ideally, our fi ndings need to be validated by a large prospective cohort 
study.
The current European Society of Cardiology and American College of Cardiology/
American Heart Association guidelines for adults with CHD do not provide specifi c 
recommendationsfor reinterventions in DSS patients.42,43 The Canadian guidelines 
state that a peak instantaneous LVOT gradient >50 mmHg is an indication for 
reoperation when patients have symptoms.44 The timing of reoperation is a highly 
complex issue that should take various factors into account: the peak LVOT gradi-
ent, progression rate of the LVOT gradient, severity and progression of AR, left 
ventricular volume and function, presence of (exercised-induced) symptoms, and 
risk of sudden death. Unfortunately, the optimal timing of reoperation, when all 
these factors are combined, in adult patients with DSS cannot yet be derived from 
the present study.
Conclusions
Although survival is excellent after surgery for DSS, most patients will require a 
reoperation for recurrent DSS at some point during their lifetime. Postoperatively, 
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the LVOT gradient progresses slowly and mild AR is common but nonprogressive 
over time in most patients. Myectomy should not be performed routinely because 
it does not reduce the risk of recurrence or reoperation and increases the risk of a 
complete heart block.
Clinical Perspective
Discrete subaortic stenosis is a narrowing of the left ventricular outfl ow tract just 
beneath the aortic valve. In childhood, discrete subaortic stenosis is known for 
its unpredictable and sometimes rapid hemodynamic progression. Furthermore, 
aortic regurgitation is present in 30% to 80% of patients. Because reoperation 
rates have been reported to be high (8%–34%), there is ongoing debate about the 
timing of surgical intervention and type of surgery. This is the fi rst large study to 
evaluate the surgical outcome in adult patients. In contrast to children, the left ven-
tricular outfl ow tract gradients in adults progress slowly. Mild aortic regurgitation 
is common but nonprogressive over time in the majority of patients. Patients with 
a preoperative peak left ventricular outfl ow tract gradient ≥80 mm Hg, however, 
are at risk for progression to moderate aortic regurgitation. Survival after surgery 
for discrete subaortic stenosis is excellent, with survival rates comparable to those 
of the normal population. The reoperation rate in young adult patients, however, 
is high (2%/year). Given the excellent survival in this young patient population, 
most patients face a reoperation for recurrent discrete subaortic stenosis through-
out their lifetime. Additional myectomy does not reduce the risk for reoperation 
but signifi cantly increases the risk of a complete heart block requiring pacemaker 
implantation. Therefore, myectomy should not be performed routinely.
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ABSTRACT
Young women who require aortic valve replacement need information on the po-
tential cardiac and obstetric complications of pregnancy for the diff erent available 
valve substitutes. We, therefore, assessed the pregnancy outcomes in women who 
had received an autograft, homograft, or mechanical valve in the aortic position.
Women who were pregnant after surviving AVR at our institution from 1987 to 2011 
were included. Information on cardiac status and pregnancy outcome was obtained 
through hospital medical records and by an extensive patient questionnaire.
A total of 40 women experienced 67 pregnancies of which 55 (82%) were com-
pleted pregnancies, 6 (9%) were miscarriages, and 6 (9%) were terminated. Of the 
40 women, 18 (45%) women had a pulmonary autograft, 13 (32%) a homograft, 
and 9 (23%) a mechanical valve. The mean age at the fi rst pregnancy was 30.0 ± 5.7 
years. No maternal mortality but 1 fetal death (1.8%) and 1 neonatal death (1.8%) 
occurred. Maternal cardiac complications occurred in 13% and obstetric complica-
tions in 38% of the completed pregnancies. Heart failure (9%), arrhythmias (7%), 
hypertension-related disorders (7%), preterm delivery (24%), and small for gesta-
tional age infants (15%) were most often encountered. Mechanical valve recipients 
had the highest incidence of both cardiac and obstetric complications.
In conclusion, pregnancy-associated complications after AVR were common, 
and human tissue valves should be considered in the discussion for the optimal 
aortic valve substitute in a young woman. However, careful obstetric monitoring is 
mandatory.
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INTRODUCTION
When a young woman requires aortic valve replacement (AVR), it is important to 
incorporate reliable information on potential pregnancy complications and preg-
nancy outcomes when considering the available surgical options. In mechanical 
valve recipients, complications due to anticoagulation therapy represent a threat 
for both the mother and her unborn child.1-3 Accelerated valve dysfunction due to 
degeneration could be a point of concern for biological valve substitutes, although 
more recent studies have reported that pregnancy does not increase structural de-
terioration or reduce survival.4-6 Limited evidence is available on the rate of cardiac 
and obstetric complications in young women who become pregnant after AVR. 
Most available information concerns mechanical –mainly mitral- valve recipients 
and showed increased risks of anticoagulation-related complications and increased 
maternal and fetal mortality and morbidity.1,2,5,7-10 Reports on pregnancy related 
outcomes are also scarce for human tissue valve recipients.5,10-12 Therefore, the 
aim of the present study was to determine the occurrence of cardiac and obstetric 
complications in women who experienced a pregnancy after implantation of an 
autograft, homograft, or mechanical valve in the aortic position at our institution.
METHODS
Women who were pregnant after surviving an AVR with a pulmonary autograft, ho-
mograft, or mechanical valve prosthesis at the Erasmus University Medical Center, 
were aged ≤50 years at surgery, had undergone AVR from April 1987 to January 
2011, and were ≥16 years at the last clinical follow-up, were invited to participate. 
The Institutional Review Board approved the study protocol (MEC 2010-272), and 
all patients provided informed consent. All patients who received a human tissue 
valve substitute at our institution were followed up prospectively (MEC 2000-813). 
Eligible patients were identifi ed through our prospective cohort study of human tis-
sue valve recipients and through our departmental patient information system.13,14
Information on pregnancy and cardiac status of the patients until January 1, 2011 
was obtained from the hospital medical records and structured patient question-
naire that was completed from December 1, 2010 to September 1, 2011. We collected 
data on underlying valve etiology at last surgery, hemodynamic diagnosis, previous 
surgical/interventional procedures, age at surgery, type (and size) of aortic valve 
substitute, concomitant procedures, interval from surgery to fi rst pregnancy, age at 
conception, and preconceptional systolic left ventricular function, maximum aortic 
jet velocity, and peak pulmonary artery pressure.
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Pregnancy was defi ned as positive human chorionic gonadotropin test or obstet-
ric ultrasound fi ndings. Miscarriage was defi ned as spontaneous loss of pregnancy 
at <20 weeks of gestation. Information about each completed pregnancy (duration 
>20 weeks of gestation) included New York Heart Association (NYHA) functional 
class, medication, physical examination, pregnancy duration, and mode of delivery. 
For each infant, the gender, birth weight, and APGAR score was registered.
The registered cardiac complications were arrhythmia (symptomatic, sustained, 
documented arrhythmia), heart failure (requiring treatment), persistent NYHA 
functional class deterioration (≥1 year postpartum), syncope, thromboembolic 
complications, aortic dissection, and/or endocarditis. Obstetric complications 
included pregnancy-induced hypertension (de novo onset of hypertension after 
≥20 weeks of gestation), preeclampsia (hypertension and proteinuria), eclampsia 
(preeclampsia with grand mal seizures), HELLP (hemolysis elevated liver enzymes 
low platelets) syndrome, preterm, premature rupture of membranes (membrane 
rupture <37 weeks’ gestation), premature labor (spontaneous onset of labor <37 
weeks’ gestation), postpartum hemorrhage (>1,000 ml), placental abruption, 
premature delivery (<37 weeks’ gestation), small-for-gestational-age (birth weight 
<10th percentile), fetal death (≥20 weeks’ gestation), and neonatal death (<30 days 
postpartum).15 The incidence of complications and mode of delivery in the present 
study was compared to data derived from the 2008 Dutch Perinatal Registry. In 
this registry, maternal and fetal data of all deliveries occurring in the Netherlands 
are recorded (about 180,000; 96% complete). It included both home as well as 
hospital deliveries and contained information on the presence of cardiovascular 
disease in the mother (no additional specifi cation) and neonatal congenital defects 
( cardiac 0.41%; non-cardiac 2.38%).16
The anticoagulation therapy administered in our institution to mechanical valve 
recipients was according to our local protocol and initiated in close collaboration 
with the hematologist.17 As soon as pregnancy was confi rmed, acenocoumarol was 
changed to a weight-adjusted therapeutic dose of low-molecular-weight-heparin 
(LMWH) until the end of the fi rst trimester and when necessary was monitored 
by measuring the anti-factor Xa levels. Acenocoumarol was then restarted until 36 
weeks of gestation. Then, a therapeutic dose of LMWH was given until spontane-
ous onset of labor or the day before the induction of labor or elective cesarean 
section. After delivery, LMWH was initiated again, along with acenocoumarol, until 
2 consecutive, appropriate international normalized ratio levels were reached.
The normality of the distribution of continuous data was tested with the Kol-
mogorov-Smirnov test with Lilliefors’ correction. Continuous data are displayed as 
the mean ± SD or in case of a skewed distribution, as the median and interquartile 
range and were compared using the one-way analysis of variance test or the Krus-
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Table 1. Patient characteristics of the 40 women who experienced ≥1 pregnancy after aortic valve 
replacement
All Autograft Homograft MP p-value
Variable (n=40) (n=18) (n=13) (n=9)
Intervention/surgery before AVR
0 23 (58%) 10 (56%) 9 (69%) 4 (44%) .46
1 8 (20%) 2 (11%) 4 (31%) 2 (22%) .46
> 1 9 (23%) 6 (33%) 0 3 (33%) .07
Diagnosis
Aortic stenosis 15 (38%) 10 (56%) 4 (31%) 0 .02
Aortic regurgitation 13 (33%) 3 (17%) 6 (46%) 5 (55%) .10
Mixed 12 (30%) 5 (28%) 3 (23%) 4 (44%) .61
Etiology
Congenital 26 (65%) 16 (89%) 8 (62%) 2 (22%) <.01
Rheumatic 12 (30%) 2 (11%) 4 (31%) 6 (67%) .01
Aneurysm/Dissection 2 (5%) 0 1 (8%) 1 (11%) .49
Age at last surgery (years) 25.4 ± 7.7 21.5 ± 6.6 26.9 ± 5.0 31.2 ± 9.0 <.01
Concomitant procedures
None 28 (70%) 16 (89%) 8 (62%) 4 (44%) .04
Coronary bypass 3 (8%) 1 (6%) 0 2 (22%) .23
Mitral valve surgery 6 (15%) 0 3 (23%) 3 (33%) .04
Size prosthesis (mm) - - 22 (21-22) 21 (21-23)
Time surgery-1stpregnancy (years)* 3.1 (1.6-6.1) 5.5 (1.8-9.4) 2.3 (1.4-4.6) 2.1 (1.5-4.6) .14
Total number of pregnancies 67 33 22 12 .39
1 40 (60%) 18 (55%) 13 (59%) 9 (75%) .46
2 20 (30%) 11 (33%) 6 (27%) 3 (25%) .83
3 7 (10%) 4 (12%) 3 (14%) 0 .46
Pregnancy age (years)*
1st (n=40) 30.0 ± 5.7 27.0 ± 4.1 30.2 ± 4.6 35.7 ± 5.9 <.01
2nd (n=20) 30.9 ± 4.7 30.0 ± 3.9 31.9 ± 5.0 32.1 ± 8.0 .75
3rd (n=7) 32.1 ± 5.5 32.7 ± 7.0 31.3 ± 4.0 - .86
LVF preconceptional (n=66)
Good 64% 61% 77% 50% .18
Moderate 36% 39% 23% 50% .18
PAP preconceptional (mmHg) (n=62) 6 (3-15) 13 (9-18) 3 (2-3) 4 (1-11) <.01
Vmax preconceptional (m/s)*
1st pregnancy (n=38) 1.78 ± 0.69 1.36 ± 0.42 1.85 ± 0.60 2.60 ± 0.55 <.01
2nd pregnancy (n=19) 1.70 ± 0.54 1.41 ± 0.46 2.01 ± 0.36 2.23 ± 0.38 .01
3rd pregnancy (n=7) 1.83 ± 0.80 1.41 ± 0.48 2.39 ± 0.87 - .23
Completed pregnancies 55 (82%) 28 (85%) 20 (91%) 7 (58%) .05
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kal-Wallis test. Discrete data are presented as absolute numbers and percentages 
and compared using the Pearson’s chi-square test or Fisher’s exact test.
Univariate logistic regression analysis was performed to identify possible factors 
associated with the incidence of pregnancy-related complications. Missing values 
were imputed by the mean. Age at surgery, maternal age at fi rst pregnancy, valve 
type, interval from surgery to fi rst pregnancy, duration of pregnancy, cesarean sec-
tion, pre-conceptional left ventricular function, maximum aortic jet velocity, and 
pulmonary artery pressure were considered as covariables in the univariate model 
for cardiac and obstetric events. For comparison of the event incidence with the 
general Dutch population the chi-square test was used. All statistical tests were 
2-sided and a p-value ≤0.05 was considered signifi cant. For data analysis SPSS, 
version 17.0, for Windows (SPSS, Chicago, Illinois) was used.
RESULTS
A total of 40 patients experienced ≥1 pregnancy after AVR in our institution (Table 1), 
with 67 singleton pregnancies. Of these 67 pregnancies, 55 continued >20 weeks 
(47% male infants) in 35 women. All 6 spontaneous miscarriages were <14 weeks 
of gestation. Six pregnancies were terminated (Table  1). The only termination of 
pregnancy for maternal cardiac reason was performed in a mechanical valve recipi-
ent with pulmonary hypertension, tricuspid insuffi  ciency, and moderate stenosis of 
the mechanical prosthesis in aortic position of 3.3 m/s. One termination was per-
formed in a fetus with spina bifi da. No acenocoumarol-associated embryopathies 
developed. The mode of delivery for the 55 completed pregnancies, diff erentiated by 
type of valve substitute, is listed in Table 2. Figure 1 illustrates the modes of delivery 
compared to the Dutch general population. No maternal mortality occurred.
Table 1. Patient characteristics of the 40 women who experienced ≥1 pregnancy after aortic valve 
replacement (Continued)
Miscarriage 6 (9%) 3 (9%) 0 3 (25%) .05
Termination pregnancy 6 (9%) 2 (6%) 2 (9%) 2 (17%) .64
Social reasons 4 (6%) 2 (6%) 2 (9%) 0 .70
Maternal cardiac indication 1 (1%) 0 0 1 (17%) .18
Fetal spina bifi da 1 (1%) 0 0 1 (8%) .18
MP = mechanical aortic valve prosthesis, n = number of patients, AVR = aortic valve replacement, 
LVF = systolic left ventricular function, PAP = peak pulmonary artery pressure, * = all 67 pregnan-
cies, including miscarriages and terminations. Data are presented as number of patients (%), unless 
indicated otherwise. Continuous variables are presented as mean ± standard deviation or as median 
with interquartile range.
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Heart failure was the most common cardiac complication, with persistent NYHA 
deterioration in 3 patients (Table 3). One mechanical valve recipient with permanent 
atrial fi brillation developed prosthetic valve thrombosis and subsequent heart fail-
ure at 33 weeks’ gestation. Anticoagulation was converted to intravenous heparin, 
and the woman underwent caesarean section at 36 weeks. A female infant of 2,150 
g was born. Five weeks later, she underwent repeat AVR with another mechanical 
valve.
The most common obstetric complications concerned hypertension-related 
disorders, preterm delivery, and small-for-gestational-age infants (Table  3 and 
Figure  2). Of the 13 pregnancies that ended prematurely, 5 were induced before 
37 weeks because of cardiac indication: congestive heart failure in 2 patients (1 
mechanical valve prosthesis, 1 pulmonary autograft), prosthetic valve thrombosis 
(mechanical valve prosthesis), Marfan syndrome (homograft), and dilated aortic 
root with aortic and pulmonary regurgitation (pulmonary autograft).
One fetal death occurred in a mechanical valve recipient at 20 weeks and 4 days 
that presented with an absent heart rate, growth restriction, and fetal hydrops on ul-
trasonography. A macerated male infant (190 gram) with a placenta of 30 gram was 
born. Fetal autopsy was declined by the parents. Placental pathologic examination 
showed severe placental insuffi  ciency. One postnatal death occurred in a pulmonary 
Table 2. Mode of delivery of the 55 completed pregnancies in 35 women who underwent aortic valve
replacement
Variable
All
(n=55)
Autograft
(n=28)
Homograft
(n=20)
MP
(n=7)
p-value
Vaginal delivery* 42 (76%) 19 (68%) 17 (85%) 6 (86%) .32
Spontaneous 11 (20%) 3 (11%) 5 (25%) 3 (43%) .25
Assisted delivery 13 (24%) 7 (25%) 5 (25%) 1 (14%) .67
Epidural anesthesia 11 (20%) 4 (14%) 5 (25%) 2 (29%) .80
Induction of labour 20 (36%) 11 (39%) 7 (35%) 2 (29%) .53
Elective caesarean section 8 (15%) 5 (18%) 2 (10%) 1 (14%) .89
Maternal cardiovascular risk 5 (9%) 3 (11%) 2 (10%) 0 .72
Prosthetic valve thrombosis 1 (2%) 0 0 1 (14%) .13
Fetal presentation 1 (2%) 1 (4%) 0 0 1.00
Fetopelvic disproportion 1 (2%) 1 (4%) 0 0 1.00
Emergency caesarean section 5 (9%) 4 (14%) 1 (5%) 0 .42
Fetal distress 2 (4%) 1 (4%) 1 (5%) 0 1.00
Placental abruption 1 (2%) 1 (4%) 0 0 1.00
Fetopelvic disproportion 2 (4%) 2 (7%) 0 0 .62
MP = mechanical valve prosthesis, n = number of pregnancies, fetal distress = decelerations on car-
diotocography, * = overlapping categories.
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autograft recipient who was on oral anticoagulation therapy because of a protein 
C defi ciency and previous deep venous thrombosis. At 19 weeks, she experienced 
preterm premature rupture of the membranes and fetal growth restriction. Despite 
the poor prognosis, the woman chose expectant management. At 30 weeks, she 
spontaneously delivered a 600-g boy who died on the fi rst postnatal day from lung 
hypoplasia.
No potential predictors of cardiac complications could be identifi ed. Obstetric 
complications were more common in patients with cardiac complications during 
pregnancy (odds ratio 13.2, 95% confi dence interval 1.5 to 119.5; p = 0.02). No cor-
relation was found between the preconceptional maximum aortic jet velocity over 
the aortic valve and the birth weight (r -0.01; p = 0.95).
Two women with a completed pregnancy were not treated according to the cur-
rent European Society of Cardiology guidelines for the use of anticoagulation in 
pregnant mechanical valve patients.17 One patient received an insuffi  cient dose 
of oral anticoagulation therapy and developed a prosthetic valve thrombosis. The 
other patient was treated with a combination of acenocoumarol and LMWH until a 
healthy female infant was born by spontaneous vaginal delivery at 40 weeks’ gesta-
tion.
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Figure 1. Mode of delivery of 55 completed pregnancies compared to Dutch Perinatal Registry. 
CS = caesarean section.
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DISCUSSION
Pregnancy in patients after AVR with a human tissue valve or a mechanical valve 
substitute was associated with serious maternal cardiac and obstetric complications 
in half of the patients in our study. However, all patients survived pregnancy. Hu-
man tissue valve recipients had a lower incidence of cardiac maternal and obstetric 
Table 3. Outcome of the 55 completed pregnancies in 35 women who underwent aortic valve replace-
ment
Variable All
(n=55)
Autograft
(n=28)
Homograft
(n=20)
MP
(n=7)
p-value
Pregnancy duration (weeks) 38 (36-40) 38 (35-40) 39 (38-40) 36 (31-39) .20
Birth weight (kg) (n=54) 3.0 (2.5-3.3) 3.0 (2.4-3.3) 3.1 (2.9-3.3) 2.7 (1.9-3.0) .11
Birth weight percentile (n=54)* 31 (14-54) 30 (11-54) 34 (21-54) 16 (11-80) .47
APGAR score ≥8 at 5 minutes 94% 96% 95% 86% .55
Cardiac complications** 7 (13%) 4 (14%) 1 (5%) 2 (29%) .21
Heart failure 5 (9%) 2 (7%) 1 (5%) 2 (29%) .20
Supraventricular arrhtymias 4 (7%) 1 (4%) 1 (5%) 2 (29%) .09
Persistent NYHA deterioration 3 (5%) 1 (4%) 1 (5%) 1 (14%) .71
Valve thrombosis 1 (2%) 0 0 1 (14%) .13
Obstetric complications** 21 (38%) 11 (39%) 6 (30%) 4 (57%) .50
Hypertension related disorders 4 (7%) 0 4 (20%) 0 .02
PIH 2 (4%) 0 2 (10%) 0 .14
Preeclampsia 2 (4%) 0 2 (10%) 0 .14
Premature labor 4 (7%) 3 (11%) 0 1 (14%) .33
PPRoM 3 (5%) 3 (11%) 0 0 .26
Placental abruption 1 (2%) 1 (4%) 0 0 1.00
Preterm delivery 13 (24%) 8 (29%) 2 (10%) 3 (43%) .14
Spontaneous 5 (9%) 4 (14%) 0 1 (14%) .24
Cardiac maternal indication 5 (9%) 2 (7%) 1 (5%) 2 (29%) .20
Obstetric indication 3 (5%) 2 (7%) 1 (5%) 0 1.00
Small for gestational age 8 (15%) 5 (18%) 3 (15%) 0 .67
Fetal death 1 (2%) 0 0 1 (14%) .13
Postpartum hemorrhage 2 (4%) 2 (7%) 0 0 .36
Postpartum blood loss (ml) 300 (200-425) 300 (200-650) 350 (300-400) 200 (200-500) .48
Neonatal death 1 (2%) 1 (4%) 0 0 1.00
MP = mechanical aortic valve prosthesis, n = number of pregnancies, APGAR = appearance, pulse, 
grimace, activity, respiration, NYHA = New York Heart, Classifi cation, PIH = pregnancy induced hy-
pertension, PPRoM = preterm premature rupture of membranes, * = adjusted for gestational age, 
fetal sex, and parity, ** = overlapping categories. Data are presented as number of pregnancies (%) 
and continuous variables are presented as median with interquartile ranges.
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complications than did patients with mechanical valve prostheses. The mechanical 
valve recipients were at risk of miscarriage, supraventricular arrhythmias, heart 
failure, and preterm delivery.
Pregnancy elicits major hemodynamic changes.18,19 In addition, pregnancy 
induces alterations in the maternal coagulation cascade that make it diffi  cult to 
provide suffi  cient anticoagulation therapy in mechanical valve recipients and is, 
therefore, associated with maternal morbidity and mortality.1,9,10 However, more 
intensive anticoagulation can lead to hemorrhage. A recent review of maternal 
mortality considers care to be suboptimal when management of anticoagulation 
hab been inappropriate, which can contribute to maternal cardiac death.20 A Danish 
cohort study described 2 maternal deaths in 107 mechanical valve recipients, of 
which 1 was anticoagulation related.1 The mechanical valve patient in our cohort 
who developed a prosthetic valve thrombosis had failed to comply with her anti-
coagulation therapy, leading to inadequate anticoagulation. Although appropriate 
dosing of oral anticoagulation can be challenging in pregnancy, patient compliance 
must also be taken into account.
Another important cardiac complication in our study population was symptom-
atic heart failure during pregnancy, occurring in 5 patients, of whom 3 experienced 
persistent NYHA deterioration after 1 year. Heart failure is a serious complication in 
pregnant patients who have undergone previous valve replacement.1,21-23 It has been 
the cause of maternal death1, but also been an indication for pregnancy termina-
tion.22 Of the 5 patients with heart failure in our study, 2 were advised against preg-
nancy prior to conception; both had persistent NYHA deterioration after pregnancy. 
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Figure 2. Incidence of obstetric and perinatal complications of 55 completed pregnancies compared 
to Dutch Perinatal Registry16. PIH = pregnancy-induced hypertension.
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Although preconceptional counseling includes the intention to reduce the risk on 
severe maternal cardiac events during pregnancy, it is the patient and her family 
who fi nally decides to pursue or decline a pregnancy according to their informed 
wishes and expectations.
In the present study, hypertension-related disorders occurred signifi cantly more 
often in homograft recipients. Of the reports on pregnancy outcomes in homograft 
patients2,10,21,24,25, only 1 study has described a case of preeclampsia.24 The aortic 
gradient increases signifi cantly in homograft patients during pregnancy, but this 
is also seen in mechanical valve recipients21 and probably refl ects the increased 
cardiac output (increased stroke volume) and decrease in systemic vascular 
resistance. However, we could not identify a specifi c reason for the increase in 
hypertension-related disorders among the homograft patients.
Almost all newborns of mechanical recipients were delivered vaginally, without 
excessive maternal hemorrhage during labor or cesarean section (Figure 2). The 
Danish cohort, however, reported a postpartum bleeding incidence of 12% and 1 
fatal bleeding episode.1 This underlines the importance of careful anticoagulation 
monitoring during delivery. Our study has illustrated that through careful antico-
agulation monitoring during delivery, it is possible for mechanical valve recipients 
to deliver an infant without extensive bleeding.
In our series, 1 fetal death and 1 postnatal death occurred, both in patients receiv-
ing oral anticoagulation therapy. Although the risks appears to be decreasing in the 
past few decades, mechanical valve recipients still have ≤9% fetal death risk.1,9,26 
Perinatal death risk is reported to be ≤6% in mechanical valve recipients9,26,27 and 
≤8% in the mostly small cohorts of human tissue valve recipients.10-12,21,24,25 Dore 
and Somerville reported 1 perinatal death among 14 pregnancies in pulmonary 
autograft patients, although the death was not directly related to cardiac reasons.11
Preterm delivery occurred more often (24%) in our study population than in the 
general Dutch population, especially in mechanical valve recipients. This high rate 
of preterm delivery was also found in the Danish cohort, which had a rate of 49%.1 
Of the 13 cases of preterm delivery in the present study, 8 were induced because of 
a medical indication, 5 of which were for cardiac reasons. Because preterm delivery 
is the leading cause of infant mortality and morbidity, it is crucial to understand 
which risk factors are associated with preterm delivery.28 Perhaps the treating 
physicians were too cautious with this particular patient group, and, therefore, it 
was mainly ‘physician decision’ to intervene earlier as compared to in the normal 
Dutch population. Perhaps with good advice on how to guide the anticoagulant 
management during delivery (new European Society of Cardiology guidelines) and 
some reassurance, from on our fi ndings, fewer preterm deliveries could be reached.
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The counseling of young female patients who require AVR and might contemplate 
pregnancy requires a multidisciplinary discussion that includes several important 
issues. These patients should be individually informed about the advantegs and 
disadvantages of the diff erent available valve substitutes and corresponding po-
tential pregnancy-associated maternal and fetal complications.3 The high incidence 
of preterm delivery and valve thrombosis in mechanical valve recipients illustrates 
that these valves are far from ideal for patients during pregnancy. However, the 
curious fi nding of a high incidence of hypertension-related disorders in homograft 
recipients requires additional studies and careful monitoring of the last stage 
of pregnancy in this patient group. Although human tissue valves needs careful 
obstetric monitoring, they provide female patients with a biological solution that 
eliminates the daily burden of anticoagulation, in particular during pregnancy, and 
their durability is not infl uenced by pregnancy.29 Therefore, human tissue valves 
should be considered as aortic valve substitute of choice for young patients with 
severe aortic valve disease who are planning to become pregnant.
Just as with most studies on this topic, the patient numbers in the present study 
were relatively small, and treatment occurred at a tertiary hospital, necessitating 
careful interpretation of the results.
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PREGNANCY AND DURABILITY OF HUMAN AORTIC VALVE SUBSTITUTES
TO THE EDITOR
There is insuffi  cient published evidence about the potential degenerative eff ects 
of pregnancy on the homograft and pulmonary autograft in the aortic position. To 
assess the association between pregnancy and accelerated degeneration of human 
aortic valve substitutes, we conducted a retrospective analysis of a prospective co-
hort study of female patients who received a human tissue valve in aortic position 
at our institution.
All patients who have received a homograft or autograft in aortic position in our 
center since 1987 are enrolled in an ongoing prospective follow-up study.1 Patients 
undergo annual clinical follow-up and biennial standardised serial echocardiogra-
phy (aortic gradient (Vmax), aortic regurgitation (AoI), annular and sinotubular 
junction diameter (AD and STJ). We identifi ed 108 female patients who underwent 
59 homograft and 49 autograft procedures, and were ≤50 years old at the time of 
surgery and at least 16 years old at the time of study (age 29 ± 13 years). Informed 
consent was obtained from the patients to interview them (December 2010) for 
additional information on pregnancy and cardiac status (institutional review board 
number: 2010-272).
Freestanding root replacement with reimplantation of the coronary arteries was 
performed in most patients. Fifteen homograft patients underwent a subcoronary 
homograft implantation, and 2 autograft patients an inclusion cylinder aortic root 
replacement.
Outcome was reported according to the 2008 American Association of Thoracic 
Surgery/European Association of Cardio-Thoracic Surgery/Society of Thoracic Sur-
geons guidelines for reporting mortality and morbidity after cardiac valve interven-
tions. Mixed-eff ects models were used to assess changes in echocardiographic 
measurements over time while accounting for within-patient correlation between 
repeated follow-up measurements.2 Total follow-up was 1,448 patient years and 
99% complete. Ninety-nine patients had ≥1 echocardiographic examinations (me-
dian 6; range 1 to 11).
Thirty-one patients (13 homografts and 18 autografts) experienced 55 pregnan-
cies, including 48 completed pregnancies, 4 elective abortions for noncardiac 
reasons, and 3 miscarriages. Homograft recipients without pregnancies were older 
than homograft recipients who became pregnant (35 versus 28 years; p = 0.02). 
There were no other diff erences in patient characteristics between homograft and 
autograft patients without pregnancies and those who became pregnant.
During follow-up, 9 homograft patients and 4 autograft patients died. Fifteen-year 
survival in homograft patients was 80.0 ± 7.3% for patients without pregnancies 
and 100% for patients with pregnancies; in autograft patients, this was 94.1 ± 4.0% 
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for patients without pregnancies and 94.4 ± 5.4% for patients with pregnancies 
(p = NS).
Fifteen homograft patients required reoperation for a calcifi ed and degenerated 
homograft; 2 additional homograft patients were reoperated for paravalvular leak. 
Twelve autograft patients were reoperated for neoaortic regurgitation and dilatation 
of the neoaortic root, including 11 autograft replacements and 1 valve-sparing aortic 
root replacement (Yacoub procedure). Freedom from aortic valve reoperation at 15 
years was 63% (95% confi dence interval (CI): 57 to 69%) in homograft patients; in 
autograft patients, this was 75% (95% CI: 63 to 87%). Freedom from reoperation 
was comparable between patients who experienced pregnancy and those who did 
not, in both homograft and autograft recipients (p = NS).
Figure 1 shows progression of Vmax, STJ diameter, AD, and AoI over time. Preg-
nancy was not associated with changes in Vmax over time, STJ diameter over time, 
AD over time, or AoI grade over time for either valve type.
Pregnancy is known to provide signifi cant hemodynamic changes, with an in-
crease in heart rate, plasma volume, and cardiac output.3 This may impose a burden 
on biological valve substitutes, accelerating degeneration. However, we found that 
pregnancy was not associated with either homograft or pulmonary autograft valve 
reoperation and echocardiographic valve function over time. This is in concordance 
with previous, but very limited, evidence.4,5
The question remains as to what the best valve substitute choice is for young 
female patients who require aortic valve replacement, and who may contemplate 
pregnancy. Bioprosthetic valves are an option, but valvular deterioration seems 
to accelerate during pregnancy.6 Mechanical prostheses are far from ideal during 
pregnancy because of anticoagulation therapy-related complications, although in 
some patients mechanical valves are the only option. Human tissue valves do not 
require anticoagulation therapy and have good haemodynamic performance, but 
homografts –in contrast to autografts- do not increase in size with the growing 
child. In addition, autografts have a superior hemodynamic profi le,7 which par-
ticularly during pregnancy has potential benefi cial eff ects on cardiac function. In 
contrast, neoaortic root dilatation and neoaortic regurgitation cause an increased 
need for reoperation.8
Because human tissue valve durability is not infl uenced by pregnancy, it off ers an 
attractive biological option for aortic valve replacement in young female patients. 
Young female patients who (may) contemplate pregnancy should consider human 
tissue valves as a suitable aortic valve substitute.
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DISCUSSION
INTRODUCTION
The aim of this thesis was to provide insight in the natural history, treatment, and 
prognosis of adult patients with aortic stenosis (AS). From the studies included in 
this thesis several observations emerged, illustrating the complexity of AS and the 
challenges it poses in current clinical practice.
This chapter will address the research questions that were formulated and discuss 
how the insights obtained from this thesis may help treating physicians to optimize 
clinical decision-making with respect to the diagnostic process, treatment strategy, 
and monitoring patients with AS disease. Finally, prospects and recommendations 
for future research will be presented.
WHAT IS THE NATURAL COURSE OF AS DISEASE?
Progression of valvular AS disease is very heterogeneous as evidenced from the 
cardiac catheterization and echocardiographic studies that are described in Chapter 
2, 3, and 4. This heterogeneity may be explained by several factors: patient charac-
teristics, diff erent methods of measuring AS severity, and by the heterogeneous 
course of AS disease itself.
Older age is associated with an increased prevalence of AS disease.1 In patients 
with normal or sclerotic valves (mean age >70 years), advanced age has been 
reported a signifi cant predictor for progression to AS.2 This thesis showed that in 
patients with moderate to severe AS, older age was associated with a lower rate of 
AS progression. Lower AS progression estimates may be caused by age-dependent 
infl ammatory and atherosclerotic pathways underlying AS pathophysiology.3-7 
However, by using mixed model analysis in Chapter 5 in which information about 
baseline aortic valve area was included, age was no longer a predictor for AS pro-
gression rate. An explanation for this could be the limited follow-up duration of the 
study population included in the mixed model analysis which allowed only minor 
progression over time. To rule out this shortcoming, a longer follow-up period is 
needed.
Cardiovascular co-morbidities seem to be associated with a lower AS progression 
rate. As the pathway of AS disease also involves atherosclerotic characteristics, one 
would expect the opposite: a faster AS progression rate in patients with cardiovas-
cular co-morbidities.8,9 A possible explanation is that the presence of co-morbidities 
may urge treating physicians to more frequent patient monitoring and therefore 
earlier detection of AS disease, which in general is accompanied by lower aortic 
gradients. As a lower baseline peak aortic gradient is associated with a lower AS pro-
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gression rate compared to patients with a higher baseline gradient, this may cause 
lower AS progression estimates in patients with cardiovascular co-morbidities.10
Several classifi cations are used for defi ning AS severity as described in Chapter 2, 3, 
and 5. Although aortic valve area (AVA), maximum aortic jet velocity (Vmax), mean 
and peak aortic gradient (MAG, PAG) are recommended by the current American 
and European guidelines for the management of valvular heart disease,11,12 these 
criteria have shown to be inconsistent in patients with AS disease, even in patients 
with a normal left ventricular (LV) function.13,14 Using AVA will overestimate AS 
severity as compared with Vmax and MAG, and this overestimation is only partly 
due to reduced stroke volume. A uniform classifi cation of AS disease worldwide 
would greatly improve the comparability of available reports and allowed enhanced 
estimation of AS progression.
As aortic valve calcifi cation is identifi ed as one of the few known predictors for 
AS progression, there is need for a universal method to measure aortic valve cal-
cifi cation.15,16 Unfortunately, this is not the case and a wide range of tests are used 
to assess aortic valve calcifi cation, employing transthoracic and transoesophageal 
echocardiography, computed tomography, or magnetic resonance imaging.17-19 The 
development of an imaging modality that allows measurement of all aspects of cal-
cifi cation from early sclerosis to advanced calcifi c thickening of the leafl ets, would 
greatly enhance assessment of AS severity and patient prognosis.
Our attempts to capture the natural history of aortic stenosis undoubtedly have 
been infl uenced by study design and several types of bias. In general, patient selec-
tion in randomized controlled trials is subject to more strict inclusion criteria as 
compared to observational studies.20 In addition, observational studies are more 
prone to publication bias as compared to randomized controlled trials.21 Even a 
meta-analysis that carries one of the highest levels of evidence if properly performed, 
may induce bias by including only published studies, arbitrarily determined cut-off  
values of continuous values and proportions, data-driven subgroup analysis, us-
ing diff erent outcomes measures (single or composite endpoint), and inadequate 
control of all confounding factors due to the often incomplete adjustment of 
confounding factors in observational studies.22 In an ideal world one would like to 
prospectively study all patients with AS in a uniform manner and at pre-specifi ed 
intervals. This can only be achieved through agreement on the defi nitions of AS 
severity, standardization of methods to measure AS severity, and the initiation of 
large international consortia that collaborate to further unveil the natural history of 
AS and its determinants.
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WHAT IS THE ADDED VALUE OF DIFFERENT DIAGNOSTIC MARKERS 
FOR AS?
In severe AS, subendocardial fi brosis may develop. As a result, subendocardial 
ischemia may occur, with associated increased morbidity and mortality.23 Therefore, 
subendocardial ischemia should be diagnosed and monitored properly. There are 
several manifestations of subendocardial ischemia: the presence of angina, elec-
trocardiographic strain pattern, and changing echocardiographic LV deformation 
parameters.
In patients with AS disease, LV geometry changes by the increased LV load in 
order to preserve normal ejection fraction despite depressed LV myocardial systolic 
function.24,25 LV deformation parameters such as rotation, shortening, and strain, 
provide a direct measure of myocardial deformation which enables assessment 
of LV myocardial systolic function.26-30 LV twist, the measure of instantaneous api-
cal-basal systolic rotation resulting from the dynamic interaction of counteracting 
muscle fi bres arranged in subendocardial and subepicardial spiral loops, increases 
proportionally to AS severity and might serve as a compensatory mechanism to 
maintain systolic function in patients with severe AS as described in Chapter 6. LV 
hypertrophy contributes to LV diastolic dysfunction and is associated with a delayed 
LV untwist and reduced untwisting rate.31-33 However, the observation in this thesis 
that peak diastolic untwisting velocity is higher in AS patients as compared to 
age-matched healthy controls, needs further exploration. Serial echocardiographic 
data are needed to reveal the longitudinal course of LV twisting and rotation and its 
diagnostic value in monitoring AS disease.
In addition, this thesis shows that electrocardiographic strain, defi ned as ST-seg-
ment depression, is associated with impaired systolic LV longitudinal velocities in 
patients with severe AS and normal LV function without coronary artery disease or 
left bundle branch block as described in Chapter 7. In patients with asymptomatic 
AS, electrocardiographic strain was independently predictive of a poor prognosis 
such as a 3.1-fold higher risk of (in-study) myocardial infarction.34 In patients with 
AS, echocardiographic strain is reportedly associated with higher LV mass, concen-
tric LV geometry, and more severe AS, and has incremental prognostic value over 
traditional risk markers including hemodynamic severity, symptom class, and LV 
ejection fraction.30,35 Evidence about the diagnostic value of electrocardiographic 
strain is scarce and needs to be further explored in larger studies with longitudinal 
data and compared to echocardiographic strain studies.
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WHAT IS THE CLINICAL COURSE OF SEVERE AS DISEASE IN 
CONTEMPORARY CLINICAL PRACTICE?
The current American and European guidelines for the management of valvular 
heart disease state that a symptomatic patient with severe AS has an indication 
for aortic valve replascement (AVR).11,12 In the absence of serious co-morbidities, 
AVR is indicated in symptomatic patient with severe AS and should be performed 
promptly after onset of symptoms.11,12 However, half of the patients in the AVARIJN 
study did not undergo AVR or transcatheter aortic valve implantation (TAVI) as 
described in Chapter 8.
Several possible explanations for a conservative treatment strategy in these 
patients are already reported: high anticipated operative risk, presence of serious 
co-morbidities, misclassifi cation of AS severity and symptoms, and patient prefer-
ences.36 In addition, age-related factors like frailty may play a role when selecting a 
treatment strategy. These are currently not taken into account in surgical risk scores 
but may be of great value in improving the performance of surgical risk models for 
elderly patients with severe symptomatic AS. Referral to a multidisciplinary heart 
team is encouraged, since it allows for a guidelines-driven team approach that 
formally includes patients’ preferences to achieve optimal evidence-based and well 
informed decisions for symptomatic patients.37,38
Nowadays, as described in Chapter 4, TAVI is emerging for candidates who cannot 
undergo surgery for symptomatic severe AS.39 Not all patients want to be treated 
despite a clear understanding of the individual risks and benefi ts which takes into 
account patient wishes, life expectancy, quality of life, cardiac and non-cardiac 
co-morbidities. Future studies are needed to identify those patients who in fact will 
benefi t from TAVI and those who will take advantage of conservative treatment. 
One of the major challenges in the next few years is to determine a better balance 
between undertreatment and overtreatment of AS: while some patients are cur-
rently denied invasive treatment and the prospect of a better quality of life, the suf-
fering of other patients –usually those at the end of their life- may be unnecessarily 
prolonged by invasive treatment of AS.
Chapter 8 of this thesis showed that three asymptomatic patients with severe 
AS disease in the AVARIJN cohort underwent aortic valve surgery. Performing an 
AVR in asymptomatic patients and more specifi cally the time of this intervention, 
remains a matter of controversy.12 Morbidity and mortality due to the procedure 
itself plus long-term mortality and morbidity due to valve-related complications 
have to be balanced against potential benefi ts such as a decreased risk of sudden 
cardiac death and LV dysfunction. Although the number of prognostic markers is 
growing, critical appraisal of these markers in asymptomatic patients with severe 
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AS still shows diffi  culty to identify which markers adequately predict a high risk of 
sudden death.40 A recent decision-analytic study showed that immediate surgery, 
as compared to watchful waiting, in asymptomatic severe AS does not improve 
outcomes unless the risk of sudden death pre-AVR and heart failure postoperative 
are higher than currently reported.41 These results support the current American 
and European guidelines for the management of valvular heart disease of frequent 
clinical follow-up.11,12
HOW DOES AS TREATMENT IN CONTEMPORARY PRACTICE AFFECT 
QUALITY OF LIFE?
Given their limited lifespan, quality of life becomes an important measure of disease 
burden and outcome in elderly patients. Regardless of treatment strategy, AVARIJN 
patients with severe symptomatic AS had an impaired quality of life as compared to 
asymptomatic patients with severe AS and as compared to the general population 
as described in Chapter 9. Regardless of age, both physical and mental components 
are signifi cant lower in symptomatic patients. This indicates that patients in each 
health domain aged from 40 years to over 70 years suff er equally from severely 
impaired quality of life due to severe AS disease.
Even patients with only mild symptoms experience a lower quality of life com-
pared to asymptomatic patients or the general population. With increasing severity 
of symptoms, both mental and physical quality of life decrease and correspond to 
the severity of symptoms according to the New York Heart Association classifi ca-
tion. This indicates that the SF-36v2 is a valid tool to measure quality of life in this 
population.
Quality of life in surviving AVR patients improves in most health domains while 
symptomatic patients who were treated conservatively –for example due to advanced 
age or co-morbidities- were left with a clearly impaired quality of life. Especially 
these conservatively treated symptomatic patients should be referred for the multi-
disciplinary heart team because it has been shown that they may potentially benefi t 
from TAVI.42 As life expectancy is increasing and hardly any evidence about quality 
of life in patients with severe AS is available, the information on quality of life from 
AVARIJN is important and can be applied for individual shared decision-making 
purposes, since most patients can be operated with acceptable risks of morbidity 
and mortality nowadays.
The ‘watchful waiting’ strategy in asymptomatic AVARIJN patients proved to be 
right at fi rst presentation as they had the same quality of life as compared to the 
general population. However, as a substantial part became symptomatic within 2 
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years, the debate about preventive early (surgical) intervention in asymptomatic 
patients with severe AS is on-going.41 Future, randomised controlled trials with a 
longer follow-up are required to reveal the potential benefi t of early AVR or TAVI by 
preventing an increase in disease burden.
WHAT IS THE NATURAL HISTORY AND SIRGUCAL OUTCOME OF 
DISCRETE SUBAORTIC STENOSIS IN ADULT PATIENTS?
In the spectrum of AS disease, discrete subaortic stenosis (DSS) is part of con-
genital subvalvular AS disease which represents a small and very specifi c patient 
population. Compared to childhood DSS, adult DSS progresses slowly as described 
in Chapter 11.43,44 An explanation for this may be that adult patients with conserva-
tively treated DSS represent a mild phenotype in the spectrum of DSS. However, 
the observed faster progression of patients with concomitant other congenital heart 
disease (CHD) needs further exploration to test the hypothesis whether CHD itself, 
the concomitant prior cardiac surgery, or other factors are associated with this 
faster progression.
The current indication for surgery is mainly based on DSS severity and prevention 
of progressive aortic regurgitation.45-47 This thesis showed that initial severity of 
DSS is not associated with DSS progression over time which is another contrast to 
the existing paediatric studies.44,48,49 Also aortic regurgitation does not signifi cantly 
progress over time.50 Given this information, the current indication for DSS surgery 
according to the American guidelines seems too aggressive by applying the cut-off  
value of 50 mmHg for the left ventricular outfl ow tract (LVOT) peak gradient and 
may need a revision.45
In our study concerning the surgical outcome of DSS in adults, the re-operation 
rate for DSS was 1.8% per patient-year (Chapter 12) and comparable to other large 
series.51,52 Although this rate appears to be low, given the excellent survival of pa-
tients after DSS surgery, a majority will require a reoperation for recurrent DSS 
later in life. Postoperative mild aortic regurgitation is common, but not progressive. 
Surprisingly, older age at the time of DSS diagnosis is a strong predictor for an 
increasing postoperative LVOT gradient which may be explained by aging itself 
or the fact that when DSS is discovered late in adulthood, patients might be in 
an advanced stage of the disease. As expected, progression of the postoperative 
LVOT gradient and incomplete removal of the LVOT obstruction are risk factors 
for re-operation. Curiously, female gender is a strong predictor for re-operation for 
DSS too, possibly due to hormonal and/or genetic changes and future studies have 
to explore the pathophysiological background of this gender diff erence further.53,54
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With regard to myectomy, several hypotheses for recurrence of DSS exist55 and 
evidence about the value of an additional myectomy to decrease DSS recurrence 
is confl icting.52,56-61 Chapter 12 showed that myectomy was of no additional value 
with regard to preventing reoperations and did not decrease postoperative LVOT 
gradient progression rate. In addition, myectomy was associated with an increase 
in complete AV-block. Given these observations, additional myectomy should not 
be performed routinely.
CHOICE FOR AORTIC VALVE SUNSTITUTE IN YOUNG FEMALE PATIENTS 
WITH AS
When a young female patient requires aortic valve replacement, she needs to be 
counselled on the advantages and disadvantages of each available valve substitute 
including the potential pregnancy-associated complications accompanying these 
valve substitutes. Evidence on these clinically relevant issues is scarce.
Pregnancy itself induces several alterations in the maternal body such as an 
increase in blood volume, cardiac output, and heart rate, a decrease in systemic 
vascular resistance, and alterations in the coagulation cascade which result in 
hypercoagulability.62-64 Chapter 13 of this thesis described that, although survival is 
excellent, pregnancy after AVR with a human tissue valve or mechanical prosthesis 
is associated with serious maternal cardiac, obstetric, or perinatal complications 
in 50% of the patient population. Especially mechanical valve recipients are at risk 
for maternal cardiac and perinatal complications. Heart failure and arrhythmias 
were reported relatively common in mechanical valve recipients and may be related 
to the increased hemodynamic forces on the static mechanical valve prosthesis 
during pregnancy and labour. Additionally, it is diffi  cult to provide adequate anti-
coagulation therapy in mechanical valve recipients due to the altered coagulation 
cascade which indirectly may contribute to maternal morbidity and even mortality.64 
In contrast, surprisingly, almost all newborns of mechanical valve recipients were 
delivered without excessive maternal haemorrhage during labour or caesarean 
section despite anticoagulation therapy. A limitation of the study in Chapter 13 is 
the lack of an (universal) anticoagulation protocol because most patients became 
pregnant before the introduction of the recent European Society of Cardiology 
(ESC) guidelines on the management of cardiovascular disease during pregnancy.65 
The clinical implementation of these current ESC guidelines results hopefully in a 
decrease of anticoagulation associated complications. Finally, preterm delivery was 
a common complication regardless of the implanted valve substitute, but especially 
in mechanical valve recipients. As preterm delivery is the leading cause of infant 
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morbidity and mortality, it is important to understand the underlying mechanism 
and to attempt -if possible- to reduce iatrogenic induced preterm deliveries.66 In 
this study, induced preterm deliveries were mostly performed because of maternal 
cardiac reasons. Possibly, the multidisciplinary team of treating physicians is over-
cautious with this particular patient group and therefore intervenes earlier.
Given our observations on pregnancy after AVR, for young female patients who 
may contemplate pregnancy, human tissue valves seem the favourable aortic 
valve substitutes with excellent hemodynamic performance and absent need for 
anticoagulation therapy although careful obstetric monitoring is necessitated and 
valve durability is limited.67 Nevertheless, pregnancy may potentially aff ect human 
tissue valve durability. Evidence about pregnancy-associated valve degeneration of 
bioprosthesis remains confl icting. Biological valve prosthesis have been reported 
to degenerate faster during or shortly after pregnancy68 while more recent stud-
ies showed no long term pregnancy-associated degeneration of bioprosthesis.69,70 
Chapter 14 of this thesis showed that the durability of pulmonary autografts and 
homografts is not infl uenced by pregnancy as measured by the need for homograft 
or pulmonary autograft valve reoperation and echocardiographic valve function 
over time. A recent randomized controlled trial showed that pulmonary autograft 
implantation is superior over homograft implantation with regard to patient survival 
and valve durability.67 However, the problem of neo-aortic root dilatation and regur-
gitation which necessitates a reoperation later in life, has still to be solved.67,71,72 
Individual counseling of young female patients who require AVR should include 
information on the (dis)advantages of the diff erent available valve substitutes, the 
corresponding potential pregnancy-associated maternal and fetal complications, 
and the risk of a reoperation later during life. These (surgical) aspects as well as 
informed patient preferences are the basis for informed shared decision making to 
select the most appropriate aortic valve substitute in the individual patient.
CONCLUSIONS
In conclusion, several important insights emerge from this thesis:
1. The heterogeneous natural history of AS disease demands careful monitoring 
of patients with (a)symptomatic AS disease, employing uniform standardized 
diagnostic criteria for assessment and description of AS disease severity.
2. LV systolic deformation parameters should be considered as additional, early 
markers of subendocardial ischemia since they add additional information above 
the standard echocardiographic parameters in contemporary practice which 
may allow earlier diagnosis of LV dysfunction.
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3. The observation that many symptomatic patients with severe AS are not referred 
for evaluation for invasive treatment, emphasizes the need for a systematic 
evidence-based multidisciplinary team approach to optimise individual treat-
ment selection.
4. Patients with symptomatic AS disease have a markedly reduced quality of life. 
Aortic valve replacement in patients with symptomatic AS disease is associated 
with a marked improvement of quality of life.
5. Isolated DSS progresses slowly in adulthood.
6. Surgery for DSS shows excellent long-term results and is postoperatively ac-
companied by mild aortic regurgitation and slowly increasing LVOT gradient. 
Myectomy should be only performed in case of marked septal hypertrophy and 
re-operation is indicated when the peak LVOT gradient approaches 80 mmHg.
7. Cardiac maternal, obstetric, and perinatal complications are common in young 
female patients with aortic valve substitutes, especially in mechanical valve 
recipients.
8. There is no association between pregnancy and the durability of pulmonary au-
tografts and aortic homografts as measured by valve function and dimensions, 
and the need for re-operation. Human valve substitutes therefore off er young 
female patients who require aortic valve or root replacement a good biological 
solution.
CLINICAL IMPLICATIONS, RECOMMENDATIONS AND PROSPECTS
The knowledge emerging from this thesis may be helpful in clinical practice in 
several ways.
This thesis emphasizes both the heterogeneous nature of AS disease and the 
varying methods to assess AS disease and intensifi es the call for uniform and care-
ful monitoring of patients. Not only patients, but also clinicians and scientists will 
greatly benefi t from uniform and careful monitoring, since it allows for standardiza-
tion of clinical care and the potential to better compare outcome reports between 
institutions. National and international registries may also play an important role 
in this regard.
In an eff ort to identify potential genetic, anatomic (echocardiographic), and 
clinical predictors for the onset of AS disease and its progression, several aspects 
should be highlighted. First, long-term serial echocardiographic studies are 
needed which by using LV deformation parameters in combination with electro-
cardiographic strain, identify patients with subendocardial ischemia and may help 
clinicians to optimize the timing of (surgical) aortic valve intervention. Second, an 
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international tissue bank of aortic valves (and roots) donated by patients of all ages 
would greatly enhance basic biological research of the aortic valves. As biomark-
ers emerge on the horizon and their added value is investigated for the diff erent 
diseases in AS spectrum, it is likely that this research accelerates the identifi cation 
of potential, new predictors for faster disease progression. It is also expected that 
tissue engineered heart valves may help in providing the ultimate living and durable 
aortic valve substitute and potentially decrease the use of mechanical devices which 
require life-long anticoagulation therapy.
The observation that a substantial part of the symptomatic patients with severe 
AS disease does not undergo aortic valve (surgical) intervention will hopefully 
encourage physicians to refer patients for multidisciplinary heart team discussion 
to off er each patient an objective patient tailored and individualised treatment 
advice. Also the fi nding that symptomatic patients with severe AS disease have 
a markedly decreased quality of life which improves after (surgical) intervention, 
hopefully stimulates physicians to take quality of life into account when considering 
the diff erent treatment options and furthermore, as potential tool to optimize the 
timing of treatment.
In case of present concomitant other CHD in patients with DSS, treating phy-
sicians should be alert of potentially faster DSS progression with necessitates 
cautious patient monitoring. DSS severity should not be used as only criterion for 
intensifying surveillance or performing surgery. In addition, on the basis of expected 
progressive aortic regurgitation in adult patients with conservatively treated DSS, 
prophylactic surgery to prevent future valve damage seems not justifi ed. Given this 
information, the current indication for DSS surgery can be seen as aggressive in 
applying the cut-off  of 50 mmHg for the LVOT peak gradient as formulated in the 
American guidelines and may need a revision. Additional myectomy for DSS should 
be considered very carefully and seems only justifi ed in patients with clear septal 
hypertrophy.
Finally, the high occurrence of pregnancy-associated complications in female AVR 
patients should be confi rmed by larger cohort studies, preferable in a large inter-
national registry setting to ascertain suffi  cient numbers which include all currently 
available aortic valve prostheses.
As pregnancy-associated complications are common, careful and frequent 
monitoring during pregnancy and postnatal period by a multidisciplinary team is 
recommended.
Information on the occurrence of pregnancy- and prosthetic valve-associated 
complications should be part of preconceptional counselling as well as part of the 
consultations during pregnancy. In addition, since pregnancy is not associated with 
human tissue valve durability, pulmonary autografts and aortic homografts provide 
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a suitable biological valve substitute in young female patients who need an AVR and 
(may) contemplate pregnancy, at the cost of a reoperation later in life. Also here, 
informed patient preferences should be part of the shared decision making process 
aiming for the most suitable treatment for the individual patient.
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SUMMARY
This thesis provides an insight in several aspects of the natural history, the diff erent 
treatment options, and prognosis of adult patients with aortic stenosis (AS).
Chapter 1 describes the prevalence of aortic stenosis, the disease spectrum, the way 
in which it is diagnosed, today’s treatment options, and patient prognosis including 
pregnancy. Aortic stenosis is a common disease among elderly, the prevalence of 
this disease increases with age up to 5% among people aged over 75 years. Within 
38 years, in 2052, the estimated world population will have increased to 9.3 billion of 
whom at least 280 million inhabitants will have AS disease that requires treatment.
Chapter 2 and 3 focus on the progression of AS disease and the factors potentially 
associated with AS progression and clinical outcome. In addition, chapter 2 also 
provides a historical perspective of AS disease.
In literature, AS progression rates varies widely in usually small study populations. 
Therefore, chapter 3 presents a systematic literature review on the rate of AS pro-
gression in adults patients. The meta-analysis showed a pooled annual progression 
rate of the peak aortic gradient of 3.7 mmHg/year in randomised controlled trials 
and 6.0 mmHg/year in observational studies. Due to the heterogeneous nature 
of AS disease, the various methods of monitoring and individual patient factors, 
optimal and uniform monitoring of AS disease is needed to ultimately assist in 
tailoring the best treatment for the individual patient.
Chapter 4 emphasizes the course of severe AS disease in symptomatic patients 
who underwent medical treatment, open heart surgery or transcatheter aortic valve 
implantation. In general, elderly patients have an increased morbidity and mortality 
after a surgical or transcatheter intervention as compared with younger patients. 
Therefore, management decisions in elderly high-risk patients with severe symp-
tomatic AS should be made individually and based on patients’ life expectancy and 
quality of life, patients’ wishes, and comorbidities. Medical treatment could be a 
better option in a 85-year old patient with severe AS, mild angina and co-morbidities 
as compared to a 85-year old patient with severe AS, congestive heart failure and no 
further co-morbidity.
Chapter 5 evaluates progression of AS disease and potential predictors for AS 
progression with a mixed-model analysis of serial echocardiographic aortic valve 
area measurements in 186 patients in the multicenter prospective AVARIJN cohort 
study. Analysis of AS progression is usually done with standard statistical methods 
which introduce bias. Therefore, the more advanced mixed-model analysis was se-
lected for these study. On average, AVA decreased -0.034cm2/year in adult patients 
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with severe aortic stenosis. In particular older female patients with severe AS who 
present with a relatively large AVA have the highest rates of AS disease progression, 
over a 2 year time period.
Chapter 6 presents a broad spectrum of left ventricular (LV) rotation parameters 
to understand the mechanical properties of the LV in AS disease in patients with 
an aortic valve area <2.0 cm2 and LV ejection fraction >50%. The results were com-
pared to age-matched healthy control patients. The LV peak systolic twist increases 
in patients with AS disease and was proportionally to the severity of LV outfl ow 
obstruction. This might serve as a compensatory mechanism to maintain systolic 
LV function in the pressure overloaded LV. Diastolic untwisting rate was decreased 
in patients with AS.
Chapter 7 provides insight in the association between LV longitudinal velocities, a 
marker for subendocardial ischemia, and electrocardiographic ST-segment depres-
sion (strain) in 122 patients with severe AS with or without angina. Patients with 
strain had lower mean and septal systolic mitral annular velocities and a higher 
LV mass. Electrocardiographic strain was a predictor for lower LV velocities and 
could be a potential tool for identifying patients at risk for sudden cardiac death in 
patients with severe AS.
Chapter 8, 9 and 10 describe the AVARIJN study, a multicenter prospective cohort 
study which included 191 patients with severe AS in the Rotterdam area.
Chapter 8 analyzes the treatment strategy and survival by assessing clinical 
and echocardiographic assessments at baseline, 6, 12 and 24 months. The 2-year 
cumulative incidence of aortic valve replacement or transcatheter aortic valve im-
plantation was 56% in symptomatic patients. In particularly, elderly symptomatic 
patients with co-morbidities did not undergo invasive treatment. The 2-year survival 
of these symptomatic surgical treated patients was 90% as compared to 73% of the 
symptomatic conservatively treated patients. In addition, 68% of the asymptomatic 
patients became symptomatic during the 2-year follow-up period, illustrating the 
progressive nature of AS that demands watchful waiting.
Chapter 9 provides insight in the quality of life of both symptomatic and asymp-
tomatic AVARIJN patients by assessing the SF-36v2 Health Survey at baseline, 6, 
12 and 24 months. It It turned out that even minor symptoms have major impact 
on patient well-being and result in a strongly impaired quality of life as compared 
to the general age-matched Dutch population. The quantifi cation of this burden by 
using the SF-36v2 can assist in tailoring the best individual treatment.
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Chapter 10 focuses further on the quality of life in symptomatic AVARIJN patients 
who were treated either conservatively or surgical. After aortic valve replacement, 
patients experience a better physical quality of life, but also general health percep-
tion, vitality and emotional aspects improve to the level of the general age-matched 
Dutch population. In conservatively treated symptomatic patients who survive the 
long term, especially physical quality of life worsens over time.
Chapter 11 and 12 describe the course and outcome of patients with discrete su-
baortic stenosis (DSS) who were treated conservatively or previously underwent 
surgery.
Chapter 11 evaluates the natural history of 149 conservatively treated DSS patients 
and identifi ed risk factors for progression of DSS, aortic regurgitation (AR) and 
intervention-free survival. The median age was 20 years and median follow-up was 
6.3 years. The baseline peak LV outfl ow tract (LVOT) gradient was 32 mmHg and 
progresses slowly into adulthood with 0.8 mmHg/year. Not baseline LVOT gradient 
or age, but presence of associated congenital heart disease (CHD) was associated 
with a faster DSS progression. Therefore, these patients should be monitored 
cautiously. Mild AR was common, but did not evidently progress over time. The 
median intervention-free survival was 16 years and was associated with baseline 
LVOT gradient, DSS progression and AR.
Chapter 12 presents the surgical outcome of 313 adult patients who previously 
underwent surgery for DSS. The mean age at baseline was 20 years and median 
follow-up was 13 years. The peak instantaneous LVOT gradient decreased from 76 
mmHg preoperatively to 15 postoperatively and thereafter increased over time with 
a rate of 1.3 mmHg/year. Mild regurgitation was common, but did not evidently 
progress over time. Eighty percent required at least 1 re-operation and this risk was 
not reduced by additional myectomy. Predictors for reoperation were female sex 
and progression of the LVOT gradient.
Although survival is excellent after DSS surgery, progression of the LVOT gradient 
postoperatively is slow, and mild AR is common, reoperation for recurrent DSS 
is not uncommon. Due to the increased risk of complete heart block, additional 
myectomy should not be performed routinely.
Chapter 13 and 14 presents the results of the DIAMOND study, a single-center 
retrospective cohort study which assessed pregnancy outcomes in patients who 
previously underwent AVR and evaluate the potential infl uence of pregnancy on the 
durability of human tissue valve substitutes.
Chapter 13 provides insight in the 67 pregnancy outcomes of 40 women who 
had received an pulmonary autograft, homograft, or mechanical valve in aortic 
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position in the Erasmus University Medical Center from 1987 to 2011. Mean age 
at fi rst pregnancy was 30 years and 55 pregnancies were completed. There was no 
maternal mortality, but 1 fetal death and 1 neonatal death. Maternal cardiac com-
plications occurred in 13% and obstetric complications in 38% of the completed 
pregnancies and emphasized careful obstetric monitoring. Especially mechanical 
valve recipients experienced the greatest incidence of both cardiac and obstetric 
complications. In the discussion for the optimal aortic valve substitute in a young 
woman, human tissue valves should be considered.
Chapter 14 shows that pregnancy did not infl uence the durability of human aortic 
valve substitutes in 108 women who underwent 59 homograft and 49 pulmonary 
autograft procedures. Homograft recipient without pregnancies were older than 
homograft recipients who became pregnant. There were no other diff erences in 
patient characteristics and freedom of reoperation between the pregnant and 
non-pregnant women in both valve groups. Pregnancy was not associated with 
changes in aortic gradient, AR, annular and sinotubular junction diameter for either 
valve substitute. Therefore, human tissue valves should be considered as a suitable 
aortic valve substitute in young patients who (may) contemplate pregnancy.
Chapter 15 provides a general discussion, conclusions, clinical implications, recom-
mendations and prospects emerging from this thesis. To optimize management of 
(female) patients with (severe) AS, several fi elds should be of interest for patients, 
physicians, and scientists.
Regarding the diagnostic fi eld, a uniform classifi cation and assessment of AS 
worldwide would allow for enhanced estimation of AS progression, identify predic-
tors for this progression and enhance comparability of outcome reports. Potential 
new diagnostic (bio)markers could also help the diagnostic process. However, 
both need to be validated in longitudinal serial (echocardiographic) AS studies or 
registries. An international tissue bank of aortic valves (and roots) would greatly 
enhance biological research of aortic valves.
In the fi eld of treatment and prognosis, available treatment options should be 
individually weighed and selected for each patient including preoperative risk fac-
tors, surgical aspects, prognosis including improvement of experienced quality of 
life, and informed patient preferences.
The high occurrence of pregnancy-associated complications demand larger 
cohort studies to confi rm these results. Nevertheless, objective and comprehen-
sible information on the (dis)advantages of each aortic valve substitute including 
pregnancy-associated complications should be part of the preconceptional coun-
selling of young women who require aortic valve replacement as well as part of the 
consultation during pregnancy.
I don’t believe medical discoveries are doing much 
to advance human life. As fast as we create ways to 
extend it we are inventing ways to shorten it. 
C.N. Barnard
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SAMENVATTING
Dit proefschrift biedt inzicht in enkele aspecten van het natuurlijk beloop, de ver-
schillende behandelmogelijkheden en de prognose van volwassen patiënten met 
ernstige aortaklepstenose (AS).
Hoofdstuk 1 beschrijft de prevalentie van AS, het ziektespectrum, de manier waarop 
dit wordt gediagnosticeerd en de prognose van patiënten inclusief zwangerschap. 
AS is een veelvoorkomende ziekte onder ouderen; de prevalentie van deze ziekte 
loopt op tot 5% van de mensen ouder dan 75 jaar. De verwachting is dat binnen 
38 jaar, in 2052, de wereldpopulatie toeneemt naar 9.3 miljard waarvan tenminste 
280 miljoen mensen een ernstige AS zullen hebben waarvoor zij moeten worden 
behandeld.
Hoofdstuk 2 en 3 richten zich op de progressie van de ziekte AS en de factoren 
die mogelijk van invloed zijn op AS progressie en klinische uitkomst. Aanvullend 
beschrijft hoofdstuk 2 de ziekte AS in historisch perspectief.
In de literatuur varieert de toename in AS progressie fors in de vaak kleine stud-
iepopulaties. Daarom beschrijft hoofdstuk 3 een systematische literatuur review 
over de toename in AS progressie in volwassen patiënten. De meta-analyse toont 
een gepoolde jaarlijkse progressie van de maximale aortagradiënt van 3.7 mmHg/
jaar in gerandomiseerde gecontroleerde trials en 6.0 mmHg/jaar in observationele 
studies. Vanwege het heterogene beloop van de ziekte AS en de verschillende 
methoden van monitoren en individuele patiëntfactoren, is optimale en uniforme 
monitoring van de ziekte AS nodig om uiteindelijk te helpen bij de bepaling van de 
beste behandeling voor de individuele patiënt.
Hoofdstuk 4 benadrukt het beloop van ernstige AS in symptomatische patiënten 
die medicamenteuze behandeling, open hart chirurgie of transcutane aortaklep 
implantatie ondergaan. In het algemeen hebben oudere patiënten een hogere mor-
biditeit en mortaliteit na een chirurgische of transcutane interventie vergeleken met 
jongere patiënten. Dit is de reden dat een behandelbeslissing in oudere, hoog-risico 
patiënten met ernstige symptomatische AS individueel gemaakt moet worden en 
gebaseerd moet zijn op de levensverwachting, kwaliteit van leven, wensen en co-
morbiditeiten van de patiënt. Medicamenteuze behandeling kan een betere optie 
zijn voor 85-jarige patiënt met ernstige AS, milde angina en comorbiditeiten, terwijl 
een 85-jarige patiënt met ernstige AS en hartfalen zonder comorbiditeiten waarschi-
jnlijk meer gebaat is bij een invasieve behandeling.
Hoofdstuk 5 evalueert AS progressie en potentiële predictoren voor deze progressie 
met een mixed-model analyse van seriële echometingen van het aortaklepoppervlak 
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in 186 patiënten in de multicenter prospectieve AVARIJN cohort studie. Analyse 
van AS progressie wordt meest verricht met standaard statistische methoden welke 
bias introduceren, derhalve werd gekozen voor de meer geavanceerde mixed-model 
analyse in deze studie. In volwassen patiënten met ernstige AS nam het aortakle-
poppervlak gemiddeld met 0.034cm2/jaar af. In het bijzonder oudere vrouwelijke 
patiënten met ernstige AS die zich presenteren met een relatief groot aortaklepop-
pervlak, hebben de snelste ziekteprogressie gemeten over een periode van 2 jaar.
Hoofdstuk 6 presenteert een breed spectrum aan linker ventrikel (LV) rotatie pa-
rameters om inzicht te krijgen in de mechanische eigenschappen van het LV in AS 
in patiënten met een aortaklepoppervlak <2.0 cm2 en LV ejectiefractie >50%. De 
resultaten werden vergeleken met gezonde, leeftijd-gematchte controle patiënten. 
De LV systolische ‘twist’ nam toe in patiënten met AS en was proportioneel aan de 
ernst van de LV outfl ow obstructie. Mogelijk dient dit als compensatiemechanisme 
om zodoende de systolische LV functie in de door druk overbelaste LV te hand-
haven. Diastolische ‘untwisting’ snelheid was afgenomen in patiënten met AS.
Hoofdstuk 7 geeft inzicht in de associatie tussen longitudinale snelheden van 
het LV, een marker voor sub-endocardiale ischemie, en elektrocardiografi sche 
ST-segment depressie (strain) in 122 patiënten met ernstige AS, met of zonder 
angina. Patiënten met strain hadden een lagere gemiddelde en septale systolische 
mitraalannulus snelheid en een hogere LV massa.
Electrocardiografi sche strain was een predictor voor lagere LV snelheden en kan 
een mogelijke middel zijn voor identifi catie van patiënten met ernstige AS die een 
verhoogd risico lopen op plotse hartdood.
Hoofdstuk 8, 9 en 10 beschrijven de AVARIJN studie, een multicenter prospectieve 
cohort studie waarin 191 werden geïncludeerd met ernstige AS in de regio van Rot-
terdam.
Hoofdstuk 8 analyseert de behandelstrategie en overleving met behulp van 
klinische en echocardiografi sche metingen bij patiënten-inclusie in de studie en 
daarna op 6, 12 en 24 maanden. De cumulatieve 2-jaars incidentie van aortak-
lepvervanging en transcutane aortaklepimplantatie was 56% in symptomatische 
patiënten. In het bijzonder oudere symptomatische patiënten met comorbiditeiten 
ondergingen een conservatieve behandeling. De 2-jaars overleving van deze symp-
tomatische, chirurgisch behandelde patiënten was 90% vergeleken met 73% van 
de conservatief behandelde symptomatische patiënten. Aanvullende bleek dat 68% 
van de asymptomatische patiënten symptomatisch werden gedurende de 2 jaar 
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follow-up. Dit illustreert het progressieve beloop van AS dat ‘watchful waiting’ vere-
ist.
Hoofdstuk 9 biedt inzicht in de kwaliteit van leven in zowel symptomatische 
als wel asymptomatische AVARIJN patiënten door middel van de SF-36v2 Health 
Survey afgenomen bij patiënten-inclusie in de studie en daarna op 6, 12 en 24 
maanden. Het bleek dat zelf minimale symptomen een grote invloed hebben op 
het welzijn van patiënten en resulteren in een sterk verminderde kwaliteit van leven 
wanneer vergeleken met de algemene, leeftijd-gematchte Nederlandse bevolking. 
De kwantifi catie van deze (gezondheids)belasting door middel van de SF-36v2 kan 
bijdragen bij het bepalen van de beste individuele behandeling.
Hoofdstuk 10 gaat dieper in op de kwaliteit van leven in symptomatische AVARIJN 
patiënten welke conservatief of chirurgisch werden behandeld. Patiënten ervaren na 
een aortaklepvervanging een betere fysieke kwaliteit van leven, maar ook verbeteren 
het algemene gezondheidsbesef, vitaliteit en emotionele aspecten tot het niveau 
van de algemene, leeftijd-gematchte Nederlandse bevolking. In de conservatief 
behandelde symptomatische patiënten die overleefden was het voornamelijk de 
fysieke kwaliteit van leven die afnam over tijd.
Hoofdstuk 11 en 12 beschrijven het beloop en de uitkomst van patiënten met dis-
crete subaortale stenose (DSS), in een multicenter setting, welke conservatief dan 
wel chirurgisch waren behandeld.
Hoofdstuk 11 evalueert het natuurlijk beloop van 149 conservatief behandelde 
DSS patiënten en identifi ceert risicofactoren voor DSS progressie, aortaklep regur-
gitatie en interventie-vrije overleving. De mediane leeftijd was 20 jaar en de mediane 
follow-up was 6.3 jaar. De baseline piek linker ventrikel outfl ow tract (LVOT) gradiënt 
was 32 mmHg en nam langzaam toe met 0.8 mmHg/jaar. Niet de baseline LVOT 
gradiënt of leeftijd waren geassocieerd met een snellere DSS progressie, maar de 
aanwezigheid van een geassocieerde congenitale hartaandoening. Om deze reden 
dienen deze patiënten zorgvuldig gevolgd te worden. Milde AR kwam vaak voor, 
maar toonde geen evidente progressie over tijd. De mediane interventievrije over-
leving was 16 jaar en was geassocieerd met baseline LVOT gradiënt, DSS progressie 
en AR.
Hoofdstuk 12 presenteert de chirurgische uitkomst van 313 volwassen patiënten 
die eerder DSS chirurgie hadden ondergaan. De gemiddelde leeftijd bij aanvang van 
de studie was 20 jaar en de mediane follow-up was 13 jaar. De piek ‘instantaneous’ 
LVOT gradiënt reduceerde van 76 mmHg preoperatief naar 15 postoperatief en nam 
daarna met een snelheid van gemiddeld 1.3 mmHg/jaar toe.
Milde regurgitatie kwam vaak voor, maar toonde geen evidente progressie over 
tijd. Tachtig procent had tenminste 1 reoperatie nodig en het risico hierop werd 
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niet gereduceerd door een additionele myectomie. Predictoren voor een reoperatie 
waren vrouwelijk geslacht en progressie van de LVOT gradiënt. Alhoewel de overlev-
ing na DSS chirurgie excellent was, progressie van de LVOT gradiënt postoperatief 
langzaam was en milde regurgitatie vaak voorkwam, bleek reoperatie voor recidief 
DSS niet ongewoon. Vanwege het risico op een totaal hartblok dient een additionele 
myectomie niet routinematig uitgevoerd te worden.
Hoofdstuk 13 en 14 tonen de resultaten van de DIAMOND studie, een singlecenter 
retrospectieve cohort studie die de uitkomsten van zwangerschap in patiënten 
die een aortaklepvervanging hadden ondergaan evalueert alsmede de potentiële 
invloed van zwangerschap op de duurzaamheid van humane weefselkleppen.
Hoofdstuk 13 biedt inzage in de uitkomsten van 67 zwangerschappen van 40 
vrouwen die een pulmonale autograft, homograft of mechanische klep in aorta 
positie hadden ontvangen in het Erasmus Universitair Medisch Centrum van 1987 
tot 2011. De gemiddelde leeftijd tijdens de eerste zwangerschap was 30 jaar en 55 
zwangerschappen waren voldragen. Er was geen maternale mortaliteit, maar wel 
1 foetale dood en 1 neonataal overlijden. Maternale cardiale complicaties kwamen 
voor bij 13% en obstetrische complicaties bij 38% van de voldragen zwangerschap-
pen en benadrukt een zorgvuldige obstetrische monitoring. Met name mechanische 
kleppatiënten ondervonden de meeste cardiale en obstetrische complicaties. In 
de discussie omtrent de optimale aortaklepvervanger voor jonge vrouwen dienen 
humane weefselkleppen overwogen te worden.
Hoofdstuk 14 toont dat de duurzaamheid van humane aortaklepvervangers niet 
beïnvloed werd door zwangerschap in 108 vrouwen die 59 homograft en 49 pulmo-
nale autograft procedures ondergingen. Homograft patiënten zonder zwangersc-
hap waren ouder dan homograft patiënten die wel zwanger werden. Er waren geen 
andere verschillen in patiënt kenmerken en vrijheid van reoperatie tussen zwangere 
vrouwen en niet zwangere vrouwen in beide klepgroepen. Zwangerschap was niet 
geassocieerd met veranderingen in aortagradiënt, aorta regurgitatie, diameter van 
annulaire en sinotubulaire overgang voor elke van de klepvervangers.
Een humane weefselklep dient derhalve overwogen te worden als een geschikte 
aortaklep substituut in jonge patiënten die een zwangerschap overwegen.
Hoofdstuk 15 beschrijft de algemene discussie, conclusies, klinische implicaties, 
aanbevelingen en prospectus voortkomend uit dit proefschrift. In het optimaliseren 
van de behandelstrategie van (vrouwelijke) patiënten met (ernstige) AS kunnen 
diverse aspecten interessant zijn voor patiënten, dokters en wetenschappers.
Inzake het diagnostisch veld, een uniforme classifi catie en beoordeling van AS 
wereldwijd zou de bepaling van AS progressie kunnen optimaliseren, predictoren 
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voor deze progressie identifi ceren en de vergelijkbaarheid van studie uitkomsten 
verbeteren.
Potentieel nieuwe diagnostische (bio)markers kunnen ook een bijdragen leveren 
aan het diagnostisch proces. Niettemin dienen beide gevalideerd te worden in lon-
gitudinale seriële (echocardiografi sche) studies of registraties. Een internationale 
weefselbank van aortakleppen (en wortels) zou een grote aanwinst zijn voor het 
experimenteel onderzoek van aortakleppen.
Op het gebied van behandeling en prognose dienen diverse behandelopties op 
individuele basis gewogen en geselecteerd te worden voor elke patiënt inclusief de 
preoperatieve risicofactoren, chirurgische aspecten, prognose inclusief verbetering 
van de ervaren kwaliteit van leven en ‘informed patient preferences’.
Het hoge percentage van zwangerschap-geassocieerde complicaties vraagt om 
grote cohortstudies om de in dit proefschrift beschreven bevindingen te kunnen 
bevestigen. Desniettemin dient het objectief en in begrijpelijke taal informeren 
van de patiënt over de voor- en nadelen van de verschillende aortaklepsubstituten, 
inclusief zwangerschaps-geassocieerde complicaties, onderdeel te zijn van de 
pre-conceptionele counseling van jonge vrouwen die een aortaklepvervanging 
nodig hebben, alsmede onderdeel van de consulten tijdens de zwangerschap.
Friends applaud, the comedy is over.
L. van Beethoven
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Dit proefschrift, een trots eindresultaat van mijn promotieonderzoek, heeft mij 
geleerd dat doorzettingsvermogen en samenwerking de key issues zijn in het 
onderzoeksbestaan.
Dit bestaan dank ik allereerst aan de enthousiaste inzet van de (AVARIJN en 
DIAMOND) patiënten die, ondanks hun persoonlijke tegenslag, weer en wind, 
toch meermaals deelnamen aan het onderzoek. Met genoegen denk ik terug aan 
de mooie en veelal humoristische contactmomenten met deze patiënten en hun 
familieleden.
Daarnaast gaat mijn dank uit naar enkele professionele en enthousiaste collegae 
waarvan ik enkele personen in het bijzonder wil danken voor hun eff orts.
Professor Bogers, geachte professor Bogers, mijn welgemeende dank voor uw niet 
afl atende en enthousiaste medewerking en geduld gedurende mijn (toch wat langer 
durende) promotietraject. Uw kort maar krachtige visie op de manuscripten result-
eerde altijd in een verbetering en aanzet tot kritische refl ectie. De effi  ciëntie, dus 
ook de snelheid, waarmee u een manuscript beoordeelt, zou als voorbeeld moeten 
dienen voor het herstel van de huidige economie.
Gezien onze wegen zich scheiden, wens ik u veel succes met de afdeling Car-
dio-thoracale Chirurgie van het Erasmus Universitair Medisch Centrum (ofwel het 
Thoraxcentrum).
Professor Takkenberg, beste Hanneke, waar te beginnen?! Als inspirerende, 
enthousiaste en drijvende kracht achter dit proefschrift aan mij de bijzondere eer 
je hiervoor hartelijk te danken. Naast een professioneel inhoudelijk advies, gaf je 
ook goede (voor mij passende) ‘tips and tricks’ voor mijn verdere carrière. Dat je 
ondanks je overvolle agenda toch altijd ‘online’ was voor een vraag, toont je grote 
betrokkenheid. Het feit dat je bij dit alles oog hebt gehad voor mijn privé, zeker 
toen het moeizaam verliep met Koenraad, heb ik zeer gewaardeerd. Ik heb dan 
ook veel van je geleerd, niet alleen professioneel inhoudelijk, maar ook het belang 
van een goede werk-prive balans. Ik wens je een inspirerende tijd toe als bijzonder 
hoogleraar Klinische besliskunde in cardio-thoracale interventies.
Leden van de leescommissie, professor De Jaegere, professor Jolien Hesseling-
Roos en Dr. Kluin, mijn welgemeende dank dat u plaats nam in de leescommissie 
en mijn manuscript wilde beoordelen. Temeer omdat hiermee zowel cardiologische 
als wel cardio-chirurgische expertise bijeenkomt.
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Jolien, mijn welgemeende dank voor je gedreven en inspirerende begeleiding 
inzake de DIAMOND studie waarbij je, ondanks je drukbezette agenda, altijd 
bereikbaar was voor een overleg moment. Ook inzake het reviewen van zwanger-
schapsgerelateerde studies vernam ik zeer vlot een praktisch antwoord. Ik wens je 
veel succes met (de uitbreiding van) het Congenitale programma.
Overige leden van de grote commissie, professor Deckers, professor Rutten-van 
Mölken, professor Wind en Dr. Utens, moge de uitkomst van de verdediging niet 
alleen mijn inzet, maar ook die van de patiënten dienen. Mijn welgemeende dank 
dat u plaats neemt in de promotiecommissie.
Professor Deckers, gezien ik u sinds mijn COEUR tijd niet meer gezien heb, 
allereerst profi ciat met uw benoeming! Dit proefschrift heeft meerdere raakvlakken 
met de Cardiologie ofwel stof genoeg voor een interessante, prikkelende discussie.
Professor Rutten-van Mölken en dr. Utens, de associatie tussen patientenzorg, 
QALY’s en kosten is een hot issue. Ik ben dan ook erg nieuwsgierig naar uw vragen!
Professor Wind, een kritische blik vanuit de Verzekeringsgeneeskunde over een 
klinisch cardio-chirurgisch proefschrift, belooft een interessante discussie te wor-
den! Ik wil u hartelijk danken dat u zich verdiept heeft in mijn proefschrift, temeer 
omdat uw expertise mijn huidige werkveld betreft en ik benieuwd ben naar uw visie.
De overige leden van de AVARIJN crew.
Professor Kappetein, professor Kappetein, ondanks een volle en veeal vliegende 
agenda wist u toch altijd tijd vrij te maken voor AVARIJN waarvoor mijn hartelijke 
dank.
Dokter Galema, beste Tjebbe, dank voor al die keren dat ik, ondanks je drukke 
werkschema, tussendoor een casus met je kon overleggen en een functioneel 
antwoord ontving.
Dokter Geleijnse, beste Marcel, dank voor de brainstormsessies inzake AVARIJN. 
Ik wens je veel succes met je klinische (onderzoeks)carrière.
Dokter Van Thiel, dank dat u als onafhankelijke onderzoeksarts de AVARIJN 
patiënten te woord wilde staan. Dat ik u niet vaak gesproken heb, is in dit geval 
geruststellend!
Martijn van Geldorp, beste Martijn, AVARIJN is af; dank voor de samenwerking. 
Succes met je carrière als cardio-thoracaal chirurg met bovenal een goed privéleven!
Marianne en Wim, echolaboranten in het Erasmus MC, dank dat jullie mij bij 
aanvang van de AVARIJN studie wegwijs maakte in de wereld van de ‘echo cor’.
Alle echolaboranten en ondersteunend personeel van de extern participerende 
AVARIJN ziekenhuizen, in het bijzonder Renate en Lianne (ASZ), Luce (Havenziek-
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enhuis), Mireille (SFG), Anneke (Vlietland), Patricia, Annemarie en Kitty (Zuider), 
dank voor de gezellige ‘outdoor’ momenten en het maken van de vele echo’s.
Heren thoraxchirurgen, dokter Bekkers, dokter Bol Raap, dokter De Jong, dokter 
Maat, dokter Oei en dokter Van de Woestijne, u heeft mij niet veel op de OK gezien, 
maar deze afwezigheid is niet representatief voor mijn waardering voor u en uw 
werk. Met plezier denk ik terug aan de korte contactmomenten en wens u veel 
succes toe binnen uw expertise.
Nalini M. Rajamannan, dear Nalini, thank you for giving me the opportunity to work 
together in the dynamic and very interesting fi eld of aortic valve stenosis. It was 
truly an honor to join you in writing the fi rst chapter of your excellent book!
Dokter Cornette, beste Jerome, dank voor de gewaardeerde samenwerking inzake 
onze pregnancy studie. Het feit dat je korte en duidelijke communicatielijnen han-
teert in een academische setting, is door mij zeer gewaardeerd.
Collegae van de research groep, beste Marijke, beste Liesbeth, beste Liz, beste 
Usha, beste Els, beste Angeliek, beste Marion, beste Solita, dank voor de overleg-
momenten en de gevulde koffi  ebekers. Life is ‘reuring’….
Usha, dank voor het inbinden van mijn manuscript en de vele brieven die je voor 
mij hebt gemaakt tijdens de afrondingsfase van mijn boekje! Dat scheelde mij weer 
een rit naar Rotterdam.
Collegae van het secretariaat Thoraxchirurgie, beste Annet, beste Rianne, beste Jos, 
beste Caroline, beste Maureen, beste Marja, beste Sabine, ik heb jullie niet veel 
gezien, maar weten hoe de fax werkt, was voor mij ook heel belangrijk!
Annet, mijn welgemeende dank voor je accurate hulp bij het maken van afspraken.
Gepromoveerde collegae, Denise van der Linde, Bas van Dalen, Linda de Heer, 
Mostafa Mokhles, Ruben Osnabrugge en Stuart Head, dank voor de overleg mo-
menten en/of advies.
Denise, lady, dank voor de leuke samenwerking inzake SUBVAS. Veel succes bij je 
verdere (onderzoeks)carriere; het was een leuke tijd in Barcelona!
Bas, dank dat ik deelgenoot mocht worden van je echostudies (en de online 
overlegmomenten). Ik wens je veel succes in het SFG!
Linda, ik zal onze Heart Valve Disease congressen gaan missen (alsmede onze 
veldtocht door the Big Apple en onze tijd aan de bar in Olive Garden). Ik wens je 
heel veel succes toe met je opleiding tot cardio-thoracaal chirurg; word de beste!
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Collegae van het UWV, in het bijzonder collegae staf-arts Rolf van Hes, opleider 
Renske Jansen en mentor Luuk Looij, dank voor jullie enthousiaste support, 
to-the-point correcties en opleiding. Mijn wens is om, samen met jullie, het veel-
zijdige en boeiende vak van de Verzekeringsgeneeskunde verder te ontdekken, 
verdiepen en promoten.
Natuurlijk kan bovenstaande niet zonder de ervaren hulp van de andere collegae: 
Annet, Ben, nogmaals Ben, Dennis, Erik, Guda, Ida, Ilse, Kathelijne, Marc, Marlies, 
Onno, Sake, Soeresh, Tjeerd en Ties (ik hoop dat ik niemand vergeten ben!).
Eveline, dank voor je support inzake mijn opleiding, die, zoals je inmiddels hebt 
ervaren, een belangrijk onderdeel van mijn werk en werkplezier vormt. Of zoals 
Aristoteles zei: “Opleiding is de beste proviand op de reis naar de ouderdom.”
Mijn medestrijders binnen de WIA, Cornelia Hup Middelkamp en Riza Ozsoy, 
ik waardeer onze korte (koffi  e-, thee- en lunch)bijeenkomsten; ook in de toekomst 
gaan we er samen een mooie tijd van maken samen. Cornelia, wat leuk dat we 
samen verder kunnen!
En last but not least, dank aan alle collegae van de afdeling Ziektewet, de afdeling 
Bezwaar&Beroep, alle dames en heren teamondersteuners, arbeidsdeskundigen en 
procesbegeleiders en de dames van het secretariaat voor de aangename en leer-
zame samenwerking. Jelle, Reinier en René, dank voor het wegwijs maken binnen 
de Ziektewet! Irma, leuk dat meedoet in Utrecht!
Collegae promovendi, Elrozy Andrinopoulou, Aart Mookhoek en Nelleke Korteland, 
ik wens jullie veel succes bij de afronding van jullie proefschrift en ben benieuwd 
naar jullie eindresultaat. Maak er een mooie tijd van!
Elrozy, thank you very much for your eff orts in fi nisching chapter 5. Communica-
tion between a statician and a clinician is sometimes a bumpy road, but neverthe-
less, the fi nal result counts.
Medisch studenten en/of co-assistenten (of mogelijk al afgestudeerd) Bardia Arab-
khani, Ahmad Bashir, Ebru Ertekin, Lisa Elmont, Eline Hartman, Ilse Groenendijk 
en Deriah Top, heel veel succes met het afronden van jullie studie/opleiding.
Bardia, dank voor de leuke en succesvolle samenwerking inzake de DIAMOND 
studie; met plezier denk ik terug aan onze belavonden voor DIAMOND. Ik wens jou 
en Carina veel geluk, gezondheid en een mooie carrière toe.
Dr. Dawson, beste dokter Dawson, mijn tijd als operatieassistente bij de Heelkunde 
is de initiator geweest van mijn huidige carrière. Uw enthousiaste aanzet tot en 
motiverende begeleiding tijdens de beginfase van deze carrière waardeer ik nu al-
leen maar meer. Jammer dat we niet meer samenwerken! Ik wens u als chirurg en 
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als opleider in het IJsselland Ziekenhuis veel succes toe. En, vergeet de kabel niet 
bij het snoeien van de heg….
Collegae van de Spoedeisende Hulp AMC, ondanks dat ik mijn toekomst niet op de 
Spoedeisende Hulp zag, heb ik genoten en geleerd van de korte tijd bij jullie. Dank 
daarvoor!
Oud-collegae operatieassistenten uit het IJsselland Ziekenhuis, het Maasstad 
Ziekenhuis locatie Zuider en sector Oost I van het UMC Utrecht, dank voor 
jullie enthousiaste medewerking inzake mijn studieplannen; de combinatie 
studeren-werken-onderzoek was een uitdaging waardig.
Mijn paranimf, Hilde de Pee-Heuvelman, beste Hilde, dank dat je naast mij wilt 
staan tijdens dit belangrijke moment. Je moet maar denken, als een soort van 
tegenprestatie voor al die momenten dat ik als tiener ongevraagd je kleding leende…
Vroeger op het schippersinternaat was jij mijn grote zus. Als 6-jarige kwam mij 
dat weleens goed uit, met name als ik het niet eens was met de juf! Vandaag moet 
ik het echter alleen doen…
Mijn andere paranymf, Elske Weber, dear Elske, tijdens je vakantie naar Rotterdam 
komen om naast mij te staan, waardeer ik nu alleen maar meer. Wat een schit-
terend nieuws dat jij en Guido een wereldburger verwachten; ik ben natuurlijk reuze 
benieuwd! Eindelijk ben ik niet de enige mama meer…
Met plezier denk ik terug aan onze leuke, maar te korte tijd in Utrecht! Ook onze 
tijd in de kelder van het AMC was kort, maar ik hoop nog vele gezellige diners 
en borrels samen gedurende de komende decennia. Tot slot, veel succes met je 
opleiding tot kinderarts!
Papa en mama, dank dat u mij in de gelegenheid stelde Geneeskunde te stud-
eren terwijl een extra hand aan boord destijds ook goed te gebruiken was. De vele 
vaaruren die u heeft gemaakt kunnen als voorbeeld dienen voor de slaapuren van 
Jan-Wycherd….
Mijn 3 broers en 4 zussen, dank voor de ondersteuning tijdens mijn studie Ge-
neeskunde en promotietraject.
Marinus, de meeste dank gaat uit naar jou! Dank voor je onvoorwaardelijke en 
humoristische support. Ik beschouw het als een groot genoegen en voorrecht om 
elke morgen naast je wakker te worden en samen te genieten van het forse stem-
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volume van onze zoons! Ik hoop van harte dat we nog lang van elkaar, Koenraad en 
Jan-Wycherd mogen genieten.
Koenraad, mama’s grote letterboek is af (je kan dit inmiddels al een beetje lezen); 
nu kunnen we eindelijk samen op strooptocht met onze jongensclub!
Jan-Wycherd, je krijgt er nog niet veel van mee, maar papierscheuren kan je als de 
beste, zo ook uit mama’s boek…
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PhD training Year Workload
(ECTS)
Research skills
- Master in Health Sciences, specialisation of Clinical 
Epidemiology
2004-2009 30.4
- BROK course Nov 2008 0.9
- BROK re-registration Sep 2014 0.1
- Regression analysis for Clinicians Jan 2009 1.9
- CPO course Feb 10th 2009 0.3
- Biomedical English Writing and Communication Apr-Jul 2009 4.0
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In-depth courses
- Arrythmia Research Methodology (COEUR) Jan 2009 1.5
- Congenital Heart Disease (COEUR) Feb 2009 1.5
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ACC  American College of cardiology
AD  Annular diameter
AHA  American Heart Association
AoI  Aortic regurgitation
AR  Aortic regurgitation
AS  Aortic stenosis
AVA  Aortic valve area
AVR  Aortic valve replacement
CABG  Coronary artery bypass grafting
CAD  Coronary artery disease
CAVS  Calcifi c aortic valve stenosis
CHD  Congenital heart disease
DSS  Discrete subaortic stenosis
EACTS  European Association of Cardio-Thoracic Surgery
ESC  European Society of Cardiology
EuroSCORE European System for Cardiac Operative Risk Evaluation
GUCH  Grown-Up Congenital Heart
HOCM  Hypertrophic obstructive cardiomyopathy
HR  Hazard ratio
IQR  Interquartile range
LDL  Low density lipoprotein
LV  Left ventricular / ventricle
LVEF  Left ventricular ejection fraction
LVOT  Left ventricular outfl ow tract
MAG  Mean aortic gradient
MRI  Magnetic resonance imaging
NT-proBNP N-terminal pro-brain natriuretic peptide
NYHA  New York Heart Association
PAG  Peak aortic gradient
QoL  Quality of life
RCT  Randomized controlled trial
Rotmax  Left ventricular peak systolic rotation during ejection
SE  Standard error
SF-36v2™ Short Form 36 version 2
STE  Speckle tracking echocardiography
STJ  Sinotubular junction
STS  Society of Thoracic Surgery
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TAVI  Transcatheter aortic valve implantation
Twistmax  Instantaneous left ventricular peak systolic twist
Vmax  Transaortic peak velocity
VSD  Ventricular septal defect
…Still another is that no man, on a mountain or 
elsewhere, gets more out of anything than he puts 
into it. If it is a discredit to me that I was a step 
behind Hillary, then I must live with that discredit. 
But I do not think it was that.…
Sherpa Tenzing, 1914-1986
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